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[571 ABSTRACT 
The present invention discloses nucleic acid enzymes 
capable of cleaving nucleic acid molecules, including 
single-stranded DNA, in a site-specific manner under physi- 
ologic conditions, as well as compositions including same. 
The present invention also discloses methods of making and 
using the disclosed enzymes and compositions. 
(1991). 
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OPTIMIZED CATALYTIC DNA-CLEAVING 
RIBOZYMES 
DESCRIPTION 
(1990)), as well as to RNAs bound to a ligand that is 
attached to a solid support (Tuerk, et al., Science 249: 505 
(1990); Ellington, et al., Nature 346: 818 (1990)). It has also 
been applied to peptides attached directly to a solid support 
(Lam, et al., Nature 354: 82 (1991)); and to peptide epitopes 
expresded within a viral coat protein (Scott, et al., Science 
249: 386 (1990); Devlin, et al., Science 249: 404 (1990); 
Cwirla, et al., ~ N A S  USA 87: 6378 (1990)). 
However, as disclosed herein, we have achieved aremark- 
10 able degree of success in engineering new enzymatically 
active oligonucleotide molecules. Therefore, the discoveries 
and inventions disclosed herein are particularly significant, 
in that they highlight the potential of in vitro evolution as a 
means of designing increasingly more efficient catalytic 
5 
This invention was mide with government Suppofl under 
NASA Grant No. NA(3W-1671 and M H  Grant No. 
AI30882. The government has certain rights in the inven- 
tion. 
TECHNICAL FIELD 
The present invention relates to nucleic acid enzymes or 
enzymatic RNA molecules for cleaving DNA under physi- 
ologic conditions, compositions containing and to 
methods of making and using such enzymes and composi- l5 
tions. 
BRIEF SUMMARY OF THE INVENTION 
Site-directed mutagenesis has now been improved by in 
Vitro selected amplification techniques for generating large 
context or which catalyze reactions that are not represented n u h e r s  of mutants with subsequent Selection of Some 
in nature has resulted in the development of “enzyme desirable property. Individual macromolecules are selected, 
engineering” technology. The usual route taken in enzyme and those Selected are then amplified to generate a Progeny 
engineering has been a “rational design” approach, relying distribution of favorable mutants. The process is repeated 
upon the understanding of natural enzymes to aid in the 25 until only those individuals with the most desirable proper- 
construction of new enzymes. Unfortunately, the state of ties remain. 
proficiency in the areas of protein structure and chemistry is Therefore, in various disclosed embodiments of the 
insufficient to make the generation of novel biological present invention, enzymatic nucleic acids, particularly 
catalysts routine. enzymatic RNA molecules, are prepared, selected, and syn- 
Recently, a different approach for developing novel cats- 3O thesized in useful quantities for Various uses. Selection 
lysts has been applied. This method involves the COnstruC- criteria include, without limitation, the ability of the enzy- 
tion of a heterogeneous pool of macromolecules and the matic RNA m o ~ e c ~ l e  to catalyze a SWence-SPecific r e x -  
application of an in vitro selection procedure to isolate tion, to cleave nucleic acids, to bind substrate DNA and/or 
molecules from the pool that catalyze the desired reaction. RNA, to display an improved tm~over  ate, and the like. 
Selecting catalysts from a pool of macromolecules is not 35 Therefore, the present invention contemplates enzymatic 
dependent on a comprehensive understanding of their struc- RNA molecules capable of specifically cleaving a single- 
tural and chemical properties. Accordingly, this process has stranded nucleic acid molecule under physiologic condi- 
been dubbed “irrational design” (Brenner and Lerner, PNAS tions, wherein the enzymatic RNA molecules include one or 
USA 89: 5381-5383 (1992)). more point mutations which improve the enzymatic perfor- 
The process of Darwinian evolution, by which enzymes 40 mance of the enzymatic RNA molecules. In various embodi- 
arise in nature, does not operate by generating a diverse ments, the enzymatic RNA molecule further includes one or 
population of variants and harvesting the most advantageous more point mutations which affect the substrate specificity 
individuals. In biological systems, diversity is maintained by of the enzymatic RNA molecule. 
ongoing mutations, and the population is shaped by selec- 45 In one variation, the enzymatic performance comprises 
tion. Novel mutations augment existing variation, so that the catalytic efficiency. Alternative embodiments contemplate 
evolutionary search is biased, in an appropriate fashion, by that the enzymatic RNA molecule has a cleavage rate of 
selection events that have already occurred (Eigen, et al., J. about 0.7 min-’. 
Phys. Chem. 92: 6881 (1988)). The more advantageous It is also contemplated that enzymatic performance may 
mutants, which are relatively abundant in the Population, comprise substrate binding affinity. In various embodiments, 
give rise to larger numbers of novel Variants when compared the substrate may comprise DNA, RNA, or composites 
to the less advantageous mutants. thereof. In embodiments in which the substrate comprises 
Most efforts to date involving the rational design of DNA, an enzymatic RNA molecule may have a substrate 
enzymatic RNA molecules or ribozymes have not led to binding affinity of at least lO-’M. In other variations, an 
molecules with fundamentally new or improved catalytic 55 enzymatic RNA molecule of the present invention binds 
function. However, the application of irrational design meth- DNA with a KD of less than 10 ph4. In alternative embodi- 
ods via a process we have described as “directed molecular ments, an enzymatic RNA molecule of the present invention 
evolution” or “in vitro evolution”, which is patterned after binds DNA with a K, of less than 1 pM; with a KD of less 
Darwinian evolution of organisms in nature, has the poten- than 50 nM; or with a K, of less than 10 nM. 
desirable functional characteristics. an enzymatic RNA molecule preferably binds RNA with a 
This technique has been applied with varying degrees of K, of less than 1.0 nM, and more preferably, with a K, of 
success to RNA molecules in solution (see, e.g., Mills, et al., 0.5 nM or less. In other embodiments, an enzymatic RNA 
PNAS USA 58: 217 (1967); Green, et al., Nature 347: 406 molecule has an RNA substrate cleavage rate up to three 
(1990); Chowrira, et al., Nature 354: 320 (1991); Joyce, 65 times greater than that of wild-type ribozymes. Still other 
Gene 82: 83 (1989); Beaudry and Joyce, Science 257: embodiments contemplate enzymatic RNA molecules 
635-641 (1992); Robertson and Joyce, Nature 344: 467 wherein enzymatic performance comprises substrate speci- 
BACKGROUND 
The need for catalysts that operate outside of their native 20 
tial to lead to the production of RNA molecules that have 60 In embodiments in which the substrate comprises RNA, 
5,580,967 
3 
ficity. In various embodiments, that specificity is changed 
via altering the recognition sequence. As noted above, 
substrates may comprise DNA, RNA, or composites thereof. 
In embodiments in which the substrate comprises DNA, 
an enzymatic RNA molecule invention preferably has a 
DNA substrate cleavage rate 10-102, 102-103, 103-104, or 
even 104-105 times greater than that of wild-type 
ribozymes. A cleavage rate exceeding lo5 is also contem- 
plated in various embodiments. 
The present invention further contemplates enzymatic 
RNA molecules derived from group I, 11,111, or IV introns. 
Preferably, an enzymatic RNA molecule of the present 
invention is derived from a group I intron. In one variation, 
the group I intron is a Tetrahymena group I intron. In another 
variation, an enzymatic RNA molecule contemplated herein 
comprises the portions of a Tetrahymena group I intron 
having catalytic activity. In yet another embodiment, an 
enzymatic RNA molecule of the present invention is derived 
from an L-19 or L-21 RNA molecule and includes the 
portions of the L-19 or L-21 RNA molecule having the 
catalytic activity. 
Various embodiments of the disclosed invention contem- 
plate that an enzymatic RNA molecule of the present inven- 
tion includes one or more mutations not typically found in 
wild type enzymatic RNA molecules or ribozymes. In vari- 
ous embodiments, the mutations are selected from the group 
consisting of: 44:G+A; 51/52:insert AGAA; 87:A+ 
deleted; 94:A-N; 94:A-C; 115:A+U; 116:GjA; 
138:C+A; 166:C+A; 167:U+G; 17O:C+U; 188:G+A; 
190:U+A; 191:G+U; 205:U+C; 215:G+A; 239:U+A; 
258:U+C; 312:G+A; 313:G+U; 313:G-K; 314:A-+G; 
317:U+G; 317:U+C 317:U+A; 333:U+C; 350:C+U; 
and 364:C+U. 
In various alternative embodiments, an enzymatic RNA 
molecule of the present invention has 1-4 point mutations, 
5-8 point mutations, 9-12 point mutations, or 13 or more 
point mutations. In various exemplary embodiments, the 
point mutations may comprise a 215:G+A mutation, a 
258:U+C mutation, or both. In another embodiment, an 
enzymatic RNA molecule includes the following mutations: 
94:A+Y, 215:C+A, and 313-314:GAjUG. Still another 
example includes the mutations 94:A+Y, 215:G+A, 
313-314:GA+UG, and 317:U+R, while yet another 
example includes the mutations 94:A+Y, 215:G+A, 
313-314:GA+UG, and 333:U-C. 
In another embodiment, an enzymatic RNA molecule 
includes the following mutations: 94A-+Y and 
313-314:GAjUG. Still another example includes the fol- 
lowing mutations: 215:G+A and 313-314:GA+UG. In yet 
another embodiment, an enzymatic RNA molecule of the 
present invention includes the following mutations: 94:A+ 
Y, 115:A+U, 116:G+A, 188:G+A, 90:U+A, 191:G+U, 
205:U+C, 215:G-+A, and 313-314:GA+UG. 
In another variation, the invention contemplates an enzy- 
matic RNA molecule including the following mutations: 
44:G+A, 87:A+del, 94:A+U, 115:A+U, 116:G+A, 
166:C+A, 17O:C+U, 188:G+A, 190:U+A, 191:G+U, 
205:U+C, and 215:G+A. 
Other examples of combinations of mutations which may 
be present in enzymatic RNA molecules of the present 
invention include the following: (a) 98:C+U and 
R; (c) 94:A+Y and 215:G+A; (d) 94:A+Y, 205:U+C, 
and 313-314:GAjUG; (e) 94:A+Y, 98:C+U, and 
333:U-C; (f) 44:G+A, 94:A+U, 115:A+U, 116:G+A, 
138:C+A, 188:G+A, 190:U+A, 191:G+U, 205:U+C, 
313-314:GAjUG; (b) 98:C+U, 205:U+C, and 317:U+ 
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4 
215:G+A, 312:G+A, and 317:U+G, (g) 44:G+A, 
94:A+U, 115:A+U, 116:G+A, 138:C+A, 167:U+G, 
188:G+A, 190:U+A, 191:G+U, 205:U+C, 215:G+A, 
239:U-+A, and 312:G-+A; (h) 44:G+A, 51/52:insert 
AGAA, 87:A+del, 94:A+U, 115:A+U, 116:G+A, 
166:C+A, 17O:C+U, 188:G+A, 190:U+A, 191:G+U, 
205:U+C, 215:G+A, 239:U+A, 312:G+A, 350:C+U, 
and 364:C+U; or (i) 44:G+A, 51/52:insertAGAA, 87:A+ 
del, 94:A+U, 115:A+U, 116:G+A, 166:C-+A, 170:C+ 
U, 188:G+A, 190:U+A, 191:G+U, 205:U+C, 215:G+ 
A, 313:G+C, and 314:A+G. 
In various disclosed embodiments, the mutations are 
concerted. In one exemplary embodiment, the concerted 
mutations comprise a tandem 313-314: GA+UG mutation. 
In another example, the concerted mutations comprise a 
215:G-+A mutation and a 258:U-K mutation. 
In yet another variation, the concerted mutations comprise 
mutations at nucleotide positions 188, 190, and 191. In still 
another variation, the concerted mutations comprise muta- 
tions at nucleotide positions 115, 116, and 205. Another 
embodiment includes concerted mutations comprising muta- 
tions at nucleotide positions 115, 116, 188, 190, 191, and 
205. 
The present invention further contemplates an enzymatic 
RNA molecule capable of specifically cleaving single- 
stranded DNA under physiologic conditions, wherein the 
enzymatic RNA molecule includes one or more point muta- 
tions which affect the enzymatic performance of the mol- 
ecule. In various embodiments, an enzymatic RNA molecule 
of the present invention further includes one or more point 
mutations which affect the substrate specificity of the mol- 
ecule. 
The present invention also contemplates various methods 
of making and using enzymatic RNA molecules according to 
the present invention. For example, a method for specifically 
cleaving a single-stranded DNA molecule under physiologic 
conditions, is contemplated herein, which comprises the 
steps of  
(a) providing an enzymatic RNA molecule having a 
deoxyribonuclease activity; 
(b) contacting the enzymatic RNA molecule with a single- 
stranded DNA molecule under physiologic conditions; 
and 
(c) maintaining the contact for a sufficient time to allow 
the enzymatic RNA molecule to cause the single- 
stranded DNA molecule to be cleaved. 
In another embodiment, the method further comprises 
providing the enzymatic RNA molecule in a reaction 
medium at a concentration sufficient to cause cleavage of 
about one molecule of DNA per molecule of enzymatic 
RNA per minute. In yet another embodiment, the method 
further comprises providing the enzymatic RNA molecule in 
a reaction medium, wherein the enzymatic RNA molecule is 
present at a concentration sufficient to cause cleavage of at 
least 10% of a population of DNA molecules in an hour. 
In one variation of the disclosed methods for specifically 
cleaving a single-stranded DNA molecule under physiologic 
conditions, an enzymatic RNA molecule comprises a bind- 
ing site for single-stranded DNA, which binding site is 
complementary to nucleotides adjacent to a cleavage site on 
the single-stranded DNA molecule. In another variation of 
the disclosed methods, an enzymatic RNA molecule of the 
present invention comprises a binding site for single- 
stranded DNA, which binding site is complementary to 
nucleotides adjacent to a cleavage site on the single-stranded 
DNA molecule. 
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The invention also contemplates a method of producing 
an enzymatic RNA molecule having a predetermined cata- 
lytic activity, comprising: 
(a) subjecting a population of enzymatic RNA molecules 
to mutagenizing conditions to produce a diverse popu- 5 
lation of mutant RNA molecules; 
(b) selecting an enzymatic RNA molecule having a pre- 
determined activity from the diverse population of 
mutant enzymatic RNA molecules; and 
lation of mutant RNA molecules. 
open squares represent RNA population size after selective 
am lification, quantitated by acid precipitation at 4” C. of 
FIG. 5 illustrates the cleavage of [3’-32P]dA-labeled 
d(GGCCCTCT-A3 (TA3)3[5’-32p1A) (SEQ ID NO 13). 
Cleavage of [3’-32P]dA-labeled d(GGCCCTCT-A3(TA3), 
[5’- 32P]A) (SEQ ID NO 13) was conducted under reaction 
conditions as described hereinabove prior to autoradiogram. 
Substrate (S), enzyme/product (EP), and product (P) were 
10 separated by electrophoresis in a 20% polyacrylamide-8M 
quantitated by Cerenkov counting. Data points are the 
comprise conditions that introduce defined or random nucle- different days with two &Eerent preparations of substrate. 
otide substitutions within an enzymatic RNA moleculc. In 15 
another variation, the mutagenizing conditions comprise 
FIG. 6 illustrates Eadie-Hofstee plots used to determine chemical modification, incorporation of randomized 
K, (negative slope) and V, (y-intercept) for cleavage of mutagenic oligodeoxynucleotides, or inaccurate copying by 
(5’-32P)-labeled d (GGCCCTCT-A, (TA3),) (SEQ ID NO 6) a polymerase. In yet another variation, the mutagenizing 
merase chain reaction, or self-sustained sequence replica- 20 tion 9. Closed circles represent the wild type; closed squares 
represent clone 29; and closed triangles represent clone 23. tion. 
Each data point is the average of three independent deter- 
prises the ability to cleave DNA under physiologic condi- minations of initial velocity. The extent of the reaction was 
linear over the chosen time interval (rm:,=O.94, r,,,=0.99). tions. 
Another variation of the foregoing methods hurther com- FIG. 7 illustrates the overall in vitro evolution procedure 
prises the step of amplifying the enzymatic RNA molecules disclosed herein. I-Cleavagc of the DNA substrate via 
selected from the diverse population. In one embodiment, PhoSPhoeSter transfer results in ligation of the 3’ Portion of 
the amplifying is performed using a polymerase chain the substrate to the 3’ end of the ribozyme. 2-selective 
reaction, another embodiment, the amplifying is per- 3o isothermal amplification of DNA-cleaving ribozymes: first, 
formed using self-sustained sequence replication. selective Primer la  hybridizes to the extended 3’ terminus of 
active molecules and initiates cDNA synthesis in the pres- 
ence of reverse transcriptase (RT); next, Primer 2, which 
contains a T7 promoter sequence, hybridizes to the cDNA 
FIG. 1 illustrates the secondary structure Of the wild-type and initiates second-strand DNA synthesis; finally, T7 RNA 
Tetrahymena ribozyme (L-21 form) (SEQ ID NO 26). Paired 35 polymerase (T7 pol) produces multiple copies of the 
structural elements are designated by Pi. Joining regions selected RNA, each of which can enter a new round of 
between paired elements i and j, referred to as J i/j, are not amplification. 3-Selective cDNA synthesis employing 
labeled. Nucleotide positions that were partially randomized Primer l a  and reverse transcriptase. &pCR amplification 
in the initial population are indicated by shaded regions. The employing nonselective Primer 1b and Primer 2, restores the 
internal guide sequence (IGS) is shown in bold, and the 40 original terminus of the ribozyme-encoding gene and intra- 
DNA substrate is shown in lowercase letters. Nucleotide duces occasional mutations. 5 - 4 ,  vitro transcription to 
positions discussed in the text (see esp. Example 2) are produce the progeny population of ribozymes, 
FIG. 8 (A-C) illustrates sites at which mutations occurred labeled. 
FIG. 2 (A and B) illustrates the general Procedure for over the course of evolution, superimposed on the secondary 
selective amplification Of catalytic RNA. In FIG. 2A, the 45 structure of the Tetrahymena ribozyme. Box height cone- 
overall procedure for RNA amplification is shown. “RT= sponds to the frequency of mutations (%) at each nucleotide 
reverse transcriptase; “T7 POr’=T7 Polymerase; “Prom”= position, based on 50 subclones sequenced at generations 9 
Promoter, and “RNA’’ represents the enzymatic RNA mol- (G9; FIG. 8A), 18 (G18; FIG. 8B), and 27 (G27; FIG. 8C). 
ecule. 5o Non-mutable primer binding sites are shaded; substrate is 
In FIG. 2B, the procedure for selective amplification shown in black. Commonly-occumng mutations (>30% 
based on phosphoester transfer activity of a group I frequency) are labeled. 
ribozyme is shown. “E’ represents the enzymatic RNA FIGS. 9A and 9B illustrate the improvement in substrate 
molecule; ‘‘S” represents substrate; “ES” represents binding affinity Over 27 successive generations of in vitro 
enzYme/SubStrate complex; and ‘*El’’’ represents enzyme/ 55 evolution. FIG. 9A represents a typical binding curve show- 
product complex. ing data obtained for the G27 population of ribozymes. J and 
FIG. 3 illustrates the secondary structure of the Tetrahy- B indicate data from two different gel-shift experiments. 
menaribozyme (L-21 form) showing those regions that were Data was fit by a least squares method to a theoretical 
randomly mutagenized (boxed segments). binding curve (indicated by solid line), given by the equa- 
FIG. 4 illustrates the course of evolution over 10 succes- 60 tion: y=[EI/([E]+K,), where y is the fraction of product (P) 
sive generation, highlighting changes in RNA population bound to ribozYme (E). In this case, K F 5 1  (*2) m. FIG. 
size over time. Closed circles represent RNApopulation size 9B Shows the KD for the Population of ribozYmeS at every 
after transcription, quantitated by [3H]uracil content; open third generation. F&ndard errors averaged l1%. 
circles represent RNA population size at the start of each FIG. 10 illustrates sites at which mutations occurred over 
generation, based on 20-pmol portions; closed squares rep- 65 the course of evolution, superimposed on the secondary 
resent RNA population size after reaction with substrate, structure of the Tetrahymena ribozyme. Box height cone- 
estimated by the assay described in subsection 4 herein; and sponds to the frequency of mutations (%) at each nucleotide 
[a- P Z  PIGTP-labeled progeny RNA. 
(c) separating the RNA molecule from the diverse Popu- urea gel. In&vidual bands were Cut from the gel and 
In one alternative method, the mutagenizing conditions average of five replicate experiments performed on three 
bars conespond to SD. 
conditions comprise use of site-directed mutagenesis, poly- by type ribozymes and 29 and 23 from genera- 
In various embodiments, the predetermined activity 
BRIEF DESCRIPTION OF THE DRAWINGS 
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position, based on 50 subclones sequenced at generation 36. 
Non-mutable primer binding sites are shaded; substrate is 
shown in black. Commonly-occuning mutations (>30% 
frequency) are labeled (dark bars). 
as a “base sequence” or “nucleotide sequence”, and their 
grammatical equivalents, and is represented herein by a 
formula whose lcft to right orientation is in the conventional 
direction of 5’-terminus to 3’-terminus, unless otherwise 
“Nucleotide analog” generally refers Lo a purine or pyn- 
midine nucleotide that differs structurally from A, T, G, C, 
or U, but is sufficiently similar to substitute for the normal 
A. Dcfinitions nucleotide in a nucleic acid molecule. As used herein, the 
As used herein, the term “ribozyme” is used to describe 10 term “nucleotide analog” encompasses altered bases, differ- 
an RNA-containing nucleic acid that is capable of function- ent sugars, or a combination of thc two. A listing of 
ing as an enzyme. In the present disclosure, the term exemplary analogs wherein the base has been altered is 
“ribozyme” includes endoribonucleases and endodeoxyri- provided in Example 1 ; in Example 2, a nucleotide analog 
bonucleases of the present invention. Another term used including an arabinose sugar is described. 
interchangeably with nbozYme herein is ‘‘enzymatic RNA 15 “Oligonucleotide or polynucleotide” generally refers to a 
molecule”, which should be ~~nderstood to include polymer of single- or double-stranded nucleotides. As used 
ribozymes and enzymatically active portions thereof, herein, “oligonucleotide” and its grammatical equivalents 
whether derived from Tetrahymena or from other organisms will include the full range of nucleic acids. An oligonucle- 
or sources. otide will typically refer to a nucleic acid molecule com- 
The term “enzymatic RNA molecules” includes RNA 20 prised of a linear strand of ribonucleotides. The exact size 
molecules which have complementarity in a substrate-bind- will depend on many factors, which in turn depends on the 
ing region to a specified oligonucleotide target or substrate; ultimate conditions of use, as is well known in the art. 
it also has an enzymatic activity which is active to specifi- As used herein, the term “physiologic conditions” is 
cally cleave the oligonucleotide substrate. Stated in another meant to suggest reaction conditions emulating those found 
fashion, the enzymatic RNA molecule is capable of cleaving 25 in mammalian organisms, particularly humans. While vari- 
the oligonucleotide substrate intermOleCUlarly. This COmple- ables such as temperature, availability of cations, and pH 
mentarity functions to d 0 W  sufficient hybridization Of the ranges may vary as described in greater detail below, “physi- 
enzymatic RNA molecule to the substrate oligonucleotide to ologic conditions’’ generally comprise a temperature of 
allow the intermolecular cleavage of the substrate to OCCUT. about 350-400 C., with 370 C. being particularly preferred, 
While one-hundred Percent (100%) complementarity is Pre- 30 as well as a pH of about 7.0-8.0, with 7.5 being particularly 
f e n d  complementarity in the range of 75-100%3 Or preferred, and further comprise the availability of cations, 
5&100%, is also useful and contemplated by the Present preferably divalent or monovalent cations, in a concentra- 
invention. tion of about 5-15 mM, with a concentration of about 10 
The term “enzymatic nucleic acid” as used herein encom- mM being particularly preferred. “Physiologic conditions”, 
passes enzymatic RNA or DNA molecules, enzymatic RNA- 35 as used herein, may optionally include the presence of 
DNA polymers, and enzymatically active portions or deriva- polyamine or free G,. As noted previously, preferred 
tives thereof, although enzymatic RNA molecules are a conditions are described in greater detail below. 
particularly preferred class of enzymatically active mol- B. Enzymatic Nucleic Acid Molecules 
ecules according to the present invention. Some genes have their coding sequences interrupted by 
The term “endodeoxyribonuclease”, as used herein, is an stretches of non-coding DNA. These non-coding sequences 
enzyme capable of cleaving a substrate comprised Predomi- are generally termed introns. To produce a mature transcript 
nantlY of DNA. The term “endo~bon~clease”~ as used from these genes, the primary RNA transcript (precursor 
herein, is an enzyme capable Of cleaving a substrate COm- RNA) must undergo a cleavage-ligation reaction termed 
prised predominantly. of RNA. 45 RNA splicing. This RNA splicing produces the mature 
As used herein, the term “base pair” (bp) is generally used transcript of the polypeptide coding messenger RNA 
to describe a partnership of adenine (A) with thymine (T) or (mRNA), ribosomal RNA, or transfer RNA (RNA). Introns 
uracil (U), or of cytosine (C) with guanine (G), although it are grouped into four categories (groups I, 11, 111, and IV) 
should be appreciated that less-common analogs of the bases based on their structure and the type of splicing reaction they 
A, T, C, and G may occasionally participate in base pairings. 5o undergo. 
Nucleotides that normally pair up when DNA or RNA RNA molecules capable of cleaving other RNA molecules 
adopts a double stranded Configuration may d S 0  be referred have recently been described. Such RNA-cleaving RNA 
to herein as “complementary bases”. molecules, which may also be referred to as ribozymes or 
“Complementary nucleotide sequence” generally refers to enzymatic RNA molecules, may be chosen from group I, 11, 
a sequence of nucleotides in a single-stranded molecule of 55 111, or IV introns, with group I and I1 introns being of 
DNA or RNA that is sufficiently complementary to that on greatest interest. Other enzymatic RNA molecules of interest 
another single strand to specifically hybridize to it with herein are those formed in ribozyme motifs known in the art 
conscquent hydrogen bonding. as “hammerhead” and “hairpin”. Enzymatic RNA molecules 
‘‘Nucleotide'' generally refers to a monomeric unit of of interest herein also include hepatitis delta virus ribozymes 
DNA or RNA consisting of a sugar moiety (pentose), a 60 and RNaseP or RNaseP-like RNA. 
phosphate group, and a nitrogenous heterocyclic base. The Of particular interest to the present invention are the 
base is linked to the sugar moiety via the glycosidic carbon group I introns. Group I introns undergo an intra-molecular 
(1’ carbon of the pentose) and that combination of base and RNA splicing reaction leading to cyclization that does not 
sugar is a “nucleoside”. When the nucleoside contains a require protein cofactors, Cech, Science 236: 1532-1539 
phosphate group bonded to the 3’ or 5’ position of the 65 (1987). (The disclosures of all references cited within this 
pentose, it is referred to as a nucleotide. A sequence of application are incorporated by reference herein, where 
operatively linked nucleotides is typically referred to herein appropriate.) 
5 specified. 
DETAILED DESCRIPTION OF THE 
INVENTION 
40 
5,580,967 
9 10 
The group I introns, including the intron isolated from the nucleotides 215 to 258, the third spacer region is located at 
large ribosomal RNA precursor of Tetrahymena themzo- nucleotides 259 to 261 and the third stem loop is located at 
phila, catalyze a sequence-specific phosphoester transfer nucleotides 262 to 314. 
reaction involving RNA substrates. Zaug and Cech, Science To date, group I introns have been shown to cleave 
229: 1060-1064 (1985); and Kay and Inoue, Nature 327: 5 substrates comprising either RNA, or an RNA-DNA poly- 
343-346 (1987). This sequence-specific phosphoester trans- mer, with cleavage in the latter occumng at the RNA-DNA 
k r  reaction leads to the removal of the group I intron from ‘Ijunction”. zaug et al., Science 23 1: 470-475 (1986); sug- 
the precursor RNA and to ligation of two exons in a process imoto et al., ~ ~ ~ l ~ i ~  Acids R ~ ~ .  17: 355-371 (1989); and 
known as RNA splicing. The splicing reaction catalyzed by Cech, Science 236: 1532-1539 (1987). A DNA segment 
group I introns Proceeds via a two-step transesterification 10 containing 5 deoxycytosines was shown not to be a cleavage 
mechanism. The details of this reaction have been reviewed substrate for the Tetrahymena IVS, a group I intron, in Zaug 
by Cech, Science 236: 1532-1539 (1987). et al., Science 231: 470-475 (1986). Therefore, the identi- 
The splicing reaction of group I introns is initiated by the fication, enhancement and modification of enzymatic RNA 
binding of guanosine or a guanosine nucleotide to a site molecules capable of cleaving DNA-particularly under 
within the group I intron structure. Attack at the 5’ splice site 15 physiologic conditions, as described herein-is a remark- 
by thc 3’-hydroxyl group of guanosine results in the covalent able and useful development. 
linkage of guanosine to the 5’ end of the intervening intron The term “enzymatic nucleic acid”, as used herein, is used 
sequence. This reaction generates a new 3’-hydroxyl group to describe an RNA- and/or DNA-containing, nucleic acid 
on the uridine at the 3’ terminus of the 5’ exon. The 5’ exon that is capable of functioning as an enzyme. 
subsequently attacks the 3’ splice site, yielding spliced exons 20 The term ribozyme is used to describe an RNA-containing 
nucleic acid that is capable of functioning as an enzymc. As and the full-length linear form of the group I intron. 
The linear group I intron Usually cyclizes following used herein, the term “ribozyme” may be used interchange- 
Splicing. CyCliZatiOn occurs via a third transesterification ably with “enzymatic RNA molecules”. Both terms encom- 
reaction, involving attack of the 3’-terminal guanosine at an pass endoribonucleases and endodeoxyribonucleases of the 
interval site near the 5’ end of the intron. The group I introns 25 present invention. 
also undergo a sequence-specific hydrolysis reaction at the An enzymatic RNA molecule of the present invention 
splice site sequences as described by Inoue et al., J. Mol. from a wild-type, RNA. B i d .  189: 143-165 (1986). This activity has been used to which tend to generate &her 
cleave RNA substrates in a sequence-specific manner by 3o 
Zaug et al., Nature 324: 429-433 (1986). ods useful in generating enzymatic RNA molecules that 
The structure of group I introns has been reviewed by J. include mutations not normally found in wild-type 
Burke, Gene 73: 273-294 (1988). The structure is charac- ribozymes include PCR (polymerase chain reaction), 3SR 
t e r h d  by nine base Paired regions, h m e d  p1-p9. (See, (self-sustained sequence replication), and site-directed 
e.g., Burke et al., Nucleic Acids Res. 15: 7217-7221 (1987).) 35 mutagenesis. 
The folded structure of the intron is clearly important for the preferably, enzymatic RNA molecules produced as dis- 
catalytic activity of the group I introns, as evidenced by the closed herein are capable of cleaving a DNA substrate, J~ 
loss of catalytic activity under conditions where the intron is one preferred embodiment, the DNA subs&ate is single- 
denatured. In addition, mutations that disrupt essential base- although enzymatic RNA molecules capable of 
paired regions of the group I introns result in a loss of ,.leaving  loop^, RNA and DNA (i,e,, nucleic acids found in 
catalytic activity. Burke, Gene 73: 273-294 (1988). Corn- 40 Stem loops and the like) and double-strmded DNA are also 
pensatory mutations or second-site mutations that restore contemplated, In another preferred variation, an enzymatic 
base-pairing in these regions also restore catalytic activity. RNA molecule of the present invention is able to cleave 
Williamson et al., J. Biol. Chem. 262: 14672-14682 (1987); DNA under physiologic conditions, Many enzymatic RNA 
and Burke, Gene 73: 273-294 (1988). 
45 molecules of the present invention are also capable of 
Several different deletions that remove a large nucleotide cleaving a single-stranded RNA substrate or a modified 
segment from the SOUP I introns (FIG. 1) without destroy- DNA substrate containing a uracil at the cleavage site rather 
ing its ability to cleave RNA have been reported. Burke, than a thymine, whereas various enzymatic RNA molecules 
Gene 73: 273-294 (1988). However, attempts to combine show a marked preference for DNA as the substrate of 
large deletions have resulted in both active and inactive 5o choice, 
introns. Joyce et al., Nucleic Acid Res. 17: 7879 (1989). An enzymatic RNA molecule of the present invention 
FIG. 1 illustrates the secondary structure of the Tetrahy- may comprise RNA, modified RNA, RNA-DNA polymer, a 
menu themophila pre-rRNA intron, with the recognition modified RNA-DNA polymer, a modified DNA-RNA poly- 
sequence and the core structure that is the most conserved mer or a modified RNA-modified DNA polymer. RNA 
region among group I introns shown in bold. The mmen- 55 contains nucleotides comprising a ribose sugar and adenine, 
clature used to denote various structural features is the guanine, uracil or cytosine as the base at the 1’ position. 
standard nomenclature (see, e.g., Burke et d., Nucleic Acids Modified RNA contains nucleotides comprising a ribose 
Pes. 15:7217-7221 (1987). The nine conserved pairing sugar and adenine, thymine, guanine or cytosine and option- 
regions, Pl-P9, and the various loops are shown. The ally uracil as the base. An RNA-DNA polymer contains 
nucleotide sequence is numbered beginning at the 5’ termi- 60 nucleotides containing a ribose sugar and nucleotides con- 
nus of the molecule. taining deoxyribose sugar and adenine, thymine andlor 
As illustrated in FIG. 1, the recognition site is located at uracil, guanine or cytosine as the base attached to the 1‘ 
nucleotide 19 to 27, the first spacer region is located at carbon of the sugar. A modified RNA-DNA polymer is 
nucleotides 27 to 28 and 94 to 95, the P3[5’] region is located comprised of modified RNA, DNA and optionally RNA (as 
at nucleotides 96 to 103, the second spacer region is located 65 distinguished from modified RNA). Modified DNA contains 
at nucleotides 104 to 106, the first stem loop is located at nucleotides containing a deoxyribose sugar and nucleotides 
nucleotides 107 to 214, the second stem loop is located at containing adenine, uracil, guanine, cytosine and possibly 
may be engineered or 
cleaving ribozyme via 
or ~~non-random,7 mutations. Examples of 
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thymine as the base. A modified DNA-RNA polymer con- 
tains modified DNA, RNA and optionally DNA. A modified 
RNA-modified DNA polymer contains modified RNA- 
modified DNA, and optionally RNA and DNA. 
An enzymatic RNA molecule of the present invention is 
capable of cleaving DNA 3' of a predetermined base 
sequence. An enzymatic RNA molecule of this invention 
may also be characterized by a nucleotide sequence defining 
a recognition site that is contiguous or adjacent to the 5' 
terminus of the nucleotide sequence, a first spacer region 
located 3'-terminal to the recognition site, a P3[5'] region 
located 3'-terminal to the first spacer region, a second spacer 
region located 3'-terminal to the P3[5'] region, a first stem 
loop located 3'-terminal to the second spacer region, a 
second stem loop located 3'-terminal to the first stem loop, 
a third spacer region located 3-'terminal to the second stem 
loop, and a third stem loop located 3'-terminal to the third 
spacer region, the third stem loop comprising a 5' stem 
portion defining a P3[3'] region capable of hybridizing to the 
P3[5'] region. 
It is also to be understood that an enzymatic RNA 
molecule of the present invention may comprise enzymati- 
cally active portions of a ribozyme or may comprise a 
ribozyme with one or more mutations, e.g., with one or more 
loops or spacers absent or modified, as long as such dele- 
tions, additions or modifications do not adversely impact the 
molecule's ability to perform as an enzyme. 
The recognition site of an enzymatic RNA molecule of the 
present invention typically contains a sequence of at least 2 
to about 8 bases, preferably about 4 to about 7 bases, which 
are capable of hybridizing to a complementary sequence of 
bases within the substrate nucleic acid giving the enzymatic 
RNA molecule its high sequence specificity. For example, an 
enzymatic RNA molecule of the present invention con- 
structed with a recognition site base sequence of 3'-GG- 
GAGG-5' was able to recognize the base sequence 
5'-CCCTCT-3' present within a single-stranded DNA sub- 
strate and to cleave same (see, e.g., Example 1). Similarly, 
an enzymatic RNA molecule with a recognition sequence of 
3'-UCGCCG-5' was used to cleave the target sequence 
This same recognition site also allows the enzymatic RNA 
,molecule to cleave modified DNA substrates with high 
sequence specificity. Modification or mutation of the recog- 
nition site via well-known methods allows one to alter the 
sequence specificity of an enzymatic nucleic acid molecule. 
For example, the method described by Joyce et al., 
Nucleic Acids Research, 17:711-712 (1989), involves exci- 
sion of template (coding) strand of double-stranded DNA, 
reconstruction of the template strand with inclusion of 
mutagenic oligonucleotides, and subsequent transcription of 
the partially-mismatched template. This allows the introduc- 
tion of defined or random mutations at any position in the 
molecule by including polynucleotides containing known or 
random nucleotide sequences at selected positions. In 
another example, mutations may be introduced into the 
cndodeoxyribonuclease by substituting 5-Br dUTP for 1Tp 
in the reverse transcription reaction. 5-Br dU can pair with 
dG in the "wobble" position as well as dA in the standard 
Watson-Crick position, leading to A to G and G to A 
transitions. Similarly, substituting 5-Br UTP for UTP in the 
forward transcription reaction would lead to C to U and U 
to C transitions in the subsequent round of RNA synthesis. 
Enzymatic nucleic acid molecules of the present invention 
include those with altered recognition sites. In various 
embodiments, these altered recognition sites confer unique 
5'-AGCGGT-3'. 
12 
sequence specificities on the enzymatic nucleic acid mol- 
ecule including such recognition sites. 
The exact bases present in the recognition site determine 
the base sequence at which cleavage will take place. Cleav- 
age of the substrate nucleic acid occurs immediately 3' of the 
substrate cleavage sequence, the substrate nucleotide 
sequence that hybridizes to the recognition site. This cleav- 
age leaves a 3' hydroxyl group on the substrate cleavage 
sequence and a 5' phosphate on the nucleotide that was 
originally immediately 3' of the substrate cleavage sequence 
in the original substrate. Cleavage can be redirected to a site 
of choice by changing the bases present in the recognition 
sequence (internal guide sequence). See Murphy et al., Proc. 
Natl. Acad. Sci. USA 86: 9218-9222 (1989). 
Moreover, any combination of bases may be present in the 
recognition site if a polyamine is present. See, for example, 
Doudna et al., Nature 339: 519-522 (1989). Examples of 
useful polyamines include spermidine, putrescine or sper- 
mine. A spermidine concentration of about 5 mM was shown 
20 to be effective in particular embodiments, as further 
described hereinbelow, although concentrations ranging 
from about 0.1 mh4 to about 10 mh4 may also be useful. 
The recognition site may also be provided as a separate 
nucleic acid, an external recognition site not covalently 
25 coupled to the rest of the endodeoxynuclease. External 
recognition sites may direct endoribonuclease cleavage at a 
specific base sequence (see, e.g., Doudna et al., Nature 339: 
519-522 (1989)). If an external recognition site is used, the 
enzymatic RNA molecule used with it would probably not 
30 contain a recognition site but would tend to comprise a 
P3[5'] region, a second spacer region, a first stem loop, a 
second stem loop, a third spacer region and a third stem loop 
where the third stem loop comprises a 5' stem portion 
defining a P3[3'] region capable of hybridizing to said P3[5'] 
Use of an enzymatic RNA molecule of the present inven- 
tion with an external recognition site allows the target 
sequence to be altered by merely changing the external 
recognition site sequence. Use of a plurality of different 
40 external recognition sequences with an enzymatic RNA 
molecule of the present invention allows the substrate 
nucleic acid to be cleaved at each of the different base 
sequences encoded by the external recognition sequences. 
First spacer regions typically contain a sequence of nucle- 
45 otides of about 3 to 7, preferably about 5,  bases in length. In 
one variation, the nucleotides making up the first spacer 
have the sequence 5'-NNNNA-3' (SEQ ID NO I), where N 
represents the presence of any nucleotide at that position. In 
another variation, the first spacer region is defined by the 
sequence 5'-AACAA-3' (SEQ ID NO 2). 
In other embodiments, the first spacer region is comprised 
of a nucleotide sequence defining two spacer stem loops. In 
one variation, the first spacer stem loop is 25 nucleotides in 
55 length, and the second spacer stem loop is 36 bases in length. 
In another variation, the first spacer stem loop has the base 
GUAGUCA-3, (SEQ ID NO 3), and the second spacer stem 
loop has the base sequence 5'-GUCUUUAAACCAAUA- 
GAUUGGAUCGGUUU-AAAAGGC-3, (SEQ ID NO 4). 
As noted previously, the foregoing descriptions of loop 
and spacer regions is exemplary and is not to be construed 
as limiting the disclosed invention(s). 
A stem loop is a secondary structure formed by a nucle- 
65 otide sequence that has "folded over on itself '. A stem loop 
comprises a 5' nucleotide sequence portion, designated a 5' 
paring segment (P[5']) that is capable of hybridizing to a 
5 
35 region. 
sequence 5'-AGUUACCAGGCAUGCACCUG- 
6o 
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nucleotide sequence located 3' of the P[5'] and is designated 
the 3' pairing segment (P[3']). In a stem loop, the P[5'] and 
P[3'] are connected by a nucleotide sequence called a loop. 
The P[5'] and P[3'] hybridize and form a nucleic acid duplex. 
The nucleic acid duplex formed by the P[5'] and P[3'] does 
not have to be a perfect duplex and may contain stretches of 
nucleotides that are either unpaired or paired to a sequence 
outside the stem loop. 
In various alternative embodiments, an enzymatic RNA 
molecule of the present invention has an enhanced or 
optimized ability to cleave nucleic acid substrates, prefer- 
ably DNA substrates. 
As those of skill in the art will appreciate, the rate of an 
enzyme-catalyzed reaction varies depending upon the sub- 
strate and enzyme concentrations and, in general, levels off 
at high substrate or enzyme concentrations. Taking such 
effects into account, the kinetics of an enzyme-catalyzed 
reaction may be described in the following terms, which 
define the reaction. 
The enhanced or optimized ability of an enzymatic RNA 
molecule of the present invention to cleave a DNA substrate 
may be determined in a cleavage reaction with varying 
amounts of labeled DNA substrate in the presence of enzy- 
matic RNA molecule as described in Examples 1 and 2. The 
ability to cleave the substrate is generally defined by the 
catalytic rate (k,,,) divided by the Michaelis constant (KM).  
The symbol k,, represents the maximal velocity of an 
enzyme reaction when the substrate approaches a saturation 
value. K, represents the substrate concentration at which 
the reaction rate is one-half maximal. Values for K, and k,,, 
are determined in this invention by experiments in which the 
substrate concentration [SI is in excess over enzymatic RNA 
molecule concentration [E]. Initial rates of reaction (v,) over 
a range of substrate concentrations were estimated from the 
initial linear phase, generally the first 5% or less of the 
reaction. Typically eight data points were fit by a least 
squares method to a theoretical line given by the equation: 
v=-K&vJ[S])+Vma,. Thus, k,, and K, were determined 
by the initial rate of reaction, v,, and the DNA substrate 
concentration [SI. 
In various alternative embodiments, an enzymatic RNA 
molecule of the present invention has an enhanced or 
optimized ability to cleave nucleic acid substrates, prefer- 
ably DNA substrates. In preferred embodiments, the 
enhanced or optimized ability of an enzymatic RNA mol- 
ecule to cleave DNA substrates shows about a 10- to 
1 09-fold improvement. In more preferred embodiments, an 
enzymatic RNA molecule of the present invention is able to 
cleave DNA substrates at a rate that is about lo3- to IO7-fold 
better than wild type enzymes. In even more preferred 
embodiments, the enhanced or optimized ability to cleave 
DNA substrates is expressed as a lo4- to 106-fold improve- 
ment over the wild type. One skilled in the art will appreciate 
that the enhanced or optimized ability of an enzymatic RNA 
molecule to cleave nucleic acid substrates may vary depend- 
ing upon the selection constraints applied during the in vitro 
evolution procedure of the invention. 
Enzymatic RNA molecules of the present invention may 
also be characterized as displaying a K, value that is 
improved at least two-fold over the wild type. As noted 
above, K, represents the substrate concentration at which 
the reaction rate is one-half maximal; thus, an improved K, 
indicates an improvement in substrate processing. In various 
embodiments, enzymatic RNA molecules of the present 
invention have a KM that is 10- to 20-fold better than that of 
the wild type. In still other embodiments, enzymatic RNA 
5 
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molecules of the present invention have a K, that is 30- to 
40-fold improved over the wild type. In various other 
embodiments, enzymatic RNA molecules of the present 
invention have a K, that is 40- to 50-fold improved over the 
wild type. 
One skilled in the art will understand that the enhanced or 
optimized ability of an enzymatic RNA molecule to process 
nucleic acid (e.g. DNA) substrates may vary depending 
upon the selection constraints applied during thc in vitro 
evolution procedure of the invention and may include a 
reduction of the DNA concentration to favor enzymatic 
RNA molecules with improved substrate processing ability. 
In other embodiments, an enzymatic RNA molecule of the 
present invention has an enhanced or optimized ability to 
bind a nucleic acid substrate. The ability of an enzymatic 
RNA molecule to bind a DNA substrate is defined by the 
dissociation constant (K,). The K, is an equilibrium con- 
stant describing the dissociation of the enzymatic RNA 
mo1ecule:substrate complex into its individual components. 
The K, constant as understood in the context of this 
invention is determined by a gel shift analysis to detemiine 
the percent enzymatic RNA molecule bound to the DNA 
product, as described in Example 2. A binding curve is 
generated by plotting the percent of product bound to 
enzymatic RNA molecule over a range of enzymatic RNA 
molecule concentration. The K, is determined by fitting the 
data to a theoretical binding curve using the least squares 
method. Typically, the enzymatic RNA molecule concentra- 
tion [E] vastly exceeds the product; therefore, the theoretical 
binding curve can be represented by the equation: % bound= 
[E]/([E]+K,), where K,=[E] when half of the total product 
is bound to the enzymatic RNA molecule. 
An enzymatic RNA molecule of the present invention 
preferably binds nucleic acid substrate with a K, which is an 
improvement over wild type ribozymes. For example, an 
enzymatic RNA molecule of the present invention prefer- 
ably binds DNA with a K, having a value less than 30 pM. 
In preferred embodiments, enzymatic RNA molecules bind 
DNA with a K, having a value less than about 10 pM. In 
more preferred embodiments, the K, of a DNA-binding 
enzymatic RNA molecule is less than about 1 pM. In an even 
more preferred embodiment, the K, of a DNA-binding 
enzymatic RNA molecule is less than about 50 nM, more 
preferably less than about 25 nM, and even more preferably 
less than about 10 nM. Especially preferred enzymatic RNA 
molecules bind DNA substrate with a K, of 5 nM or less, 
e.g., with a K, of about 0.1-5 nM. 
Alternatively, the enhanced or optimized ability of an 
enzymatic RNA molecule to bind DNA substrates may be 
expressed as a five-fold or greater improvement over the 
wild type. In various embodiments, the enhanced or opti- 
mized ability of an enzymatic RNA molecule to bind DNA 
substrates comprises a 10- to 102-fold improvement. In other 
embodiments, the enhanced or optimized ability of an enzy- 
matic RNA molecule to bind DNA substrates may be 
expressed as a 10'- to 103-fold improvement over the wild 
type. In still other embodiments, binding (Le. K,) of enzy- 
matic RNA molecules of the present invention is lo4-fold 
improved over the wild type, or better. One skilled in the art 
will understand that the enhanced or optimized ability of an 
enzymatic RNA molecule to bind DNA substrates may vary 
depending upon the selection constraints applied during the 
in vitro evolution procedure of the invention and may 
include a reduction of the DNA concentration to favor 
enzymatic RNA molecules with improved substrate binding 
affinity. 
In other preferred embodiments, enzymatic RNA mol- 
ecules of the present invention preferably bind RNA sub- 
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strate with a K, which is an improvement over wild type monovalent cations are present in a concentration ranging 
ribozymes. For example, an enzymatic RNAmolecule of the from about 2-100 mM. Alternatively, the concentration of 
present invention preferably binds RNA with a K, having a monovalent cations ranges from about 2 mM-50 mM. In 
value less than 1.5 nM. In preferred embodiments, enzy- other embodiments, the concentration ranges from about 2 
matic RNA molecules bind RNA with a K, having a value mM-25 mM, with a concentration of about 2 mM-15 mM 
less than about 1.0 nM. In even more preferred embodi- being preferred. 
ments, enzymatic RNA molecules of the present invention In various embodiments, an enzymatic RNA molecule of 
bind RNA with a K, of about 0.5 nM or less. the present invention optionally includes a 3’ hydroxyl of G 
In another variation, an enzymatic RNA molecule of the (Le. guanosine, or one of its 5’-phosphorylated forms), 
present invention has an enhanced or optimized substrate io which functions as a nucleophilc-i.e., it “attacks” substrate 
turnover rate. The enhanced or optimized substrate turnover molecules, usually at a phosphodiester bond. For example, 
rate may be determined in single-turnover kinetic experi- in the L-21 ribozyme derived from the group I intron of 
ments with the enzymatic RNA molecule in excess of the Tetrahymena themophila, the G264-C3 11 base pair-which 
substrate as described in Example 2. Initial rates (kobs) were is known as the “G-site”-binds the G substrate. (See, e.g., 
obtained using no more than the first 5% of the reaction. 15 Wang and Cech, Science 256: 526-529 (1992).) 
Given that k,,,/Kek,,J[E], each k, value, obtained at Alternatively, in other embodiments, wherein an enzy- 
different enzymatic RNA molecule concentrations, provided matic RNA molecule of the present invention lacks a 3’ 
an estimate of kCa!K,w Generally, eight Or more measure- terminal Go,, the Go, may be supplied as a free (i.e., 
merits of k c a / K ~  Were o b h h d .  The value of kcat in the unattached) attacking group. In such embodiments, an enzy- 
presence of limited substrate indicates the substrate turnover 20 matic RNA molecule is able to ‘‘attack” multiple substrates 
number rate and is expressed in the number of catalytic in sequential fashion. In either case, the term “enzymatic 
cycles that are completed by the enzyme Per unit of time RNA molecules” as used in the present disclosure includes 
under the assay conditions. enzymatic RNA molecule including, as well as those lack- 
Alternatively, the enhanced or optimized substrate turn- ing, a 3’ Gow 
over rate of an enzymatic RNA moleculc may be described 25 In various embodiments, an enzymatic RNA molecule of 
as being improved about 2-fold over the wild type. In other the present invention may combine one or more modifica- 
embodiments, the enhanced or optimized substrate turnover tions or mutations including additions, deletions, and sub- 
rate of an enzymatic RNA ~-1101ecule Shows at least a 5- to stitutions. In alternative embodiments, such mutations or 
25-fold improvement Over the wild type. In Still other modifications may be generated using methods which pro- 
embodiments, the enhanced or optimized substrate turnover 30 duce random or specific mutations or modifications. These 
rate of an enzymatic RNAmolecule ofthe Present invention mutations may change the length of, or alter the nucleotide 
is about 3CUo times greater than that of the wild type. In sequence of, a stem loop, the P3[5’], the P3[3’]region, a 
preferred embodiments, the substrate turnover rate is at least spacer region or the recognition sequence. One or more 
about 50 times greater than in the wild type. One skilled in mutations within one catalytically active enzymatic RNA 
the art will understand that the enhanced or optimized 35 molecule may be combined with the mutation(s) within a 
substrate turnover rate of an enzymatic RNA molecule of the second catalytically active enzymatic RNA molecule to 
present invention may vary depending upon the selection produce a new enzymatic RNA molecule containing the 
constraints applied during the in vitro evolution procedure of mutations of both molecules. 
the invention and may include a reduction of the reaction In other preferred embodiments, an enzymatic RNA mol- 
mutations introduced into it using a variety of methods well substrate turnover rates. 
In other embodiments, an enzymatic RNA molecule of the known to those skilled in the art. For example, the method 
present invention is capable of functioning efficiently over a described by Joyce et al., Nucleic Acids Res. 17: 711-712 
wide range of temperatures. In yet another variation, an (1989), involves excision of a template (coding) strand of a 
enzymatic RNA molecule of the present invention iS capable 45 double-stranded DNA, reconstruction of the template strand 
of functioning efficiently over a wide range of pH. with inclusion of mutagenic oligonucleotides, and subse- 
In various alternative embodiments, an enzymatic RNA quent transcription of the partially-mismatched template. 
molecule of the present invention is capable of functioning This allows the introduction of defined or random mutations 
efficiently with or without added polyamine. In another 5o at any position in the molecule by including polynucleotides 
variation, an enzymatic RNA molecule of the present inven- containing known or random nucleotide sequences at 
tion is capable of functioning efficiently in the presence or selected positions. 
absence of Mg2+. Alternatively, mutations may be introduced into an enzy- 
Alternatively, an enzymatic RNA molecule of the present matic RNA molecule by substituting 5-Br dUTP for TTP in 
invention is capable of functioning efficiently in the pres- 55 the reverse transcription reaction. 5-Br dU can pair with dG 
ence or absence of divalent cations other than Mg2+. Other in the “wobble” position as well as dA in the standard 
suitable divalent cations may be selected from the group Watson-Crick position, leading to A -+ G and G + A 
comprised of Mn”, Zn2’, or Ca”. It is anticipated that transitions. Similarly, substituting 5-Br UTP for UTP in the 
cation concentrations similar to those described above for forward transcription reaction would lead to C -+ U and U 
Mg2+ will be useful as disclosed herein. 60 + C transitions in the subsequent round of RNA synthesis, 
Optionally, monovalent cations may also be present as as d e ~ r i b e d  above. 
“alternatives” for the use of divalent cations. For example, Enzymatic RNA molecules of the present invention may 
monovalent cations such as sodium (Na+) or potassium (K+) be of varying lengths and folding patterns, as appropriate, 
may be present, either as dissociated ions or in the form of depending on the type and function of the molecule. For 
dissociable compounds such as NaCl or KCl. In one embodi- 65 example, enzymatic RNA molecules derived from group I 
ment, a monovalent cation is present in a concentration introns (e.g., Tetrahymena-derived ribozymes) may be about 
ranging from about 0-200 mM. In other embodiments, 413 or more nucleotides in length, although a length not 
time t’ favor enzymatic RNA molecules with improved 40 ecule of the present invention may have random or defined 
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exceeding 413 nucleotides is preferred, to avoid limiting the 
therapeutic usefulness of molecules by making them too 
large or unwieldy. In various thcrapeutic applications, enzy- 
matic RNA molecules of the present invention comprise the 
enzymatically active portions of ribozymes. In various 
embodiments, enzymatic RNA molecules of the present 
invention comprise fewer than 400 nucleotides, fewer than 
300 nucleotides, fewer than 200 nucleotides, or fewer than 
100 nucleotides. 
In other therapeutic applications, enzymatic RNA mol- 
ecules such as "hammerhead" ribozymes are preferably no 
more than about 50 nucleotides in length, with a length of 
30-40 nucleotides being particularly preferred. Even more 
preferred are hammerhead ribozymes of about 31-36 nucle- 
otides in length. 
Moreover, if one intends to synthesize molecules for use 
as disclosed herein, the larger the enzymatic nucleic acid 
molecule is, the more difficult it is to synthesize. Those of 
skill in the art will certainly appreciate these design con- 
straints. 
Various preferred methods of modifying ribozymes and 
other enzymatic RNA molecules, ribonucleases, and deox- 
yribonucleases of the present invention are further described 
in Examples 1 - 4  hereinbelow. 
C. Methods of Cleaving Nucleic Acid Molecules 
The present invention also describes useful methods for 
cleaving any single-stranded, looped, partially or fully 
double-stranded nucleic acid; the majority of these methods 
employ the novel enzymatically active nucleic acid mol- 
ecules of the present invention. In various embodiments, the 
single-stranded nucleic acid substrate comprises single- 
stranded DNA, modified DNA, RNA and modified RNA. 
The nucleic acid substrate must only be single-stranded at or 
near the substrate cleavage sequence so that an enzymatic 
nucleic acid molecule of the present invention can hybridize 
to the substrate cleavage sequence by virtue of the enzyme's 
recognition sequence. 
A nucleic acid substrate that can be cleaved by a method 
of this invention may be chemically synthesized or enzy- 
matically produced, or it may be isolated from various 
sources such as phages, viruses, prokaryotic cells, or eukary- 
otic cells, including animal cells, plant cells, eukaryotic 
cells, yeast cells and bacterial cells. Chemically synthesized 
single-stranded nucleic acids are commercially available 
from many sources including, without limitation, Research 
Genetics (Huntsville, Ala.). 
DNA substrates may also be synthesized using an Applied 
Biosystems (Foster City, Calif.) oligonucleotide synthesizer 
according to the manufacture's instructions. Single-stranded 
phages such as the M13 cloning vectors described by 
Messing et al., PNAS USA 74: 3642-3646 (1977), and 
Yanisch-Perron et al., Gene 33: 103-119 (1985) are also 
sources of DNA substrates. Bacterial cells containing single- 
stranded phages would also be a ready source of suitable 
single-stranded DNA. Viruses that are either single-stranded 
DNA viruses such as the parvoviruses or are partially 
single-stranded DNA viruses such as the hepatitis virus 
would provide single-stranded DNA that could be cleaved 
by a method of the present invention. 
Single-stranded RNA cleavable by a method of the 
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The methods of this invention may be used on single- 
stranded nucleic acids or single-stranded portions of double- 
stranded DNA (dsDNA) that are present inside a cell, 
including eucaryotic, procaryotic, plant, animal, yeast or 
5 bacterial cells. Under these conditions an enzymatic nucleic 
acid molecule (e.g., an enzymatic RNA molecule or 
ribozyme) of the present invention could act as an anti-viral 
agent or a regulator of gene expression. Examples of such 
uses of enzymatic RNA molecules of the present invention 
are described in subsection F hereinbelow. 
In the majority of methods of the present invention, 
cleavage of single-stranded DNA occurs at the 3'-terminus 
of a predetermined base sequence. This predetermined base 
sequence or substrate cleavage sequence typically contains 
from about 2 to about 10 nucleotides. In a preferred varia- 
l5 tion, the predetermined base or substrate cleavage sequence 
comprises about 2 to about 6 nucleotides. In other preferred 
embodiments, an enzymatic RNA molecule of the present 
invention is able to recognize nucleotides either upstream, or 
upstream and downstream of the cleavage site. In various 
20 embodiments, an enzymatic RNA molecule is able to rec- 
ognize about 2-10 nucleotides upstream of the cleavage site; 
in other embodiments, an enzymatic RNA molecule is able 
to recognize about 2-10 nucleotides upstream and about 
2-10 nucleotides downstream of the cleavage site. Other 
25 preferred embodiments contemplate an enzymatic RNA 
molecule that is capable of recognizing a nucleotide 
sequence up to about 30 nucleotides in length, with a length 
up to about 20 nucleotides being preferred. 
The within-disclosed methods allow cleavage at any 
30 nucleotide sequence by altering the nucleotide sequence of 
the recognition site of the enzymatic RNA molecule. This 
allows cleavage of single-stranded DNA in the absence of a 
restriction endonuclease site at that position. 
Cleavage at the 3'-terminus of a predetermined base 
sequence produces a single-stranded DNA containing the 
substrate cleavage sequence, with a 3'-terminal hydroxyl 
group. In addition, the cleavage joins the remainder of the 
original single-stranded DNA substrate with the enzymatic 
4o RNA molecule. This cleavage reaction and products pro- 
duced from this cleavage reaction are analogous to the 
cleavage reaction and cleavage products produced by the 
Tetrahymena ribozyme described by Zaug and Cech, Sci- 
ence 231: 470-475 (1986). 
An enzymatic RNA molecule of the present invention 
may be separated from the remainder of the single-stranded 
DNA substrate by site-specific hydrolysis at the phosphodi- 
ester bond following the 3'-terminal guanosine of the enzy- 
matic RNA molecule, similar to the site-specific cleavage at 
50 this position described for the ribozyme acting on RNA by 
Inoue et al., J.  Mol. Biol. 189: 143-165 (1986). Separation 
of the enzymatic RNA molecule from the substrate allows 
the enzymatic RNA molecule to carry out another cleavage 
reaction. 
Generally, the nucleic acid substrate is treated under 
appropriate nucleic acid cleaving conditions-preferably, 
physiologic conditions-with an effective amount of an 
enzymatic RNA molecule of the present invention. If the 
nucleic acid substrate comprises DNA, preferably, cleaving 
60 conditions include the presence of MgC1, at a concentration 
of about 2-100 mM. Typically, the DNA cleaving conditions 
35 
45 
55 
present invention could be provided by  any of the RNA include MgC1, at a concentration of about 2 d t o  about 50 
viruses such as the picornaviruses, togaviruses, orthomyx- mM. Preferably, MgC1, is present at a concentration of about 
oviruses, paramyxoviruses, rhabdoviruses, coronaviruses, 5 mM to about 25 mM. More preferably, MgCl, is present 
arenaviruses or retroviruses. As noted previously, a wide 65 at a concentration of about 5 mM to about 15 mM, with a 
variety of prokaryotic and eukaryotic cells may also be concentration of magnesium ion of about 10 mM being 
excellent sources of suitable nucleic acid substrates. particularly preferred. 
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An effective amount of an enzymatic RNA molecule is the In various other methods, the present invention contem- 
amount required to cleave a predetermined base sequence plates DNA cleaving conditions including the presence of a 
present within the single-stranded DNA. Preferably, the polyamine. Polyamines useful for practicing the present 
enzymatic RNA molecule is present at a molar ratio of RNA invention include spermidine, putrescine, spermine and the 
molecule to substrate cleavage sites of 1 to 20. This ratio 5 like. In one preferred variation, the polyamine is spermidine 
may vary depending on the length of treating and efficiency and it is present at a concentration of about 0.01 mM to 
of the particular enzymatic RNA molecule under the par- about 15 mM. In another variation, the polyamine is present 
ticular DNA cleavage conditions employed. at a concentration of about 1 mM to about 10 mM. DNA 
Treating typically involves admixing, in aqueous solution, cleavage conditions may also include the Presence of 
the DNA-containing substrate, the enzyme and the MgCl, to 10 Polyamine at acOncentration of about 2 mM to about 5 mM. 
form a DNA cleavage admixture, and then maintaining the In ~ ~ o u s  preferred embodiments, the polyamine is sper- 
admixture thus formed under DNA cleaving conditions for midine. 
a time period sufficient for the enzymatic RNA molecule to D. Methods of Mutagenizing Enzymatic RNA Molecules 
cleave the DNA substrate at any of the predetermined The present invention also contemplates methods of pro- 
nucleotide sequences present in the DNA. 15 ducing nucleic acid molecules having a predetermined activ- 
In one embodiment of the present invention, the amount ity. In one preferred embodiment, the nucleic acid molecule 
of time necessary for the enzymatic RNA molecule to cleave is an enzymatic RNA molecule. In another variation, the 
the single-stranded DNA has been predetermined. The desired activity is a catalytic activity. 
amount of time is from about 5 minutes to about 24 hours In one embodiment, the present invention contemplates 
and Will Vary depending upon the COncentration of the 20 methods of synthesizing enzymatic RNA molecules which 
reactants, and the temperature of the reaction. Usually, this may then be "engineered" to catalyze a specific or prede- 
time period is from about 30 minutes to about 4 hours such termined reaction. Methods of preparing enzymatic RNA 
that the enzymatic RNA molecule c l~aves the single- molecules are described herein; see, e.g., Examples 1 , 2  and 
stranded DNA at of the Predetermined nucleotide 4 hereinbelow. In other embodiments, an enzymatic RNA 
sequences present. 2s molecule of the present invention may be engineered to bind 
The invention further contemplates that the DNA cleaving small molecules or ligands, such as adenosine triphosphate 
conditions include the presence of MgCl, at a concentration (ATP). (See, e.g., Sassanfar, et al., Nature 364: 550-553 
of about 2-100 mM. Typically, the DNA cleaving conditions (1993).) 
include MgCl, at a concentration of about 2 mM to about 50 In another embodiment, the present invention contem- 
mM. Preferably, MgC1, is Present at a COncentration of about 30 plates that a population of enzymatic RNA molecules may 
5 mM to about 25 mM. More Preferably, MgC1, is Present be subjected to mutagenizing conditions to produce a 
at a Concentration of about 5 mM to about 15 mM, with a diverse population of mutant enzymatic RNA molecules or 
COr~centration of about 10 being Particularly Preferred. ribozymes. Thereafter, enzymatic RNA molecules having 
The optimal MgCl, concentration to include in the DNA desired characteristics are selected andor separated from the 
cleaving conditions can be easily determined by determining 35 population. 
the amount of single-stranded DNA cleaved at a given Alternatively, mutations may be introduced in the enzy- 
MgCl, concentration. One skilled in the art will understand matic RNA molecule by altering the length of the recogni- 
that the optimal MgCb concentration may Vary depending tion site (internal guide sequence) of the enzymatic RNA 
on the particular enzymatic RNA molecule employed. 4o molecule. The recognition site of the enzymatic RNA mol- 
The present invention further contemplates that the DNA ecule hybridizes with a complementary sequence of bases 
cleaving conditions are at from about pH 6.0 to about pH within the substrate nucleic acid sequence. Methods of 
9.0. In one preferred embodiment, the pH ranges from about altering the length of the recognition site are known in the 
pH 6.5 to pH 8.0. In another preferred embodiment, the pH art and include PCR, for example; useful techniques are 
emulates physiological conditions, i.e., the pH is about 45 described further in the Examples. 
7.0-7.8, with a pH of about 7.5 being particularly preferred. Alteration of the length of the recognition site of the 
One skilled in the art will appreciate that the methods of enzymatic RNA molecule which retains the ability to 
the present invention will work over a wide pH range so long hybridize with the complementary sequence of bases within 
as the pH used for DNA cleaving is such that the enzymatic the substrate nucleic acid sequence may have a desirable 
RNA molecule is able to remain in an active conformation. 50 effect on the binding specificity of the enzymatic RNA 
An enzymatic RNA molecule in an active conformation is molecule. For example, an increase in the length of the 
easily detected by its ability to cleave single-stranded DNA recognition site may increase binding specificity between 
at a predetermined nucleotide sequence. the enzymatic RNA molecule and the complementary base 
embodiments, the DNA cleaving conditions sequences Of the nucleic acid. In addition, an increase in the 
also include a variety of temperature ranges; as noted 55 length of the recognition site may also increase the affinity 
previously, temperature ranges consistent with physiological with which it binds to the nucleic acid substrate. In various 
conditions are especially preferred, In one embodiment, the embodiments, these altered recognition sites in the enzy- 
temperature ranges from about 150 c. to about 600 c. In matic RNA mokcule confer increased binding specificity 
another variation, the DNA cleaving conditions are from and aflinity between the enzymatic RNA molecule and its 
about 30" C. to about 56" C. The temperature of the DNA 60 nucleic acid substrate. 
cleaving conditions are constrained only by the desired One of skill in the art would realize that the enzymatic 
cleavage rate and the stability of that particular enzymatic RNA molecules of this invention can be altered at any 
RNA molecule at that particular temperature. In yet another nucleotide sequence, such as the recognition site, by various 
variation, DNA cleavage conditions include a temperature methods disclosed herein, including PCR and 3SR. Addi- 
from about 35" C. to about 50" C. In a preferred embodi- 65 tional nucleotides can be added to the 5' end of the enzy- 
ment, DNA cleavage conditions comprise a temperature matic RNA molecule by including the additional nucleotides 
range of about 37" C. to about 42" C. in the primer used to introduce the T7 promoter binding site. 
In 
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The additional nucleotides would be included in the primer 
between the T7 promoter sequence and the nucleotide 
sequences which hybridize to the enzymatic RNA molecule 
at the 5‘ end. 
Enzymatic RNA molecules of the present invention may 
also be prepared or engineered in a more non-random 
fashion via use of methods such as site-directed mutagen- 
esis. For example, site-directed mutagenesis may be carried 
out essentially as described in Morinaga, et al., Biotechnol- 
ogy 2: 636 (1984), which is incorporated herein by refer- 
ence. Site-directed mutagenesis techniques are described in 
grcater detail hereinbelow; see, e.g., Example 1. 
In various embodiments, the population of group I nucleic 
acids is made up of at least 2 group I nucleic acids. In one 
variation, group I nucleic acids are nucleic acid molecules 
having a nucleic acid sequence defining a recognition site 
that is contiguous or adjacent to the 5’-terminus of the 
nucleotide sequence, a first spacer region located 3’-terminal 
to the recognition site, a P3[5’] region located 3’-terminal to 
the first spacer region, a second spacer region located 
3’-terminal to the P3[5’] region, a first stem loop located 
3’-terminal to the second spacer region, a second stem loop 
located 3’-terminal to the first stem loop, a third spacer 
region located 3’-terminal to the second stem loop, and a 
third stem loop located 3’-terminal to the third spacer region, 
the third stem loop comprising a 5’ stem portion defining a 
P3[3’] region capable of hybridizing to the P3[5’] region. 
Other characteristics of enzymatic RNA molecules produced 
according to the presently-disclosed methods are described 
in Section B above and in the Examples that follow. 
In other embodiments, mutagenizing conditions include 
conditions that introduce either defined or random nucle- 
otide substitutions within an enzymatic RNA molecule. 
Examples of typical mutagenizing conditions include con- 
ditions disclosed in other parts of this specification and the 
methods described by Joyce et ai., Nucl. Acids Res. 17: 
711-722 (1989); Joyce, Gene 82: 83-87(1989); and Beaudry 
and Joyce, Science 257: 635-41 (1992). 
In still other embodiments, a diverse population of mutant 
enzymatic nucleic acid molecules of the present invention is 
one that contains at least 2 nucleic acid molecules that do not 
have the exact same nucleotide sequence. In other varia- 
tions, from such a diverse population, an enzymatic RNA 
molecule or other enzymatic nucleic acid having a prede- 
termined activity is then selected on the basis of its ability 
to perform the predetermined activity. In various embodi- 
ments, the predetermined activity comprises, without limi- 
tation, enhance catalytic activity, decreased KM, enhanced 
substrate binding ability, altered substrate specificity, and the 
like. 
Parameters which may be considered aspects of enzyme 
performance include catalytic activity or capacity, substrate 
binding ability, enzyme turnover rate, enzyme sensitivity to 
feedback mechanisms, and the like. In certain aspects, 
substrate specificity may be considered an aspect of enzyme 
performance, particularly in situations in which an enzyme 
is able to recognize and bind two or more competing 
substrates, each of which affects the enzymes’ performance 
with respect to the other substrate(s). 
Substrate specificity, as used herein, may refer to the 
specificity of an enzymatic nucleic acid molecule as 
described herein for a particular substrate, such as one 
comprising RNA only, DNA only, or a composite of both. 
Substrate specificity also refers to whether an enzymatic 
nucleic acid molecule of the present invention preferentially 
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stranded nucleic substrate, or a nucleic acid molecule having 
both single-stranded and double-stranded regions (such as 
nucleic acid molecules with “loops”). In the case of the latter 
type of substrate, an enzymatic nucleic acid molecule of the 
present invention may preferentially bind to a particular 
region of such a composite substrate. 
Substrate specificity may also include sequence specific- 
ity; Le., an enzymatic nucleic acid molecule of the present 
invention may “recognize” and bind to a nucleic acid 
10 substrate having a particular nucleic acid sequence. For 
example, if the substrate recognition site of an enzymatic 
nucleic acid molecule of the present invention will only bind 
to nucleic acid substrate molecules having a series of six 
adenine residues in a row, then the enzymatic nucleic acid 
15 molecule will tend not to recognize or bind nucleic acid 
substrate molecules lacking such a sequence. In various 
embodiments, selecting includes any means of physically 
separating the mutant enzymatic nucleic acids having a 
predetermined activity from the diverse population of 
20 mutant enzymatic nuckic acids. Often, selecting comprises 
separation by size, by the presence of a catalytic activity, or 
by hybridizing the mutant nucleic acid to another nucleic 
acid that is either in solution or attached to a solid matrix. 
In various embodiments, the predetermined activity is 
25 such that the mutant enzymatic nucleic acid having the 
predetermined activity becomes labelled in some fashion by 
virtue of the activity. For example, the predetermined activ- 
ity may be an enzymatic RNA molecule activity whereby the 
activity of the mutant enzymatic nucleic acid upon its 
30 substrate causes the mutant enzymatic nucleic acid to 
become covalently linked to it. The mutant enzymatic 
nucleic acid is then selected by virtue of the covalent 
linkage. 
In other embodiments, selecting a mutant enzymatic 
35 nucleic acid having a predetermined activity includes ampli- 
fication of the mutant enzymatic nucleic acid (see, e.g., 
Joyce, Gene 82: 83-87 (1989); Beaudry and Joyce, Science 
257: 635-41 (1992)). 
E. Compositions 
The invention also contemplates compositions containing 
one or more types or populations of enzymatic RNA mol- 
ecules of the present invention; e.g., different types or 
populations may recognize and cleave different nucleotide 
sequences. Compositions nay further include a DNA-con- 
taining substrate. Compositions according to the present 
invention may further comprise magnesium ion or other 
divalent or monovalent cations, as discussed in section B 
above. 
Preferably, the enzymatic RNA molecule is present at a 
concentration of about 0.05 pM to about 2 pM. Typically, the 
enzymatic RNA molecule is present at a concentration ratio 
of enzymatic RNA molecule to single-stranded DNA sub- 
strate of from about 1:5 to about 150. More preferably, the 
55 enzymatic RNA molecule is present in the composition at a 
concentration of about 0.1 pM to about 1 pM. Even more 
preferably, compositions contain the enzymatic RNA mol- 
ecule at a concentration of about 0.1 pM to about 0.5 pM. 
Preferably, single-stranded DNA substrate is present in the 
60 composition at a concentration of about 0.5 to about 
1000 pM. One skilled in the art will understand that there are 
many sources of single-stranded DNA including synthetic 
DNA, phage DNA, “loop” DNA, denatured double-stranded 
DNA, viral DNA and cellular. 
Magnesium ion may also be present in the composition, 
at a concentration of about 2-100 mM. More preferably, the 
5 
40 
45 
50 
65 
binds a single-stranded nucleic acid substrate, a double- magnesium ion is present in the composition at a concen- 
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tration of about 2 mM to about 50 mM. Preferably, magne- 
sium ion is present at a concentration of about 5 mM to about 
15 mM, with a conccntration of about 10 mM being par- 
ticularly preferred. One skilled in the art will understand that 
the magnesium ion concentration is only constrained by the 
limits of solubility of magnesium in aqueous solution and a 
desire to have the enzymatic RNA molecule present in the 
same composition in an active conformation. 
The invention also contemplates compositions containing 
an enzymatic RNA molecule of the present invention, 
single-stranded DNA, magnesium ion in concentrations as 
described hereinabove, and a polyamine. Preferably, the 
polyamine is spermidine, putrescine, or spermine. More 
preferably, the polyamine is spermidine and is present at a 
concentration of about 2 mM to about 10 mM. The invention 
further contemplates compositions containing an enzymatic 
RNA molecule of the present invention, single-stranded 
DNA, magnesium ion at a concentration of greater than 20 
millimolar, a second single-stranded DNA molecule ending 
in a 3’-terminal hydroxyl, and a third single-stranded DNA 
molecule having a guanine nucleotide at its 5’-terminal end. 
Also contemplated by the present invention are cornpo- 
sitions containing an enzymatic RNA molecule of the 
present invention, singled-stranded DNA and magnesium 
ion at a concentration of greater than about 2 millimolar, 
wherein said single-stranded DNA is greater in length than 
the recognition site present on the enzymatic RNA molecule. 
E Methods of Using Enzymatic RNA Molecules 
The methods of this invention may be used to cleave 
single-stranded nucleic acids or single-stranded portions of 
double-stranded nucleic acids, whether those nucleic acids 
are present in an in vitro or ex vivo system, or whether they 
are present inside a cell, whether those cells are eucaryotic, 
procaryotic, plant, animal, yeast or bacterial cells. 
For example, if the double-stranded nucleic acid is 
dsDNA, methods of using the enzymatic RNA molecules 
described herein may be used to cleave single-stranded 
portions of dsDNA, e.g., “looped” DNA or single-stranded 
segments of DNA that are accessible during transcription or 
translation. 
It is also contemplated that enzymatic RNA molecules of 
the present invention, and the within-disclosed methods of 
using same, may be used to cleave dsDNA. In one embodi- 
ment, cleavage of dsDNA may be accomplished using 
coupled or paired enzymatic RNA molecules, wherein one 
member of the pair recognizes and cleaves one target 
nucleotide sequence, while its “partner” recognizes and 
cleaves the complementary target nucleotide sequence. In 
preferred embodiments, however, the enzymatic RNA mol- 
ecules and methods of this invention are used to cleave 
single-stranded nucleic acids or single-stranded portions of 
double-stranded nucleic acids, in vivo, in vitro or ex vivo. 
Therefore, in one embodiment, an enzymatic RNA molecule 
(ribozyme) of the present invention may be useful as an 
anti-viral agent or a regulator of gene expression. 
For example, an enzymatic RNA molecule of the present 
invention may be used to treat a virally-caused disease by 
administering to a patient in need of treatment an enzymatic 
RNA molecule which cleaves viral nucleic acid or virus- 
encoded nucleic acid. Viruses whose nucleic acids or 
encoded nucleic acids may be susceptible to cleavage by an 
enzymatic RNA molecule of the present invention include, 
for example, papillomavirus, EBV, HSV, KBV, HIV (e.g., 
HIV-1, HIV-2), T-cell leukemia virus (e.g., HTLV-I, HTLV- 
2), HCV, CMV, influenza virus, and picornavirus. 
In a related aspect of the invention, an enzymatic RNA of 
the present invention may be used to treat virally-cause 
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diseases in animals, such as feline immunodeficiency virus 
(FIV), feline leukemia virus (FLV), simian immunodefi- 
ciency virus (SIV), bovine leukemia virus (BLV), and sim- 
ian leukemia virus (e.g., STLV). Useful enzymatic RNA 
5 molecules of the present invention may be selected on the 
basis of their ability to target a selected region (or regions) 
of a viral genome. In various embodiments, such enzymatic 
RNA molecules are able to cleave the target nucleic acid 
sequence or segment in a manner which inhibits transcrip- 
1o tion, translation, or expression of the nucleic acid sequence. 
Target nucleic acid segments are selected so that inhibition 
of transcription, translation or expression will have maximal 
effect. For example, targeting the enzymatic RNA molecules 
of the present invention to nucleic acid sequences involved 
in protein synthesis, genomic replication, or packaging into 
l5 virions is expected to inhibit viral replication. 
Once an appropriate target is selected, enzymatic RNA 
molecules capable of cleaving the target nucleotide 
sequence may be identified from a pool of enzymatic RNA 
molecules via the use of oligonucleotide probes. Alterna- 
20 tively, the recognition sequence of an enzymatic RNA 
molecule of the present invention may be mutated or modi- 
fied so that it selectively targets the desired viral sequence. 
Methods of identifying suitable target sequences are avail- 
able in the art; see, e.g., published PCT application nos. WO 
25 93/23569, WO 91/04319, WO 91104324, and WO 91/03162; 
and published European patent application no. EPO 585, 
549, the disclosures of which are incorporated by reference 
herein. 
Enzymatic RNA molecules of the present invention are 
30 preferably targeted to a highly-conserved region of a viral 
nucleic acid sequence so that all strains and types of such 
viruses may be treated with a single enzymatic RNA mol- 
ecule or enzymatic RNA molecule species. Enzymatic RNA 
molecules of the present invention may be designed to target 
RNA or DNA sequences as appropriate; they may also be 
designed to target transcripts of viral nucleic acid sequences, 
whether those transcripts are comprised of RNA or DNA. 
Enzymatic RNA molecules according to the present inven- 
tion may also be designed to target antisense nucleic acid 
Enzymatic RNA molecules of the present invention may 
further be used to treat transformed eukaryotic cells--e.g., 
keratinocytes, hepatocytes or epithelial cells-in such a 
manner that they inhibit the expression of viral genes known 
45 or believed to cause cell immortalization or transformation. 
In another embodiment, enzymatic RNA molecules may be 
used to treat latent viral infections, by inhibiting gene 
expression required for the maintenance of the viral episo- 
mal genome. 
If desired, a vector such as those described hereinbelow 
may be used in a therapeutic protocol via use of the methods 
and systems described in published international application 
no. WO 92/13070, the disclosures of which are incorporated 
by reference herein. Via one of the disclosed methods, 
55 expression of a therapeutic enzymatic RNA molecule of thc 
present invention may be temporally regulated. Thus, a 
vector comprising sequences encoding therapeutic enzy- 
matic RNA molecules of the present invention preferably 
includes a promoter which expresses enzymatic RNA mol- 
60 ecules only in the presence of a nucleic acid molecule which 
is manifested when an “invading” organism or disease state 
is present. Such a “timed release” enzymatic RNA molecule 
then functions to impair or destroy the cell in which the 
unwanted organism or condition is found, to bring about 
65 reduced expression of a protein product related to the 
disease state, or to stimulate production of a “defensive” 
protein of the compromised cell. 
35 
4o sequences. 
50 
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Enzymatic RNA molecules of the present invention may the temperature is about 37" C. and divalent cations are 
also be used in vivo or in vitro to make defective viral available at a concentration of about 10 mM (e.g., 10 mM 
particles which nonetheless retain their immunogenic prop- MgCl,). Thus, the catalytic efficiencies of the enzymatic 
erties. In this way, an organism's own immune System may RNA molecules of the present invention are preferably 10 or 
be stimulated to combat infection by intact (i.e., non- 5 more times greater than that of the wild type, and the 
defective) viral particles. molecules also display improvement in both K, and kea,. 
In a related aspect, vaccines or other preparations used for In a related aspect, the enzymatic RNA molecules of this 
immunization may be formed from defective viruses (Or invention may be used to identify the nucleic acid sequence 
Portions there00 created by a method of this invention. to which a proteinaceous or nonproteinaceous adjunct binds. 
Methods for immunizing or vaccinating organisms using 10 The proteinaceous or nonproteinaceous adjunct contern- 
defective viral particles (e.g., with DNA or vectors encoding plated may bind to specific nucleotide sequences. The tern 
an enzymatic RNA molecule Of this invention under the ''adjunct'' as used herein is meant to include proteinaceous 
control of an appropriate Promoter) are also contemplated or nonproteinaceous substances which are joined or added to 
herein. the nucleic acid sequence but are not essentially a part of 
Enzymatic RNA molecules of the present invention may 15 said sequence. The adjunct may be a protein, metal, inor- 
also be conjugated or otherwise linked to viral particles or ganic molecule, lipid, or other substance. 
viruses, where the latter are used as vectors which may For example, multiple enzymatic RNA moleculcs with 
transport enzymatic RNA mOleCUkS to Cells infected with known recognition sequences may be used to identify the 
another Virus. Useful vectors Of this type may be formed Via nucleic acid sequence to which an adjunct is specifically 
standard technology; for example, denovirus vectors and 2o bound. The identification of these nucleic acid sequences 
related methodologies may be effective in this regard. may be useful in identifying specific nucleic acid target 
Diagnostic uses of enzymatic RNA molecules of the sequences involved in gene expression. 
present invention are also contemplated. For example, In a related aspect, the enzymatic RNA molecules of this 
because of the relationship b e h ~ ~ n  enzymatic RNA mol- 25 invention may be used to confirm the presence or absence of 
ecule activity and target nucleic acid structure, mutations in proteins or other adjuncts (proteinaceous or nonproteina- 
region of the target molec~~le may be detected, PmiCU- ceous) which bind a nucleic acid substrate at a specific 
1XlY where such mutations alter the base-pairing and three- recognition site. For example, if a protein or other adjunct 
dimensional structure of the target nucleotide sequence, specifically binds to a known nucleic acid sequence, an 
whether RNA or DNA. 3o enzymatic RNA molecule which is specific for the same 
Further, by using multiple enzymatic RNA molecules as nucleic acid sequences could be used to detect the presence 
described in this invention, one may map nucleotide changes or absence of such a protein or adjunct. The detection of 
important to DNA or RNA structure and function in vitro, as such proteins or adjuncts may be useful for in vivo or in vitro 
well as in cells and tissues. Cleavage of target DNAs or diagnostic assays. 
RNAs with enzymatic RNA molecules Of the present inven- 35 Enzymatic RNA molecules as described herein may also 
tion may be used to inhibit gene expression and to assist in be used to regulate a variety of reaction systems, whether 
defining the role of specified gene products in the progres- those reactions are occuning in vitro or in vivo. For 
sion of disease. In this application, other genetic targets may example, it is contemplated that one may take advantage of 
be identified as important mediators of the disease under the endonuclease activities of the molecules of the present 
investigation. Such experiments may lead to better treatment 4o invention by using them to regulate or terminate reactions in 
or modification of disease progression by providing the which transcription and/or translation are taking place. For 
possibility of combinational therapies. Examples of the example, enzymatic RNA molecules which recognize a 
latter include application Of multiple enzymatic RNA mol- specific nucleic acid residue sequence found in one or more 
ecules targeted to different genes or nucleotide sequences; of the PCR primers being used in a particular reaction may 
enzymatic RNA molecules coupled With known small mol- 45 be added to such PCR reaction system to modulate or 
ecule inhibitors; intermittent treatment with combinations Of terminate processes dependent upon the primer targeted by 
enzymatic RNA molecules and/or other chemical or biologi- the enzymatic RNA molecule, In this way, the entire PCR 
Cal molecules; and enzymatic RNA molecules administered reaction would not be stopped; rather, only those products 
in conjunction with therapeutic antisense sequences. dependent upon the targeted primer(s) would be limited or 
The present invention contemplates that enzymatic RNA 50 eliminated. 
molecules as described herein may be used as sequence- Enzymatic RNA molecules of the present invention may 
specific endoribonucleases. In various preferred embodi- also be used during the transcription of DNA sequences or 
ments, enzymatic RNA molecules cleave RNA substrates oligomers to generate truncated transcripts in the same 
with high catalytic efficiency (e.g., k,,jKm=108M-'min-'). reaction vessel in which longer transcripts are generated. For 
It is also contemplated herein that the enzymatic RNA 55 example, if one wishes to generate a population of proteins 
molecules of the present invention can act as sequence- with a membrane-spanning domain attached and a popula- 
specific endodeoxyribonucleases. In various preferred tion of proteins with the membrane-spanning domain 
embodiments, enzymatic RNA molecules of the present removed, the transcripliodtranslation reactions may be 
invention cleave DNA with high catalytic efficiency. For allowed to run for a predetermined period of time until a 
example, in one embodiment, an enzymatic RNA molecule 60 predetermined amount of "intact" (Le., non-truncated) prod- 
of the present invention has the following efficiency: K,=l.9 uct is generated. Subsequently, enzymatic RNA molecules 
pM and k,,,=0.005 min-' (k,,jK,=2700 M-' min-'). In of the present invention which have been engineered to 
another embodiment, an enzymatic RNA molecule has the cleave the transcripts at a site-specific location (Le., a locus 
following efficiency: K,=2.0 pM and k,,,=0.007 min-' adjacent to the sequence for the membrane-spanning 
(k,,jKm=3600 M-' min-'). In various embodiments encom- 65 domain) may be added to the reaction mixture, which will 
passed by the present invention, catalytic efficiencies are result in the generation of truncated transcripts (and trun- 
greatest under physiologic conditions-for example, when cated protein products translated therefrom). 
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Alternatively, the enzymatic RNA molecules may be 
engineered to cleave the gene from which the messenger 
RNAs are being transcribed, which will produce a similar 
result with regard to the protein generated thereby. One of 
sufficient skill in the art will appreciate, based on the present 
disclosure, that enzymatic RNA molecules of the present 
invention may be adapted for a variety of uses; the uses 
disclosed herein should thus be understood to be exemplary 
and not limiting. 
Use of enzymatic RNA molecules of the present invention 
in a coupled isothermal polynucleotide amplification and 
translation system could also modulate or “shut down” 
amplification processes at a predetermined time without 
simultaneously terminating the linked translation system. 
Similarly, the enzymatic RNA molecules of the present 
invention may be used to modulate or terminate therapeutic 
or diagnostic applications involving the use of “antisense” 
nucleotide sequences, e.g., by cleaving said antisense 
sequences. 
Enzymatic RNA molecules of the present invention may 
also be used in oligonucleotide (e.g. DNA) footprinting or 
footprint analysis of protein-nucleotide binding. For 
example, enzymatic RNA molecules of the present invention 
may be prepared as disclosed herein, with a variety of 
different recognition sequences, and then admixed with a 
DNA sample to which a particular protein has bound. 
Labeled DNA fragments resulting from cleavage of the 
DNA sample by enzymatic RNA molecules of the present 
invention may then be analyzed according to standard 
protocols to enable one to identify specific protein binding 
sites on the DNA sample. Additionally, the same types of 
enzymatic RNA molecules of the present invention may be 
admixed with a sample of DNA to which the particular 
protein has not been added. Labeled DNA fragments result- 
ing from cleavage of this second DNA sample may then be 
analyzed and the results compared with those generated 
when the protein-bound DNA sample was analyzed. 
A variety of protocols are available for footprinting and 
similar analyses which are easily adapted for use with the 
enzymatic RNA molecules of the present invention, wherein 
the enzymatic RNA molecules disclosed herein are substi- 
tuted in place of other nuclease enzymes. For example, see 
Ausubel, et al. (eds.), Current Protocols in Molecular Biol- 
ogy, John Wiley & Sons, Inc. (1994), for descriptions of a 
variety of protocols useful in conjunction with the enzymatic 
RNA molecules of the present invention. 
It is anticipated that enzymatic RNA molecules of the 
present invention may also be engineered and used as 
highly-specific endonucleases, which makes them uniquely 
useful in vector construction, particularly when cleavage of 
single-stranded sequences is desired. For example, as dis- 
closed above, an enzymatic RNA molecule of the present 
invention may be specifically targeted to a specific nucle- 
otide sequence of from about 2 to 30 nucleotides in length; 
thus, such a molecule may be used in the design of vectors 
and cassettes for the delivery and expression of nucleotide 
sequences, Le., by facilitating the insertion of predetermined 
nucleotide sequences into a compatible vector. 
Other uses of the within-disclosed enzymatic RNA mol- 
ecules will be apparent based on the present disclosure and 
are thus within the scope of the present invention. 
G. Vectors 
The present invention also features expression vectors 
including a nucleic acid segment encoding an enzymatic 
RNA molecule of the uresent invention situated within the 
28 
that enzymatic RNA molecule within a target cell (e.g., a 
plant or animal cell). 
Thus, in general, a vector according to the present inven- 
tion includes a bacterial, viral or eukaryotic promoter within 
5 a plasmid, cosmid, phagemid, virus, viroid, or phage vector. 
Other suitable vectors include double-stranded DNA 
(dsDNA), partially double-stranded DNA, dsRNA, partially 
dsRNA, or single-stranded RNA (ssRNA) or DNA (ssDNA). 
It should also be appreciated that useful vectors according to 
the present invention need not be circular. 
In one aspect of the present invention, a first enzymatic 
RNA molecule-encoding nucleotide sequence is transcrip- 
tionally linked to a promoter sequence. In another variation, 
one or more additional enzymatic RNA molecule-encoding 
15 nucleotide sequences are also included in the vector; said 
additional enzymatic RNA molecule-encoding sequences 
may be located on either side, or both sides, of a nucleotide 
sequence encoding the first enzymatic RNA molecule. Pref- 
erably, there are intervening nucleotides or nucleotide 
20 sequences between successive enzymatic RNA molecule- 
encoding sequences. 
In another variation, nucleotide sequences flanking each 
of the additional enzymatic RNA molecule-encoding 
sequences are preferably provided, which sequences may be 
25 recognized by the first enzymatic RNA molecule. The inter- 
vening or flanking sequences preferably comprise at least 1 
nucleotide; more preferably, intervening or flanking 
sequences are about 2-20 nucleotides in length, with 
sequences of about 5-10 nucleotides in length being par- 
The addition of polyadenine (poly(A)) tails may also be 
useful to protect the 3’ end of an enzymatic RNA molecule 
according to the present invention. These may be provided 
by including a poly(A) signal site in the expression vector, 
35 which would signal a cell to add the poly(A) tail in vivo. 
Preferably, the signal is aligned in such a fashion that it 
prevents unwanted secondary structure formation with other 
parts of the enzymatic RNA molecule. 
Alternatively, a poly(A) tail may be provided by intro- 
ducing a poly(A) sequence directly into the expression 
vector. Since the poly(A) sequence may decrease in size 
over time when expressed in vivo, the vector may need to be 
monitored over time. Care must be taken, however, in the 
45 addition of a poly(A) tail which binds poly(A) binding 
proteins, which may prevent the enzymatic RNA molecule 
from acting upon its target nucleotide sequence. Other 
vectors and methods of generating same are described in the 
art; see, e.g., published international application no. WO 
30 ticularly preferred. 
40 
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Thus, in one example, a vector may comprise a promoter 
operatively linked for expression to a nucleotide sequence 
encoding a first enzymatic RNA molecule followed, in a 
3’+5’ direction, by: (1) a “flanking” nucleotide sequence 
55 capable of being recognized and cleaved by said first enzy- 
matic RNA molecule; (2) a nucleotide sequence encoding a 
second enzymatic RNA molecule; (3) another flanking 
nucleotide sequence capable of being recognized and 
cleaved by said first enzymatic RNA molecule; (4) a nucle- 
60 otide sequence encoding a third enzymatic RNA molecule; 
(4) yet another flanking nucleotide sequence capable of 
being recognized and cleaved by said first enzymatic RNA 
molecule; and so forth. 
Preferably, a vector according to the present invention 
65 includes a plurality of nucleic acid sequences encoding the 
second enzvmatic RNA molecule, each flanked bv nucleic 
5,580,967 
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molecule. More preferably, such a plurality includes at least 
5, preferably 7, more preferably 9 or more, nucleic acid 
sequences. In other embodiments, a vector as disclosed 
herein includes a promoter which regulates expression of the 
nucleic acid encoding the enzymatic RNA molecules from 5 
the vector. 
The invention also contemplates that a promoter sequence 
is linked to a first or “releasing” enzymatic RNA molecule 
having an appropriate restriction endonuclease site. A 
Suitable restriction endonuclease sites may also be pro- 
vided to ease the construction of such a vector in DNA 
vectors or in requisite DNA vectors of an RNA expression 
system. 
The second (and any additional) enzymatic RNA mol- 
ecule may be any desired type of enzymatic RNA molecule, 
such as a ribozyme, including group I and group I1 introns, 
hammerhead, hairpin, and other types of ribozymes or 
enzymatically active portions thereof. 
single-stranded oligonucleotide is then provided which 10 m e  first enzymatic RNA molecule is selected to cleave 
encodes the two flanking regions and a second (i.e., “thera- the encoded cleavage (e.g., “flanking”) sequence, and may 
PeUtiC”) enzymatic RNA molecule. The oligonucleotides are also be any desired ribozyme-e.g,, a ribozyme derived 
then allowed to form partial duplexes via hybridization at from Teahymena-which may, for example, include an 
the flanking regions. The single-stranded sections are then embedded restriction endonuclease site in the center of a 
filled in using a DNA Polymerase and deoxYribon~cleotide self-recognition sequence to aid in vector construction. This 
triphosphates (dNTPs) to form a molecule, which l5 endonuclease site is useful for construction of, and subse- 
may then be ligated to the restriction endonuclease site to quent analysis of, a vector as described herein. 
form the desired vector. As noted above, the vector may be A vector according to the present invention is preferably 
chosen from the group comprising plasmids, cosmids3 operably linked for expression to an appropriate promoter. 
For example, a vector according to the present invention phagemids, virus, viroids, or phage. 
Preferably, the plurality Of nucleic acid sequences are 2o may comprise an enzymatic RNA molecule under the con- 
identical and are arranged in sequential fashion such that trol o f a  viral promoter, such as an Epstein-Barr virus (EBV) 
each has an identical end nearest to the promoter. If desired, promoter. A variety of viral promoters useful for this purpose 
a poly(A) sequence adjacent to the sequence encoding the are known in the art; see, e.g., those described in published 
first or second enzymatic RNA molecule may be provided to PCT application no. WO 93/23569. 
increase stability of the RNA produced by the vector andor 25 In another variation, a vector according to the present 
to enhance transport to appropriate cellular compartments. invention includes two or more enzymatic RNA molecules. 
Further, a restriction endonuclease site adjacent to the In one embodiment, a first enzymatic RNA molecule has 
nucleic acid encoding the first enzymatic RNA molecule intramolecular cleaving activity and is able to recognize and 
may be provided to allow insertion of nucleic acid encoding cleave nucleotide sequences to release other enzymatic RNA 
the second enzymatic RNA molecule during construction of 30 sequences; Le., it is able to function to “release” other 
the vector. enzymatic RNA molecules from the vector. For example, a 
If delivery of a vector construct to a eucaryotic cell is vector is Preferably cons t~~~cted  SO that when the first 
desired, cellular splicing mechanisms within the target enzymatic RNA molecule is expressed, that first molecule is 
cell(s) may be utilized or integrated to cleave out the 35 able to cleave nucleotide sequences flanking additional 
therapeutic second enzymatic RNA molecule(s) by encoding nucleotide sequences encoding a second enzymatic RNA 
recognition sequences for the second enzymatic RNA mol- molecule, a third enzymatic RNA molecule, and so forth. 
ecules within the flanking sequences of the expressed tran- Presuming said first enzymatic RNA molecule @.e., the 
script, Multiple copies of the releasing first enzymatic RNA “releasing” molecule) is able to Cleave oligonucleotide 
molecule may be provided to enhance release of the second 4o sequences in t r~olec~lar lY,  the additional (e& second, 
(Le. therapeutic) enzymatic RNA molecule if the turnover third, and SO on) enzymatic RNA molecules (i.e.3 the 
rate is slower than the degradation rate of the second “released” mOleCUleS) need not possess characteristics iden- 
enzymatic RNA molecule. If the target cell is a bacterial cell, tical to the ‘‘releasing” 
in vitro modifications and certain cell modifications may be Alternatively, the first enzymatic RNA molecule may be 
enhanced by providing appropriate nucleotide sequences 45 encoded on a separate vector from the second enzymatic 
within the vector and are useful in the enhancement of the RNA molecule(s) and may have intermolecular cleaving 
turnover rate, enzymatic stability, and cleavage activity of activity. As noted herein, the first enzymatic RNA molecule 
the within-disclosed enzymatic RNA molecules. can be a self-cleaving enzymatic RNA molecule (e.g., a 
A method of forming an enzymatic RNA molecule ribozyme), and the second enzymatic RNA molecule may be 
expression vector includes providing a vector comprising 5o any desired type of enzymatic RNA molecule (e.g., a 
nucleic acid encoding a first enzymatic RNA molecule, as ribozYme). When a vector is caused to express RNA from 
discussed above, and providing a single-saanded DNA these nucleic acid sequences, that RNA has the ability under 
molecule encoding a second enzymatic RNA molecule, also appropriate conditions to cleave each of the flanking 
as discussed above. The single-stranded DNA is then regions, thereby releasing One or more Copies of the second 
allowed to anneal to form a can 55 enzymatic RNA molecule. If desired, several different sec- 
be filled in by treatment with an appropriate enzyme, such ond enzymatic RNA molecules can be placed in the same 
as a DNA polymerase in the presence of dNTPs, to form a Cell Or carrier to Produce different ribozYmes. 
duplex DNA which can then be ligated to the vector. Large Methods of isolating and purifying enzymatic RNA mol- 
vectors resulting from use of this method can then be ecules of the present invention are also contemplated. In 
selected to insure that a high copy number of the single- 60 addition to the methods described herein, various purifica- 
stranded DNA encoding the second enzymatic RNA mol- tion methods (e.g. those using HPLC) and chromatographic 
ecule is incorporated into the vector. isolation techniques are available in the art. See, e.g., the 
A method for producing enzymatic RNA molecules thus methods described in published international application no. 
involves providing a vector as described above, expressing wo g3/23569, the 
RNA from that vector, and allowing cleavage by the first 65 herein by reference. 
enzymatic RNA molecule to release the second (and any 
subsequent) enzymatic RNA molecule. 
duplex DNA 
of which are 
It should also be understood that various combinations of 
the embodiments described herein are included within the 
5,580,967 
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scope of the present invention. Other features and advan- 
tages of the present invention will be apparent from the 
descriptions hereinabove, from the Examples to follow, and 
from the claims. 
EXAMPLES 
The following examples illustrate, but do not limit, the 
prcsent invention. 
Example 1 
In Vitro Evolution of Enzymatic RNA Molecules 
The Tetrahymena ribozyme is a self-splicing group I 
intron derived from the large ribosomal RNA (rRNA) pre- 
cursor of Tetrahymena themzophila. Its biological function 
is to catalyze its own excision from precursor rRNA to 
produce mature rRNA. This function has been expressed in 
vitro (Kruger, et al., Cell 31: 147 (1982)) and has been 
generalized to include various phosphoester transfer reac- 
tions involving RNA substrates (Zaug, et al., Science 231: 
470 (1986); Kay, et al., Nature 327: 343 (1987); Been, et al., 
Science 239: 1412 (1988); Woodson, et al., Cell 57: 335 
(1989); Doudna, et al., Nature 339: 519 (1989)). For 
example, the ribozyme has been used as a sequence-specific 
endoribonuclease (Zaug, et al., Id. (1986); Murphy, et al., 
PNAS USA 86: 9218 (1989)), a reaction that proceeds with 
high catalytic efficiency (k,,,/K,=l OSM-' m i d  ) (Her- 
schlag, et al., Biochemistry 29: 10159 (1990)). 
The Tetrahymena ribozyme consists of 413 nucleotides 
and assumes a well-defined secondary and tertiary structure 
that is responsible for its catalytic activity (Burke, et al., 
Nucleic Acids Res. 15: 7217 (1987); Kim, et al., PNAS USA 
84: 8788 (1987); Celander, et al., Science 251: 401 (1991); 
Michel, et al., J. Mol. Biol. 216: 585 (1990). Phylogenetic 
analysis, supported by site-directed mutagenesis and dele- 
tion studies, points out a distinction between a conserved 
catalytic core (comprising about one-third of the molecule) 
and surrounding stem-loop elements that offer structural 
support but are not essential for catalytic activity. (See 
Davies, et al., Nature 300: 719 (1982); Michel, et al., 
Biochimie 64: 867 (1982); Michel, et al., EMBO J. 2: 33 
(1983); Cech, et al., Gene 73: 259 (1988); Price, et al., Nucl. 
Acids Res. 13: 1871 (1985); Szostak, et al., Nature 322: 83 
(1986); Joyce, et al., Nucl. Acids Res. 15: 9825 (1987); 
Barfod, et al., Genes Dev. 2: 652 (1988); Joyce, et al., 
Nucleic Acids Res. 17: 7879 (1989); Couture, et al., J. Mol. 
Biol. 215: 345 (1990); Beaudry and Joyce, Biochemistry 29: 
6534 (1990).) 
The ribozyme can also act as a sequence-specific endodc- 
oxyribonuclease (Robertson and Joyce, Id. (1 990)), although 
the efficiency of DNA cleavage is low (k,,/Km=200M-' 
m i d ,  determined at 50" C., 10 mM MgCI,) (Herschlag, et 
al., Nature 344: 405 (1990)). The efficiency of RNA-cata- 
lyzed DNA cleavage under physiologic conditions is even 
lower (kC,jK,=36M-' min-', determined at 37" C., 10 mM 
MgCI,; see below). 
One goal achieved herein was the improvement of the 
catalytic efficiency of RNA-catalyzed DNA cleavage under 
physiologic conditions, thereby obtaining ribozymes that 
could cleave DNA in vivo. It is not obvious how one should 
change the Tetrahymena ribozyme to convert it from an 
RNA-cleaving to a DNA-cleaving enzyme. Thus, directed 
evolution was selected as a means to acquire the desired 
phenotype. 
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A method of in vitro evolution has now been developed 
for enzyme engineering. For example, the Tetrahymena 
ribozyme, an RNA enzyme that typically catalyzes 
sequence-specific phosphoester transfer reactions that result 
in cleavage or ligation of RNA substrates, is useful in the 
within-described in vitro evolutionary process. The wild- 
type enzyme can be used to cleave a single-stranded DNA 
substrate, albeit only under conditions of high temperature 
(50" C.) or high MgCl, concentration (50 mM), or both. (See 
IO Robertson and Joyce, Id. (1990).) A kinetic study showed 
that, even at 50" C., this reaction is inefficient compared to 
the "native" reaction with an RNA substrate. As noted 
above, under physiologic conditions (e.g., 37" C., 10 mM 
MgCl,), the DNA cleavage reaction using wild-type 
To obtain ribozymes that cleave DNA with improved 
efficiency under physiologic conditions, directed evolution 
was used to generate and maintain a population of 1013 
ribozymes over ten successive generations. Complete access 
20 to genotypic and phenotypic parameters for the entire popu- 
lation over the course of its evolutionary history was also 
maintained. 
Darwinian evolution requires the repeated operation of 
three processes: (a) introduction of genetic variation; (b) 
selection of individuals on the basis of some fitness crite- 
rion; and (c) amplification of the selected individuals. Each 
of these processes can be realized in vitro (Joyce, Id. 
(1989)). A gene can be mutagenized by chemical modifica- 
tion, incorporation of randomized mutagenic oligodeoxy- 
30 nucleotides, or inaccurate copying by a polymerase. (See, 
e.g., Chu, et al., Virology 98: 168 (1979); Shortle, et al., 
Meth. Enzymol. 100  457 (1983); Myers, et al., Science 229: 
242 (1985); Matteucci, et al., Nucleic Acids Res. 11: 3113 
(1983); Wells, et al., Gene 34: 315 (1985); McNeil, et al., 
35 Mol. Cell. Biol. 5: 3545 (1985); Hutchison, et al., PNAS USA 
83: 710 (1986); Derbyshire, et al., Gene 46: 145 (1986); 
Zakour, et al., Nature 295: 708 (1982); Lehtovaara, et al., 
Protein Eng. 2: 63 (1988); Leung, et al., Technique 1: 11 
(1989); Zhou, et al., Nucl. Acids Res. 19: 6052 (1991).) 
The gene product can be selected, for example, by its 
ability to bind a ligand or to carry out a chemical reaction. 
(See, e.g., Joyce, Id. (1989); Robertson and Joyce, Id. 
(1990); Tuerk, et al., Id. (1990).) The gene that corresponds 
to the selected gene product can be amplified by a reciprocal 
primer method, such as the polymerase chain reaction 
(PCR). (See, e.g., Saiki, et al., Science 230: 1350-54 (1985); 
Saiki, et al., Science 239: 487-491 (1988).) 
Alternatively, nucleic acid amplification may be carried 
50 out using self-sustained sequence replication (3SR). (See, 
e.g., Guatelli, et al., PNAS USA 87: 1874 (1990), the 
disclosures of which are incorporated by reference herein.) 
According to the 3SR method, target nucleic acid sequences 
may be amplified (replicated) exponentially in vitro under 
55 isothermal conditions by using three enzymatic activities 
essential to retroviral replication: (1) reverse transcriptase, 
(2) RNase H, and (3) a DNA-dependent RNA polymerase. 
By mimicking the retroviral strategy of RNA replication by 
means of cDNA intermediates, this reaction accumulates 
60 cDNA and RNA copies of the original target. 
In summary, a continuous series of reverse transcription 
and transcription reactions replicates an RNA target 
sequence by means of cDNA intermediates. The crucial 
elements of this design are (a) the oligonucleotide primers 
65 both specify the target and contain 5' extensions encoding 
the 'I7 RNA polymerase binding site, so that the resultant 
cDNAs are competent transcription templates; (b) cDNA 
5 
15 ribozyme is almost undetectable. 
25 
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synthesis can proceed to completion of both strands due to selective amplification product under conditions as 
the degradation of RNA in the intermediate RNA-DNA described in subsection 1 above, but omitting primer 2 and 
hybrid by RNase H; and (c) the reaction products (cDNA T7 polymerase. Subsequent PCR amplification with 0.01 
and RNA) can function as templates for subsequent steps, pmol of the selective cDNA synthesis product in a reaction 
enabling exponential replication. 5 mixture (100 pl volume) containing 0.2 pM d(CGAG- 
A major obstacle to realizing Darwinian evolution in vitro TACTCCAAAACTAATC) (SEQ ID NO 9),0.2 @Vl Primer 
is the need to integrate mutation and amplification, both of 2 (as above), 0.2 mM N P s ,  50 mM KCl, 1.5 mM MgCl,, 
which are genotype-related, with selection, which is pheno- 10 mM tris-HC1 (pH 8.3), 0.01% gelatin, and 2.5 U of Taq 
type-related. In the case of RNA enzymes, for which geno- DNA polymerase (Perkin-Elmer, Norwalk, Conn.), 30 
type and phenotype are embodied in the same molecule, the cycles of 92" C. for 1 minute, 45" C. for 1 minute, and 72" 
task is simplified. C. for 1 minutc. PCR products were purified by extraction 
with chloroform and isoamyl alcohol and by precipitation 
with ethanol, and used to transcribe RNA as described in 
possible to amplify virtually any RNA. (See Kwoh, et al., Subsection 3 below. 
PNAS USA 86: 1173 (1989); Joyce, in Molecular Biology of 15 The product of the reaction was a molecule that contained 
RNA: UCLA SYmPosia on Molecular and Cdlular Biology, the 3' portion of the substrate attached to the 3' end of the 
T. R. Cech (ed.1, m, 1989, PP. 361-371.) RNA is ribozyme (EP; see FIGS. 2A and 2B). Selection occurred 
copied to a complementary DNA (CDNA) With reverse when an oligodeoxynucleotide primer was hybridized across 
transcriptase (RT), and the resulting CDNA is transcribed to the ligation junction and used to initiate cDNA synthesis. 
RNAwithT7 RNAPolYmeraSe (T7 pol) (FIGS. 2Aand2B). 20 The primer did not bind to unreacted starting materials 
FIGS. 2Aand 2B illustrate the procedure for amplification compared to reaction products) and thus led to 
of catalytic RNA. Amplification occurs during transcription 
as a consequence of the ability of T7 RNA polymerase to 
A. Amplification 
Using a combination of two polymerase enzymes, it is 
selective amplification of the catalytically active RNAs. 
C. Introduction of Variation 
generate 2oo to l2O0 copies Of RNA transcript per Of Mutations were introduced in two ways. First, at the 
'O1. 15, 25 outset, a set of mutagenic oligodeoxynucleotides that con- 
tained random substitutions at a fixed frequency of occur- 
temp1ate et "7 in The 
p. D. Boyer (ed.), Academic Press, NY, lgS2, PP. 87-108). 
The amplification reaction is done in a single test tube at rence was used, These partially randomized oligodeoxy- 
a Constant temperatUre Of 37" c . ,  resulting in an increase Of nucleotides were produced on an automated DNA 
lo3 to lo6 times the original input of RNA after one hour synthesizer with nucleoside 3'-phosphoramidite solutions 
(Guatelk et d . ,  PNAS USA 87: 1874 (1990); Joyce, in 30 that had been doped with a small percentage of each of the 
Antisense RNA and DNA, J. A. H. Mumay (ed.1, WileY-LiSS, three incorrect monomers (McNeil, et al., Id. (1985); 
NY, 1992, PP. 353-3721, The Procedure for RNA amPlifi- Hutchison, et al., Id. (1986)). Second, after each round of 
follows. Reaction conditions: lo9 to 10' nM RNA, 1 fl by performing the PCR under mutagenic conditions (Leung, 
primers, 2 mM eachnucleoside triphosphate (N'W, 0.2 35 et al., Id. (1989); zhou, et al., Id. (1991)). 
In general, when using PCR procedures, each primer each deoxynucleoside triphosphate (dNTP), 10 mM MgCl,, 
cation, which is illustrated in FIG. 2A, is essentially as selective amplification, random mutations were introduced 
50 mM tris-HC1 (PH 7.5), mM dithiothreitol (D7T), AMv works in combination with a second primer to amplify a 
target nucleic acid sequence. The choice of PCR primer pairs transcriptase at 0.5 "& T7 RNA polymerase at 
4o for use in PCR is governed by various considerations, as 
B. Selection discussed herein. That is, the primers have a nucleotide 
The amplification was performed selectively in that indi- sequence that is complementary to a sequence conserved in 
vidual RNAs in the population were required to catalyze a the gene of choice. Useful priming sequences have been 
particular chemical reaction in order to become eligible for disclosed herein. The strategy used for cloning the selected 
amplification (Joyce, Id. (1989); Robertson and Joyce, Id. 45 genes will depend, as is well known in the art, on the type, 
(1990)). The selection was based on the ability of group I complexity, and purity of the nucleic acids making up the 
ribozymes to catalyze a sequence-specific phosphoester various genes. Other factors include whether or not the 
transfer reaction involving an oligonucleotide (or oligode- genes are to be amplified and/or mutagenized. 
oxynucleotide) substrate (see FIG. 2B). In general, the exemplary genes are comprised of poly- 
FIG. 2B illustrates the procedure for selective amplifica- 50 nucleotide coding strands, such as mRNA and/or the sense 
tion based on phosphoester transfer activity of a group I strand of genomic DNA. If the polynucleotide sequence is in 
ribozyme. The procedure for selective amplification based the form of double stranded genomic DNA, it is usually first 
on phosphoester transfer activity of a group I ribozyme is denatured, typically by melting, into single strands. A gene 
essentially as follows. sequence is subjected to a PCR reaction by treating (con- 
The 3' portion of the substrate, d(A3(TA3)3) (SEQ ID NO 55 tatting) the Sequence with a PCR Primer Pair, each member 
51, was transferred to the 3'..terminal guanosine of the of the pair having a preselected nucleotide sequence. The 
ribozyme, ~~~~~i~~ conditions for RNA-catalyzed DNA PCR primer pair is capable of initiating primer extension 
cleavage were as follows: 1 Tetrahymena fibozyme reactions by hybridizing to nucleotide sequences, preferably 
(L-21 form), 10 d(GGCCCTCTA, ( T A ~ ) ~  (SEQ ID NO at least about 10 nucleotides in length and more preferably 
6), 10 N-[2-hydroxymethyl]-pipera- 60 at least about 20 nucleotides in length, conserved within the 
zine-N-[3-propanesulfonic acid] (EPPS) (pH 7.5); 37" C., 1 gene sequence. 
hour. Selective amplification occurred as described in sub- The PCR reaction is performed by mixing the PCR primer 
section 1 above with respect to selective amplification of pair, preferably a predetermined amount thereof, with the 
catalytic RNA, with d((T3A)3T3C) (SEQ ID NO 7) as primer nucleic acids of the selected gene or DNA nucleotide 
1 and d(ATCGATAATACGACTCACTATAGGAGG- 65 sequence, preferably a predetermined amount thereof, in a 
GAAAAGTTATCAGGC) (SEQ ID NO 8) as primer 2. PCR buffer to form a PCR reaction admixture. The admix- 
Subsequent selective cDNA synthesis with 0.2 pmol of the ture is maintained under polynucleotide synthesizing con- 
U/pl; 37" C., 1 hour. 
MgC1,, 30 
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ditions for a time period, which is typically predetermined, 
sufficient for the formation of a PCR reaction product, 
thereby producing a plurality of different polypeptide-en- 
coding DNA homologs. 
method. PCR amplification methods are described in detail 
in U.S. Pat. Nos. 4,683,192, 4,683,202, 4,800,159, and 
4,965,188, and at least in several texts including “PCR 
Technology: Principles and Applications for DNA Amplifi- 
cation”, H. Erlich, ed., Stockton Press, New York (1989); 
and “PCR Protocols: A Guide to Methods and Applications”, 
Innis et al., eds., Academic Press, San Diego, Calif. (1990). 
Themzus aquaticus DNA polymerase I, which is useful in 
PCR, is described in U.S. Pat. No. 4,889,818. 
sequence arose that allowed false hybridization of one of the 
amplification primers at an internal site, generating a species 
with a 53-nucleotide deletion that was amplified more 
efficiently than the full-length ribozyme. Thus, it is impor- 
tant to monitor the populations generated and remove such 
“Parasites”, if and When they appear. 
To generate the initial population of ribozyme variants, 
random mutations were introduced throughout the catalytic 
core of the molecule. Four synthetic oligodeoxynucleotides 
were prepared, each of which randomly mutagenizes 35 
nucleotide positions at an error rate of 5% per position (FIG. 
3). 
FIG. 3 illustrates the secondary structure of the Tetrahy- 
mena ribozyme (L-21 form) showing those regions that were 
Restriction sites may also be incorporated into the 5‘ and 15 randomly mutagenized (boxed segments). The transcription 
template (containing mutagenic oligodeoxynucleotides), 2 
mM NTp’s7 l5 mM MgC1z, mM spermidine, mM Dny 
50 mM tris-HC1 (pH 7 . 3 ,  1500 U of T7 RNA polymerase 
were admixed to a volume of 60 jd and held at 37” C. for 2 
hours. RNA was purified by electrophoresis in a 5% poly- 
raphy on Sephadcx G-50. 
The PCR reaction is performed using any suitable 5 
3’ primers to enable the amplification products to be sub- conditions were essentially as follows: pmol of DNA 
cloned into sequencing or expression vectors. It may also be 
helpful to place a 4-base spacer sequence proximal to the 
restriction site to improve the efficiency of cutting amplifi- 
cation products with enzymes. 
under standard reaction conditions (see FIGS. 2A and 2B, 
and subsections 1 and 2 above), resulting in an error rate of 
approximately o, % per position per generation, A 
rate of 0.66M.13% per position (95% confidence level) has 
2o 
In study, the PCR was performed acryl-d&M urea gel and subsequent column chromatog- 
The degenerate oligodeoxynucleotides were incorporated 
to produce the mutant 
mutagenic, modified PCR procedure that provides an error 25 into a DNA temp1ate that the ribozyme, and the 
temp1ate was transcribed 
also been developed. (See Cadwell and Joyce, pC’M,&o& 
Appl. 2: 28 (1992), which is incorporated herein by refer- 
ence.) The RNAs obtained by selective amplification were 
subjected to reverse transcription, the resulting cDNAs were 30 to contain the 
PCR amplified, and the PCR products were transcribed to 
RNAs (Joyce and Inouye, Nucz. Acids Res. 17: 71 
Twenty pmol 
beginning. Thus, the generation 
(1989)). 
was used at the 
population was expected 
possible ‘-3 2-, 3-, and 
4-error mutants, and a sampling of the higher-error Imants  
molecules) Of 
ribozymc, 
produce a progeny distribution of mutant RNAs. 
Integration of the PCR with the selective RNA amplifi- 
cation procedure was useful in three other ways. First, it 
(see Table 1). 
Table 1 illustrates the composition of thc initial popula- 
tion (generation 0). The probability P of having K errors in 
increases the overall amplification by about lo3 times. 35 a doped oligonucleotide Of length 
Second, it simplifies the process of subcloning individuals 
from the evolving population. Normally, only a small par- 
and degeneracy is 
given by: PO<,v,d)=[v!/(v-k)!k)ldk(l-d)”-”. A total of 140 
positions were randomly mutagenized (‘=140) at a degen- 
tion of the DNA in the RNA amplification mixture is fully eracy of 5% per position (d4.05). The number of distinct 
stranded DNA (&DNA) is greatly increased, Third, it 40 sk. The expected number of copies per sequence is based on 
RNA-catalyzed phosphoester transfer reaction. After phos- 
phoester transfer, the ribozyme has the 3’ portion of the 
substrate attached to its 3’ end, and after selective RNA 
amplification, the substrate sequence remains attached (see 45 Errors (%) Sequences CopiedSequence 
double-stranded, but with the PCR, the amount of double- k-error sequences Of length is given by: Nk=[v!/(v-k)!k!l 
returns the RNA to a form that can participate in the a population size Of 2o pmol (1.2x10’3 
TABLE 1 
Probability 
0 (4 0.1 1 9 x io9 
1 0 6  420 2 x 108 
ribozymes is restored. 2 2.1 9 x 104 3 x 106 
3 50 1 x i07  5 x  104 
50 4 9 0  1 x 109 9 x  102 
FIGS. 2A and 2B). However, by subsequent use of PCR, 
followed by in vitro transcription, the original 3’ end of the 
D. Ribozymes: Generations 
The entire series of events, beginning with a heteroge- 5 128 1 x 10” 15 
neous population of RNAs, proceeding with RNA catalysis 6 15.2 7 x loL2 0.3 
in the target reaction, selective amplification of catalytically 7+ 55.4 
active RNAs, reverse transcription of the selective amplifi- 
cation products, mutagenic PCR, and in vitro transcription to 55 The evolution experiment spanned ten successive genera- 
produce a progeny distribution of RNAs, is referred to as tions; each generation began with 20 pmol of RNA. The 
one “generation”. Typically, a generation is completed in amount of RNA was quantified after selective amplification 
one to two working days, excluding time for analytic work. and after transcription (see FIG. 4). 
FIG. 4 illustrates the course of evolution over 10 succcs- The initial population of mutant RNAs is referred to as 
“generation o”, While subsequent POpUlatiOIlS Xi? referred to 60 sive generation, highlighting changes in RNA population 
as “generation l”, “generation 2 ’ ,  and so forth. In Principle, size over time. Closed circles represent RNA population size 
there is no limit to the number Of successive generations that after transcription, quantitated by [ 3 ~ ] ~ ~ ~ i l  content; open 
circles represent RNA population size at the start of each can be obtained. 
In practice, there is always the danger of developing a generation, based on 20-pmol portions; closed squares rep- 
“parasite” that circumvents the selection criterion and is 65 resent RNA population size after reaction with substrate, 
amplified more efficiently than the most reactive species. In estimated by the assay described in subsection 4 herein; and 
one of the within-disclosed experiments, for example, a open squares represent RNA population size after selective 
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am lification, quantitated by acid precipitation at 4" C. of urea gel and subsequent affinity chromatography on Nensorb 
[a- !Z PIGTP-labeled progeny RNA. (duPont, Wilmington, Del.). 
DNA cleavage activity for the population as a whole was The hydrolysis product forms either by direct cleavage of 
monitored by a gel electrophoresis assay involving cleavage the DNA substrate or by cleavage of the ribozyme- 
of [5'-32P]-labeled d(GGCCCTCT-A,(TA,),) (SEQ ID NO 5 d(A3(TA3),A) (SEQ ID NO 12) covalent intermediate. 
6) to yield d(GGCCCTCT) (SEQ ID NO 10) (data not Together, these reactions account for less than 5% of the 
shown). Cleavage of the substrate ("S") d(GGCCCTCT- cleaved substrate. 
A3(TA3),) (SEQ ID NO 6) in the absence of enzyme, in the After ten generations, DNA cleavage activity for the 
Presence Of the wild-type Tetrahymena ribozYme (L-21 population as a whole is 30 times higher than that of the wild 
form), and in the presence of the population of RNAs 10 type. Because selection is based on primer hybridization to 
obtained at each generation (GA n=o-lo) was masured the EPcovalent intermediate (see FIG. 2B), there is selection 
(data not shown). pressure against the subsequent site-specific hydrolysis reac- 
Reaction conditions were as follows: 0.5 pM ribozyme, tion. As a consequence, the efficiency of the hydrolysis 
0.1 pM substrate (2.6 pCi/pmol), 30 mM EPPS (pH 7.5); reaction relative to the initial phosphoester transfer evcnt 
either 10 mM MgCl,, 37" C., 1 hour (low) or 50 mM MgCI,, 15 drops from 4.9% for the wild type to 1.5% for the generation 
2 mM spermidine, 50" C., 1 hour (high). Reaction products 10 population. There is selection pressure favoring accurate 
were separated by electrophoresis in a 20% polyacrylamide- cleavage of the DNA at the target phosphodiester; inaccurate 
8M urea gel, of which autoradiograms were made; P repre- cleavage would result in partial mismatch of the primer used 
sented [5'-32P]d(GGCCCTCT) (SEQ ID NO lo), and P,, to initiate selective amplification. Theaccuracy of cleavage 
represented [5'-32P]d(GGCCCTCTA) (SEQ ID NO 11) (not 20 at first declines from 90% for the wild type to 45% for the 
shown). generation 8 population, and then rises to 60% for the 
It is expected that any given mutation would more likely generation 10 population. There are some individuals in the 
be detrimental than beneficial, although there may be a Population that Sacrifice accuracy for improved cleavage 
substantial number of neutral mutations. Indeed, DNA activity in order to enjoy an Overdl Selective advantage (See 
cleavage activity for the generation 0 population is less 25 below). Of course, a preferred result is an individual having 
efficient than for the wild type. The generation 1 population, both high accuracy and high cleavage activity. 
having been selected for DNA cleavage activity under E. Evolutionary History 
physiologic conditions, showed improved catalytic activity Although evolution in natural populations is an accom- 
compared to generation 0 and is slightly improved Over the plished fact, evolution in vitro is a work in progress that 
wild type. Though successive generations, there is contin- 30 allows the experimenter to access any time period in eve- 
ued improvement of Phenotype. BY generation 7, the POPU- lutionary history. Subclones were obtained from the evolv- 
lation as a whole cleaves DNA more efficiently at 37" C. and ing population at every generation, essentially as follows. 
10 mM MgCIz than does the wild type at the high-tempera- DNAs used to transcribe the population of RNAs at each 
ture, high-MgClz condition. Though generation 10, the rate 35 generation (see subsections 1-3 above) were amplified in a 
of improvement has yet to level off. second PCR reaction with primers 5'-CCAAGCT- 
RNAs from each generation were purified by polyacry- TGATCTCGAGTACTCCAAAACTAATC-3' (SEQ ID NO 
lamide gel electrophoresis and Sephadex chromatography. 14) and S-CTGCAGAATTCTAATACGACTCACTAT- 
To provide a more formal assay of DNA cleavage activity, AGGAGGGAAAAGTTATCAGGC-3' (SEQ ID NO 15), 
d(GGCCCTCTA,(TA3),[5'-32P]A) (SEQ ID NO 13) sub- 4o producing a 435-bp (base pair) fragment with unique restric- 
strate was prepared as follows, and formation of both the tion sites at its ends. The fragment was digested with Eco FU 
ribozyme-d(A,(TA,),A) (SEQ ID NO 12) covalent inter- and Hind I11 and ligated into a pUC18 vector that had been 
mediate and the RNA-catalyzed site-specific hydrolysis linearized with Eco RI and Hind I11 and purified in a 1.5% 
product d (A3(TA3),A) (SEQ ID NO 12) was measured (see agarose gel. The resulting plasmid DNAs were used to 
FIG. 5).  (See also Inoue, et al., J. Mol. Biol. 189: 143 45 transform competent DH5a-F cells (see Hanahan, in DNA 
(1 986).) Cloning: A Practical Approach, D. M. Glover, ed., IRL 
FIG. 5 illustrates the cleavage of [3'-32P]dA-labeled Press, Oxford, 1985, pp. 109-13% which were then grown 
~(GG~CCT~T-A,(TA,), [y_32p]~)  (SEQ ID NO 13). on ampicillin-containing plates. Individual colonies were 
Cleavage of [3'-32P]dA-labeled d (GGCCCTCT-A, (TA,), chosen at random and grown overnight in liquid media. 
[5'-32P]A) (SEQ ID NO 13) was conducted under reaction 50 DNA was Prepared by the boiling lysis method (Holmes, et 
conditions as described hereinabove prior to autoradiogram. al., Anal. Biochem. 114: 193 (1981)) and screened for the 
Substrate (S), enzyme/product (EP), and product (P) (see 
FIG. 2) were separated by electrophoresis in a 20% poly- As noted, subclones were obtained from the evolving 
acrylamide-8M urea gel. Individual bands were cut from the population at every generation. Generations 3,6, and 9 were 
gel and quantitated by Cerenkov counting. Data points are 55 chosen for detailed analysis. DNA was prepared from 25 
the average of five replicate experiments performed on three subclones at generations 3 and 6 and from 50 subclones at 
different days with two different preparations of substrate. generation 9. The nucleotide sequence of the entire 
Error bars correspond to +1 SD. ribozyme gene was determined for each of these subclones 
Substrate was prepared via the following procedure. The essentially as follows. 
[3'-32P]-labeled DNA substrate was prepared with terminal 60 Cloned individuals were sequenced by the dideoxy chain- 
deoxynucleotide transferase. Reaction conditions were as termination method (Sanger, et al., PNAS USA 74: 5463 
follows: 4 pM d(GGCCCTCT-A,(TA,),) (SEQ ID NO 6), 1 (1977); Zagursky, et al., Gene Anal. Tech. 2: 89 (1985)) with 
pM [a-32P]dATP (3 pCi/pmol), 1 mM CoCl,, 1 mM DTT, 50 reciprocal primers 5'-GTAAAACGACGGCCAGT-3' (SEQ 
mM potassium cacodylate (pH 7.2) and terminal transferase ID NO 16) and 5'-CATGATTACGAATTCTA-3' (SEQ ID 
(BRL) at 2.7 U/pl, incubated at 37" C. for 30 minutes. The 65 NO 17), which are compatible with the pUC plasmid. 
product corresponding to addition of a single dA residue was Sequencing reactions utilized modified T7 DNA polymerase 
purified by electrophoresis in a 20% polyacrylamide-8M (Sequenase, USB) and [35S](a-thiophosphate) dATP and 
by restriction digestion. 
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were analyzed by electrophoresis in a 6% polyacrylamide- E Activity of Evolved Individuals 
8M urea gel. Nucleotide sequences of individual subclones DNA from 14 subclones at generation 9 was transcribed 
were also obtained (not shown). to produce individual RNAs which were purified by poly- 
Analysis of the determined sequences indicated how acrylamide gel electrophoresis and Sephadex chromatogra- 
genotype changes over the course of evolutionary history 5 phy. The catalytic behavior of these RNAs was studied with 
(not shown). From generation 0 to generation 3, variation is [5'-32P]- and [3'-32P]-labeled DNA substrates having the 
discarded throughout much of the catalytic core of the sequence GGCCCTCTC-A,(TA,), (SEQ ID NO 25) and 
ribozyme. The mean number of mutations per subclonc with [5'-32P]- and [a-32pl-ATP-labeled RNA substrates hav- 
decreased from 7.0 at generation 0 to 2.7 at generation 3. By ing the sequence GGCCCUCUC-A3(UA3)3 (SEQ ID NO 
generation 3, a small number of mutations outside of the 10 18). The kinetic parameter most relevant to our selcction 
original zone of random mutation have occurred because of criterion was the Proportion of ribozyme molecules that 
ongoing mutation events (not shown). The consensus 
sequence is still that of the wild type, although only one of 
25 subclones has the entire wild-type sequence. 
From generation 3 to generation 6, the dramatic accumu- 
lation of mutations at five positions within the ribozyme 
coincides with a three-fold improvement in the phenotype of 
the population as a whole. From generation 6 to generation 
9, these positions are further accentuated and aggregate 
phenotype improves another three-fold. The mean number 
of mutations pcr subclone rises to 4.6 at generation 6 and to 
5.9 at generation 9 as a larger proportion of subclones adopt 
the common mutations and as mutations accumulate outside 
of the original zone of random mutation. 
The most frequent mutation is an A+Y (Y=U or C) 
change at position 94 (94:A+Y). This mutation is present, 
as A 4 J ,  in only 1 of 25 subclones at generation 3. At 
generation 6, there are 15 out of 25 occurrences, 12 as A+U 
and 3 as A+C; at generation 9, there are 35 out of 50 
occurrences, 22 as A+U and 13 as A+C. Position 94 is 
unpaired in the secondary structure of the wild-type 
ribozyme (Burke, et al., Nucleic Acids Res. 15: 7217 
(1987)). Considering the effect of site-directed mutations 
made at neighboring positions (Young, et al., Cell 67: 1007 
(1991)), the 94:A+Y change may alter the orientation of 
ribozyme-bound substrate relative to the catalytic core of the 
molecule. 
Another frequent mutation, occurring in 4 of 25 subclones 
at generation 3 , 6  of 25 subclones at generation 6, and 22 of 
50 subclones at generation 9, is a G+A change at position 
215. This mutation converts a G.U wobble pair to an A.U 
Watson-Crick pair within the catalytic core of the ribozyme. 
Among 87 group I intron sequences that have been analyzed, 
39 have a G.U and 28 have a G C ,  but only 4 have an A.U 
at this location (Michel, et al., J. Mol. Biol. 216: 585 (1990)). 
The most remarkable mutations are a G+U change at 
position 313 and an A+G change at position 314 that 
always occur together. These mutations are absent at gen- 
eration 3, but are present in 5 of 25 subclones at generation 
6 and 16 of 50 subclones at generation 9. The GA sequence 
normally present at positions 313-314 is thought to form a 
short duplex structure (the 5' half of the P9.0 pairing) that 
draws the 3'-terminal guanosine residue of the ribozyme into 
the catalytic core (Michel, et al., Nature 342: 391 (1989); 
Michel, et al., Genes Dev. 4: 777 (1990)). The 3'-terminal 
guanosine was utilized as the nucleophile in the target 
phosphoester transfer reaction. The 313-314 mutations are 
expected to destroy the P9.0 pairing, yet confer selective 
advantage with respect to DNA cleavage (see below). 
There is a frequent G+A change at position 312 that 
occurs only if the 313-314 mutations are not present. The 
312:G+A change is present in 4 of 25 subclones at gen- 
eration 3 and 8 of 25 subclones at generation 6 ,  but only 5 
of 50 subclones at generation 9. In terms of population 
frequency, the 3 12:G+A mutation declines as the 
3 13-3 14:GA+UG mutations become more abundant. 
become joined to the 3' portion of the DNA substrate after 
1 hour at 37" C. and 10 mM MgCl,. These data and 
comparable data concerning reactions with a DNA substrate 
at 50" C. and 50 mM MgCl, and with an RNA substrate at 
l5 37" C. and 10 mM MgCl, were collected and plotted (data 
not shown). 
The catalytic activity of 14 individual ribozymes obtained 
at generation 9 was determined (not shown). Ribozymes 
were transcribed and assayed according to the procedures 
2o described in subsection 4 above. RNA substrate was pre- 
pared by in vitro transcription with a synthetic oligodeoxy- 
nucleotide template; reaction conditions were as described 
previously for the data illustrated in FIG. 3, but included 
[c~-~~P]ATP at 0.003 pCi/pmol to label the 3' portion of the 
There was considerable heterogeneity among the 14 indi- 
vidual RNAs with respect to DNA cleavage activity in the 
target reaction. All were more active than the wild type, with 
the best (clones 29 and 23) being about 60 times more active. 
The five most active individuals were more active under 
physiologic conditions than under the high-temperature and 
high-MgC1, conditions. All 14 individuals showed improved 
activity with the RNA substrate, even though the population 
had never been challenged with RNA. Improved RNA 
35 cleavage activity was largely due to enhanced activity in the 
site-specific hydrolysis reaction ( ~ + 0 . 9 3 ) ,  which allowed 
enhanced turnover (data not shown). 
As mentioned previously, there is selection pressure 
4o against site-specific hydrolysis of the EP covalent interme- 
diate in the reaction with a DNA substrate. In fact, all but one 
of the 14 individuals showed decreased hydrolytic cleavage 
of the attached DNA compared to the wild type. All but one 
of the individuals show increased hydrolytic cleavage with 
45 the RNA substrate. Furthermore, there was a strong negative 
correlation ( ~ - 0 . 9 3 )  between hydrolytic cleavage of DNA 
and RNA. The population was clearly divided into two 
groups: those with low DNA and high RNA hydrolysis 
activity, and those with high DNA and low RNA hydrolysis 
5o activity (not shown). All nine members of the former group 
carry the 313-314:GA+UG mutations, while all five mem- 
bers of the latter group lacked these changes. 
FIG. 6 illustrates Eadie-Hofstee plots used to determine 
K, (negative slope) and V, (y-intercept) for cleavage of 
55 (5'-32P)-labeled d(GGCCCTCT-A,(TA,),) (SEQ ID NO 6) 
by wild type ribozymes and clones 29 and 23 from genera- 
tion 9. Reaction conditions were as follows: l @I ribozyme, 
10 mM MgCl,, 30 mM EPPS (pH 7.5),37" C.; for wild type 
10,20,40 and 80 pM substrate at 0.25,30,60, 120, 180 and 
60 240 minutes; for clone 29, 2.5, 5,  10, and 20 @I substrate 
at 0.25,5, 10 and 15 minutes; for clone 23,2.5,5, 10 and 20 
@I substrate at 0.25, 5, 10, 20 and 30 minutes. Ribozyme 
and substrate were first incubated separately in 10 mM 
MgCl,, 30 mM EPPS (pH 7.5),37" C., for 15 minutes, then 
65 mixed to start the reaction. 
Closed circles represent the wild type; closed squares 
represent clone 29; and closed triangles represent clone 23. 
25 substrate. 
30 
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Each data point is the average of three independent deter- 
minations of initial velocity. The extent of the reaction was 
linear over the chosen time interval (r,,=0.94, ru,=0.99). 
bond; reaction conditions were also as described in subsec- 
tion 4 above. 
TABLE 2 
DNA Hydro- Accu- 
Errors 94: 98: 205: 215: 313-314: 317: 333: cleavage lysis racy 
Clone (N) A + Y  C + U  U + C  G + A  G A + U G  U + R  U - t C  b, bz b3 
0.1 0.7 29 6 1 0 0 1 1 0 0 65 
23 7 1 0 0 1 1 0 0 57 0.1 0.6 
30 8 1 0 0 1 1 1 0 48 0.1 0.8 
43 8 1 0 0 1 1 0 1 32 0.0 0.4 
5 7 1 0 0 0 1 0 0 22 0.1 0.4 
37 4 0 0  0 1 1 0 0 21 0.1 0.6 
28 5 0 1 0 0 1 0 0 15 0.0 0.7 
2 5 0 0  0 0 1 0 0 11 0.0 0.8 
42 6 1 0 0 1 0 0 0 7 0.7 0.8 
8 8 1 0 1 0 1 0 0 3 0.2 1.1 
40 1 0 0  0 1 0 0 0 3 0.9 0.6 
12 6 0 1 1 0 0 1 0 3 0.7 0.8 
27 2 1 0 0 0 0 0 0 3 0.8 0.6 
11 6 1 1 0 0 0 0 1 3 1.2 0.8 
Wt 0 0 0  0 0 0 0 0 1 1.0 1.0 
xl: 10 2 -18 13 18 13 -9 
x2: 0.4 0.7 0.2 0.4 -0.4 -0.2 -0.1 
x3: 0.3 0.6 0.4 0.3 0.2 -0.1 -0.3 
avg.' 5.6 0.6 0.2 0.1 0.5 0.6 0.1 0.1 21 0.3 0.7 
G9' 5.9 0.7 0.1 0.2 0.4 0.3 0.1 0.2 21 0.3 0.6 
'Avg. = the average of the 14 individuals 
'G9 genotype is the average of the 50 subclones obtained from the 9th generation; G9 phenotype is the behavior of the G9 
population as a whole 
30 
Clones 29 and 23 were chosen for more detailed kinetic As shown in Table 2, phenotype can be represented as a 
analysis, for comparison with the wild-type ribozyme. Initial column vector b, whose entries are some measure of fitness 
rates were determined for the reaction with [5'-32P]-labeled (catalytic behavior) of the various individuals. One then 
d (GGCCCTCT-A,(TA,),) (SEQ ID NO 6) substrate at 37" seeks a row vector x that provides a best fit to the equation: 
C. and 10 mM MgCl,, with 1 pM ribozyme and excess 35 Ax=b, that is, provides a best fit linear estimation of the 
substrate. An Eadie-Hofstee plot of vo as a function of vd[S] relation between genotype and phenotype. The solution that 
was used to obtain V, and K, (FIG. 6). From this data, minimizes the least-squares error is: x=(A*A)-' A*b, where 
k, and k,JK, were calculated. For the wild-type A* is the transpose of A. In this way, one obtains a weighing 
ribozyme, K,=6.6 pM and kcu,=0.0002 min-'(k,jK,= vector x that provides an estimate of phenotype for any 
36M-I mid) .  This compares to K,=30 pM and kcu,=0.006 40 given genotype (Table 2). 
min-', previously reported for the wild-type ribozyme in a The data obtained from 14 individuals is not sufficient to 
related reaction at 50" c. and 10 mM MgCb (Herschlag, et provide a meaningful solution to the relation of genotype to 
al.9 Id. (1990)). For clone 29, Krn='.O Ph'l and kcu~=0.007 phenotype, even for those nucleotide positions that are 
min-' (kcaJK,=3600M-'min-'); for clone 23, K,=1.9 r*M known to be most significant based on their high frequency 
and kCuF0.005 fin-' (kcuJKrn=2700M-' min-') (data 45 of accepted mutation. The weighing vector x is used as a 
obtained at 37" c. and 10 mM MgClz). Thus, the Catalytic guide to help decide which mutations are sufficiently impor- 
efficiency of the two evolved RNAs was increased and was tant to warrant individual study. 
about 100 times greater than that of the wild type, because by of improvement in both K, and kcat. 
50 site-directed mutagenesis: 94:A+U, 94:A+C, 215:G-+A, 
G. Correlating Genotype and Phenotype 313:G+U, 314:A+G, and 313-314:GAjUG. Catalytic 
The relation between genotype and phenotype in the activity was studied with d(GGCCCTCT-A,~A,),[5'-32P] 
context of an RNA-based evolving system can now be A) (SEQ ID NO 13) substrate. 
formalized. Genotype can be represented as a matrix A, the Site-directed mutagenesis was carried out essentially as 
rows corresponding to individuals in the population and the 55 described in Morinaga, et al., Biotechnology 2: 636 (1984), 
COlUIIlIlS corresponding to fUIlCtiOIldly Significant positions which may be described as follows, Plasmid pT7L-21 
within the nucleotide sequence (Table 2). (Zaug, et al., Biochemistry 27: 8924 (1988)) was digested 
Table 2 shows the genotype and phenotype of 14 indi- with either (i) Eco RI and Hind I11 to remove the ribozyme 
viduals from generation 9. Genotype is represented as a coding region, or (ii) Bsa I and Xmn I to remove the 
binary matrix (shown in brackets). Phenotype is represented 60 ampicillin-resistance gene. The resulting fragments were 
as a column vector b,, with values normalized to wild purified in a 1% agarose gel and cross-hybridized in the 
t y p s l  .O. DNA cleavage and hydrolysis activity were deter- presence of a 5'-phosphorylated synthetic oligodeoxynucle- 
mined with [3'-32P]-labeled DNA substrate under physi- otide that introduces the desired mutation. The annealing 
ologic conditions, as described in subsection 4 above. Accu- mixture contained 0.06 pmol of pT7L-21(AEco-Hind), 0.06 
racy was determined with [5'-32P]-labeled DNA substrate 65 pmol pT7L-2l(ABsa-Xrnn), 15 pmol of mutagenic oligode- 
under physiologic conditions, measuring the fraction of oxynucleotide, 40 mM Tris-HC1 (pH 7.2), and 8 mM MgSO, 
substrate cleavage that occurs at the target phosphodiester in 1 2 4  volume, which was heated to 100" C. for three 
The following individual mutations were 
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minutes, then incubated at 30" C. for 30 minutes, and 0" C. 
for 10 minutes. 
The annealing product was made fully double-stranded 
with the Klenow fragment of E. coli DNA polymerase I 
(Boehringer-Mannheim, Indianapolis, Ind.) and T4 DNA 
ligase (U.S. Biochemical, Cleveland, Ohio) and then used to 
transform competent DHSa-F' cells, which were grown on 
ampicillin-containing plates. Colonies were screened by the 
colony hybridization method with [5'-32P]-labeled 
mutagenic oligodeoxynucleotide as a probe (Grunstein, et 
al., PNAS USA 72: 3961 (1975)). DNA was prepared from 
positive colonies and sequenced throughout the ribozyme 
gene, as described above. 
RNA was prepared by in vitro transcription, essentially as 
follows. Transcription conditions: 2 pmol of DNA template 
(containing mutagenic oligodeoxynucleotides), 2 mM 
nucleotide triphosphates (NTPs), 15 mM MgCl,, 2 mM 
spermidine, 5 mM dithiothreitol (DIT), 50 mM tris-HC1 (ph 
7 . 3 ,  1500 U of "7 RNA polymerase; 60 pl volume; 37" C., 
2 hours. RNA was purified by electrophoresis in a 5% 
polyacrylamide-8M urea gel and subsequent column chro- 
matography on Sephadex G-50. 
The individual mutations result in improved activity com- 
pared to the wild type, but they do not result in activity 
exceeding that of the generation 9 population as a whole. 
Data were obtained regarding the DNA cleavage activity of 
individuals obtained by site-directed mutagenesis (not 
shown). Reaction conditions were as described in subsection 
4 hereinabove, relating to FIG. 5. The symbol (-) indicates 
absence of enzyme, while G9 represents generation 9 popu- 
lation as a whole. Reaction products were separated in a 
20% polyacrylamide-8M urea gel, an autoradiogram of 
which is shown. 
Activity in the 94:A+U mutant is seven times greater and 
in the 94:A+C mutant it is two times greater than in the wild 
type. The 313-314:GAjUG double mutant is more active 
than either the 313:G+U or 314:AjG single mutant, 
explaining why the 3 13-314 mutations occur together 
among the evolved individuals examined herein. As pre- 
dicted from the analysis of 14 individuals at generation 9, 
the 313-314:GAjUG mutations result in diminished site- 
specific hydrolysis of the DNA substrate compared to the 
wild type. These mutations confer both enhanced phospho- 
ester transfer activity and diminished site-specific hydrolysis 
activity, and thus are well suited to meet the imposed 
selection constraint which depends on availability of the EP 
covalent intermediate. 
H. Extension of Directed Evolution to Develop Other 
Evolved Species 
As an in vitro model of Darwinian evolution, a population 
of macromolecular catalysts was directed toward the expres- 
sion of novel catalytic function. In the present Example, the 
development of ribozymes that cleave DNA with improved 
efliciency under physiologic conditions has been demon- 
strated. These evolved RNAs were also used to cleave a 
target DNA in vivo; ribozymes obtained from generation 9 
were expressed in E. coli and shown to prevent infection by 
M13 single-stranded DNA bacteriophage (not shown). 
The present successful phylogeny has been continued 
beyond the tenth generation, after decreasing the concentra- 
tion of DNA substrate in the target reaction, as further 
described in Example 2 hereinbelow. Through the first ten 
generations the substrate concentration was 10 pM, roughly 
matching the K,, for the wild type. Now that the evolved 
individuals have attained a K, of about 2 pM, the substrate 
concentration has been reduced to subsaturating levels to 
promote further improvement in substrate binding. In addi- 
tion, catalytic turnover in the DNA cleavage reaction is 
being improved by selecting for both phosphoester transfer 
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activity, which generates the EP covalent intermediate, and 
subsequent RNA-catalyzed site-specific hydrolysis activity, 
which frees the ribozyme to act on another substrate mol- 
ecule. 
The selection scheme used herein may be applied to 
various substrates of the form: d(CCCTCNA,(TA,),) (SEQ 
ID NO 19), where N refers to a nucleotide analog and the 
ribozyme is selected for its ability to cleave the phosphodi- 
ester bond following the sequence CCCTCN (SEQ ID NO 
10 20). Examples of nucleotide analogs useful according to the 
present invention include those listed in the following Table, 
most of which are found in the approved listing of modified 
bases at 37 CFR 41.822 (which is incorporated herein by 
reference). 
5 
TABLE 3 15 
Nucleotide Analogs 
Abbreviation Description 
20 
25 
30 
35 
40 
45 
50 
55 
60 
ac4c 
cbm5u 
cm 
C d S 2 U  
d 
fm 
gal¶ 
gm 
i6a 
mla 
mlf 
mll 
m2a 
m2g 
m3c 
m5C 
m6a 
m7g 
m a m 5 U  
mam5sZu 
-¶ 
mcm5s2u 
mo5u 
ms2i6a 
ms216a 
m k  
*2g 
mt6a 
mv 
05u 
osyw 
P 
¶ 
s2c 
s2t 
s2u 
s4u 
t 
t6a 
tm 
um 
Ym 
X 
araU 
araT 
4-acetylcytidine 
5-(carboxyhydroxylmethyl)uridinc 
Z'-O-methylcytidinc 
5-carboxymethylaminomcthyl-2- 
thioridinc 
dihydrouridine 
2'-0-methylpseudouridine 
j3,D-galactosylqueosinc 
2'-0-methylguanosine 
inosine 
N6-isopcntenyladenosine 
1-methyladenosine 
1 -methylpseudouridinc 
1-methylguanosine 
1 -methylinosine 
2.2-dimethylguanosine 
2-methyladenosine 
2-methylgnanosine 
3-methylcytidine 
5-methylcytidine 
N6-methyladenosine 
7-mcthylguanosinc 
5-methylaminomethyluridine 
5-methoxyaminomcthyl-2-~ouridine 
P,D-mannosylmcthyluridine 
5-methoxycarbonylmc~yluridine 
5-mcthoxyuridine 
2-methylthio-N6- 
isopentenyladenosine 
N-((9-j3-D-ribofuranosyl-Z- 
methylthiopurine-6- 
y1)carbamoyl)threonine 
N-((9-P-D-ribofuranosylpurine-6- 
y1)N-methyl-carbamoy1)threonine 
uridine-5-oxyacetic acid 
methylester 
uridine-5-oxyacetic acid (v) 
wybutoxosine 
pseudouridine 
queosine 
2-thiocytidine 
5-mcthyl-2-thiouridine 
2-thiouridine 
Cthiouridine 
5-methyluridine 
N-((9-j3-D-ribofuranosylpurine-6- 
y1)carbamoyl)threonine 
2'-O-methyl-5-methyluridine 
2'-O-methyluridine 
wybutosine 
3-(3-amino-3-carboxyropyl)uridine, 
j3,D-arabinosyl 
j3,D-arabinosyl 
(acp3)u 
65 Nucleotide analogs that are particularly useful in the 
enzymatic RNA molecules, nucleotide substrates, and meth- 
ods disclosed herein include those having the abbreviations 
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cm, d, gm, i, p, s2c, s2u, s4u, t, um, araU, and araT. (The 
more complete names of these analogs are shown in the 
foregoing Table 3.) 
The substrate need not be a nucleotide or nucleotide 
analog. The only requirement is that RNAs that react with 
the substrate become tagged in some way so that they can be 
distinguished from nonreactive molecules with respect to the 
amplification process. For example, reactive RNAs could 
become joined to a portion of the substrate that is attached 
to a solid support, while nonreactive RNAs would be 
washed away, leaving the bound RNAs to be selectively 
amplified. These and other methodologies are further 
described below. 
Example 2 
Optimization of a DNA-Cleaving Enzymatic RNA 
Molecule 
A. Optimization and Selection Criteria 
In a previous analysis (see Example l), an in vitro 
evolution procedure was used to obtain variants of the 
Tetrahymena ribozyme with 1 00-fold improved ability to 
cleave a target single-stranded DNA under physiologic 
conditions. Reported herein is the continuation of the in vitro 
evolution process to achieve 105-fold overall improvement 
in DNA-cleavage activity. In addition, it is demonstrated 
herein that, by appropriate manipulation of the selection 
constraints, one can optimize specific catalytic properties of 
the evolved ribozymes. 
The concentration of the DNA substrate was first reduced 
50-fold, to favor ribozymes with improved substrate binding 
affinity. Next, the reaction time was reduced 12-fold to favor 
ribozymes with improved catalytic rate. In both cases, the 
evolving population responded as expected, first improving 
substrate binding 25-fold, and then improving catalytic rate 
about 50-fold. The population of ribozymes has undergone 
27 successive generations of in vitro evolution, resulting in, 
on average, 17 mutations relative to the wild-type that are 
responsible for the improved DNA-cleavage activity. 
In vitro selection and in vitro evolution techniques allow 
new catalysts to be isolated without a priori knowledge of 
their composition or structure. Such methods have been used 
to obtain RNA enzymes with novel catalytic properties. 
Ribozymes that undergo autolytic cleavage with lead cation 
have been derived from a randomized pool of tRNAph‘ 
molecules (Pan & Uhlenbeck, Biochemistry 31: 3887-3895 
(1992)). Group I ribozyme variants have been isolated that 
can cleave DNA (Beaudry & Joyce, Science 257: 635-641 
(1992)) or that have altered metal dependence (Lehman & 
Joyce, Nature 361: 182-185 (1993)). Starting with apool of 
random RNA sequences, molecules have been obtained that 
catalyze a polymerase-like reaction (Bartel & Szostak, Sci- 
ence 261: 1411-1418 (1993)). In the present example, 
refinement of specific catalytic properties of an evolved 
enzyme via alteration of the selection constraints during an 
in vitro evolution procedure is described. 
The within-described examples utilize derivatives of the 
self-splicing group I intron of Tetrahymena themophila, a 
ribozyme that is able to catalyze sequence-specific cleavage 
of single-stranded RNA via a phosphoester transfer mecha- 
nism (Zaug & Cech, Science 231: 4 7 W 7 5  (1986); Zaug et 
al., Nature 324: 429-433 (1986)), although it is expressly to 
be understood that the invention is not limited to these 
embodiments. The ribozyme contains a template region, 
referred to as the “internal guide sequence” (IGS), which lies 
at the 5’ end of the molecule and forms Watson-Crick base 
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pairs with the target RNA substrate. The 3’-OH of guanosine, 
including a guanosine residue that lies at the 3’ end of the 
ribozyme, is directed to attack a particular phosphoester 
bond within the ribozyme-bound substrate. A phosphoester 
transfer reaction ensues, resulting in cleavage of the sub- 
strate at a position immediately downstream from the region 
of base pairing, and concomitant ligation of the 3’ portion of 
the substrate to the 3’ oxygen of the attacking guanosine. The 
wild-type Tetrahymena ribozyme can cleave a single- 
io stranded DNA substrate with low efficiency under condi- 
tions of high magnesium concentration (50 mM MgCl,) 
and/or high temperature (50” C.) (Herschlag & Cech, Nature 
344: 405-409 (1990a); Robertson & Joyce, Nature 344: 
467-468 (1990)). Under more physiologic conditions (e.g. 
15 37” C., 10 mM MgCI,, pH 7.3,  however, the DNA-cleavage 
reaction is almost undetectable. 
An in vitro evolution procedure that may be used to obtain 
variants of the Tetrahymena ribozyme that can cleave DNA 
under physiologic conditions with improved efficiency com- 
20 pared to the wild-type (FIG. 7). (See also Beaudry and Joyce 
(Science 257: 635-641 (1992).) At the beginning of this 
procedure, a population of ribozyme variants was generated 
by partially randomizing the phylogenetically conserved 
portions of the molecule that are known to be essential for 
25 catalytic activity. Superior DNA-cleaving ribozymes were 
distinguished from less active molecules based on the like- 
lihood of attachment of the 3’ portion of the substrate to the 
3’ end of the ribozyme. A DNA primer was hybridized across 
the ligation junction of successful reaction products, and 
30 used to initiate a selective isothermal amplification reaction 
(see FIG. 7, bottom). The selectively amplified molecules 
then served as templates for cDNA synthesis; the resulting 
cDNA was amplified by the polymerase chain reaction 
(PCR) (Saiki et al, Science 230: 1350-1354 (1985); Saiki et 
35 al, Science 239: 487-491 (1988)); and the PCR products 
were transcribed to generate a new pool of RNAs. The entire 
process, beginning with the cleavage reaction and followed 
by selective isothermal amplification, cDNA synthesis, PCR 
amplification, and in vitro transcription, constitutes one 
40 “generation” of the in vitro evolution procedure. 
This in vitro procedure has successfully been used to 
generate 10 successive generations, starting with a pool of 
1013 variants of the Tetrahymena ribozyme (see Example 1 
above, and FIG. 7). After the 9th generation (G9), individual 
45 ribozymes were isolated from the population and shown to 
catalyze the cleavage of a DNA substrate 100-fold more 
efficiently compared to the wild-type enzyme. This modest 
improvement in catalytic efficiency resulted from both an 
increased catalytic rate (kcaJ and a decreased value for the 
50 Michaelis constant (K,). The outcome, however, was some- 
what dissatisfying because the ribozymes were still ineff- 
cient catalysts in an absolute sense, with k,,JK, on the 
order of 1 03M-’min-’. 
For each generation, the evolving population was pro- 
55 vided with 10 pM DNA substrate and allowed 1 hr to carry 
out the DNA-cleavage reaction. By G9, K, had improved 
from 6 pM for the wild-type to about 2 pM for the evolved 
individuals (see Example 1; see also Beaudry &Joyce, Id., 
(1992)). Accordingly, it appeared that the population was no 
60 longer under stringent selection pressure to drive further 
improvement of K,,,. Individual cleavage rates, on the other 
hand, were on the order of 0.007 m i d  by G9, still slow 
enough to be constrained by the 1 hr incubation period. 
However, if the reaction rate continued to improve, then the 
65 selection constraints would eventually become insufficient 
to favor further improvement of the catalytic rate. Appar- 
ently, additional generations of in vitro evolution, under 
5 
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different selection constraints, would be necessary to obtain purified by affinity chromatography on DuPont Nensorb 
substantially greater DNA-cleavage activity. (Wilmington, Del.). The concentration of ribozyme was 
In the present example, in vitro evolution techniques were determined spectrophotometrically, based on e,,,=3.2x106 
applied with a higher level of sophistication and control. M-' cm-' (Zaug et al., Biochemistry 27: 8924-8931 (1988)). 
Because the outcome of an in vitro evolution experiment 3. In Vitro Evolution Procedure 
depends on the nature of the selection constraints, specific In vitro evolution was carried out as described previously 
catalytic properties of a ribozyme, such as substrate binding (see Example 1 above) and as depicted in FIG. 7. While 
afhity, catalytic rate, substrate specificity, and turnover, polymerase chain reaction (PCR) or self-sustained sequence 
might be improved by appropriate manipulation of the replication (3SR) methods are both useful, the within- 
reaction conditions. With this in mind, optimization of two described methodology most closely resembles the 3SR 
catalytic properties of the DNA-cleaving ribozymes, 10 method (see, e.g., Guatelli et al., PNAS USA 87: 1874-1878 
namely, substrate binding affinity and catalytic rate was a (1990)). The 3SR system is particularly useful in the detec- 
primary goal. It was hypothesized herein that ribozymes tion and nucleotide sequence analysis of rare RNAs and 
with the greatest affinity for the substrate would enjoy a DNAs. 
selective advantage when the substrate is presented at low The population of DNA-cleaving ribozymes obtained 
concentrations. Under saturating conditions, ribozymes with 15 after 9 generations Of in Vitro evolution in Example 1 above 
the fastest first-order rate of reaction would be favored when was wed as material. RibozYmes (o.l w) and DNA 
the reaction time is very short. substrate (0.2 pM) were incubated at 37" C. for 1 hr in a 100 
7.5). After ethanol precipitation, a portion of the reaction 
products (10-50%) was added to a 20 fl isothermal ampli- 27 additional generations of in vitro evolution were carried 2o fication reaction mM MgCl,, mM 
out under somewhat different reaction conditions. From KOAc, 50 mM (pH 7,5), mM Drr, mM each mp, 
generations 10 through 18, the substrate concentration was 0.2 mM each d m ,  4 clci [a-32P]GTP, 12.5 u / N  MOMLV 
reduced 5°-fo1d7 from lo fl to o.2 r*M. From generations reverse transcriptase, 50 U/N RNA polymerase, and 20 
19 through 27, the lower substrate concentration was main- pmol each of 5 ' - m A m A m A m - 3 '  (primer la, SEQ 
tained and the reaction time was reduced 12-fold, from 1 hr ID NO 21) and 5'-CTGCAGAA?TCTAATACGACTCAC- 
to 5 min. On the basis of binding and kinetic studies, the 25 TATAGGAGGGAAAAGTTATCAGGC-3' (Primer 2, SEQ 
population of ribozymes responded lo each alteration of the ID NO 15), which was incubated at 37" C. for 2 hr. Primer 
selection constraints as predicted, becoming enriched with 1 hybridizes to the 3' portion of the substrate that becomes 
tighter substrate binders during generations 10-18, and then attached to the 3' end of the ribozyme. (Primers l a  and lb ,  
with faster catalysts during generations 19-27. Generations when used, perform similarly.) Primer 2 hybridizes to the 3' 
28-36 are discussed in subsection 6 hereinbelow. 30 end of the resulting cDNA and introduces the T7 promoter 
B. Materials and Methods sequence. 
1. Materials Twenty-five percent of the isothermal amplification prod- 
Unlabeled nucleoside triphosphates (ws) and deoxy- ucts were used to generate cDNA in a 20 fl reaction mixture 
nucleoside triphosphates (dNTPs) were purchased from containing lo mM MgC1z, 50 mMTris (PH 7.5)7 mM Drr, 
Pharmacia, and dideoxynucleoside triphosphates (ddNTPs) 2 mM each NTP, 0.2 mM each dNTP, 0.2 U/fl AMV reverse 
were from u.s. Biochemical (USB, Cleveland, Ohio). 35 transcriptase and 20 pmol Primer la, incubated at 37" C. for 
1 hr. Approximately 5-10% of the resulting cDNA was 
Radiochemicals. Synthetic oligodeoxynucleotides were 1.5 m~ MgCl,, 50 m~ K-1, 10 ~ r i ~  ( P ~8.31, o.]% 
acrylamide gel electrophoresis and subsequent chromatog- CAAAACTAATC-~' (Primer ib, SEQ ID NO 91, 20 pmol 
raPhY on SePhadex (3-25. Restriction enzymes and T4 40 Primer 2, and 2.5 U Taq DNA polymerase, carried out for 30 
polynucleotide kinase were from New England Biolabs cycles of 920 C. for 1 min, 450 C. for 1 f in ,  and 720 C. for 
(Beverly, Mass.), calf intestine phosphatase from Boe- 1 min, and 1 cycle of 72" C. for 10 min. Primer l b  is 
hringcr (Indianapolis, Ind.), AMV reverse transcriptase from complementary to the 3' end of the ribozyme, allowing 
Life Sciences (St. Petersburg, Fla.), MoMLV reverse tran- regeneration of its original, active form. PCR DNA 
scriptase and Sequenase 2.0 (modified T7 DNA polymerase) 45 (-250-500 ng, 5 1 0 %  of the total) then served as template 
from U.S. Biochemical, and Taq DNA polymcrase from in an in vitro transcription reaction, carried out in a 25-50 
Cetus (Emeryville, Calif.). T7 RNA polymerase was pre- pl volume. 
pared as previously described (Davanloo et al., PNAS USA The transcribed RNA was isolated by polyacrylamide gel 
81: 2035-2039 (1984)) and purified according to a proce- electrophoresis, visualized by uv shadowing, Cut and eluted 
dure originally developed for SP6 RNA polymerase (Butler 50 from gel, purified On dupont Nensorb (duPont de Nemours, 
& Chamberlain, J. Biol. Chem. 257: 5772-5778 (1982)). WilmingtOn, Del.), and quantified spectrophotometrically, as 
described above. The entire process was repeated 18 times, 
incubation time for the cleavage reaction reduced from 1 hr 
to min. Occasionally, the cDNA was purified to improve 
P d f l  of Cut Plasmid* mM MgC1zl 50 [a-32P]dATP. Labeled cDNA was isolated by electrophoresis 
fl TriS (PH 7.5),5 mM Drr, mM each NTp, 0.005 u/f l  in a 5% polyacrylamide/SM urea gel, visualized by autora- 
inorganic PYroPhoSPhatase, and 25 u / f l  RNA Poly- diography, cut and eluted from gel, and purified on DuPont 
merase, incubated at 37" C. for 2 hr. The 23-nucleotide 3' Nensorb. 
exon sequence was removed by RNA-catalyzed site-specific 6o 4. Shotgun Cloning, Sequencing, and Preparation of Indi- 
hydrolysis (Inoue et al., J. Mol. Biol. 189: 143-165 (1986)): vidual Enzymatic RNA Molecules 
RNA was incubated in the presence of 50 mM CHES (pH The G18 subclones were obtained as previously described 
9.0) and 10 mM MgCI, at 42" C. for 1 hr. The resulting RNA (see Example 1 above). The G27 subclones were obtained 
was isolated by electrophoresis in a 5% polyacrylamide/SM using the Invitrogen TA Cloning Kit (Invitrogen, San Diego, 
urea gel, visualized by UV shadowing, eluted from the gel 65 Calif.). The PCR DNA at G27 was ligated into a linearized 
overnight at room temperature in a bufTer containing 200 plasmid, and the resulting DNA was used to transform 
mM NaCl, 10 mM Tris (pH 7 3 ,  and 0.5 mM EDTA, and competent INVaF' cells, which were grown on ampicillid 
Thc previously-characterized G9 population of DNA- fl lo mM MgCIZ and 30 mM EPPS (PH 
ribozymes (see Example 1) was LGreSUneCtecl and 
[a-32PiGTP, [g-32plATp, and [3HiUTP were from ICN 
obtained from Operon Technologies and purified by Poly- 
amplified by the PCR in a 100 fl reaction mixture containing 
gelatin, 0.2 fl each dNW, 20 pmol s'-CGAGTACTC- 
2. Preparation of Wild-Type Ribozyme 
The ~ - 2 1  form of the ~~~h~~~~~ ribozyme was pre- the first 9 as described above and the second 9 with the 
pared by in vitro transcription of Hind III-digested pT7L-21 
plasmid DNA (Zaug et al., 
(1988)). The transcription reaction mixture contained 0.1 
27: 8924-8931 55 the quality of the PCR amplification. To do so, cDNA was 
synthesized as above except in the presence of 25-50 p ~ i  
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X-gal plates. Individual colonies containing the insert were mixing with an equal volume of 0.05-1 nM (5'-32P)-labeled 
identified by their white color, chosen at random, and grown DNA product in 10 mM MgCl,, 30 mM EPPS (pH 7 3 ,  
overnight in liquid media. Plasmid DNA was prepared by 0.05% xylene cyanol, 3% glycerol, and 80 pg/pl BSA. The 
the boiling, lysis method (Holmes & Quigley, Anal. Bio- mixture was allowed to equilibrate at 37" C. for 15-60 min 
chem. 114: 193-197 (1981)) and screened for the presence before loading on a 10% polyacrylamidc gel containing 10 
of insert by restriction digestion. Cloned individuals were mM MgCl, and 30 mM EPPS (pH 7.5). The electrophoresis 
sequenced by the dideoxy chain-termination method, as buffer also contained 10 mM MgCl, and 30 mM EPPS (pH 
previously described (Sanger et al., PNAS USA 74: 7.5). The gel was run at 6 milliamps in a 37" C. room until 
5463-5467 (1977); Beaudry a Joyce, Id. (1992)). Complete the sample had entered the gel (-10 min), and then moved 
sequences of individual subclones are available upon into a 4" C. cold room where the current was increased to 30 
request. Individual ribozymes were prepared as follows: the 10 milliamps. This was done to prevent the temperature of the 
gene encoding the ribozyme was amplified by the PCR using gel from rising above 37" C. The ribozyme-product complex 
Primer l b  and Primer 2; the resulting DNA was used as a and free product were visualized by autoradiography, cut 
template for in vitro transcription; the RNA products were from the gel, and quantified by Cerenkov counting. 
isolated by polyacrylamide gel electrophoresis, and were A binding curve was generated by plotting the percentage 
purified and quantified as described above. of product bound to ribozyme (% bound) over a range of 
5. Preparation of Substrate and Product Oligonucleotides l5 ribozyme concentrations. K D  was determined by fitting the 
The DNA substrate 5'-GGCCCTCTAmATITA-3' (SEQ data to a theoretical binding curve using a least squares 
ID NO 22) and DNA product 5'-GGCCCTCT-3' (SEQ ID method. Because ribozyme was in vast excess over product, 
NO 23) were (5'-32P)-labeled in a 20 pl reaction mixture the theoretical binding curve could be represented by the 
containing 20 pmol oligonucleotide, 10 pmol(4.5 pCi/pmol) equation: % bound=[E]/([E]+K,), where KD=[E] when half 
[g-32P]ATP, 5 mM MgCl,, 25 mM CHES (pH 9.0), 3 mM 20 of the total product is bound to the ribozyme. 
DTT, and 1.25 U/pi T4 polynucleotide kinase, incubated at C. Results 
37" C. for 1 hr. Labeled oligonucleotide was isolated by 1. Evolution In Vitro 
electrophoresis in a 20% polyacrylamidel8M urea gel, visu- Beginning with the 9th generation (G9) population of 
alized by autoradiography, eluted from the gel, and purified ribozymes obtained in a previous study (Beaudry & Joyce, 
on DuPont Nensorb. Id. (1992)), 18 additional generations of in vitro evolution 
The RNA substrate 5'-GGCCCUCUAUUUAUUUA-3' 25 were carried out. Variation in the population was maintained 
(SEQ ID NO 24) was prepared by in vitro transcription using by PCR amplification, which introduces mutations at a rate 
a partially single-stranded synthetic DNA template (Milli- of -0.1 % per nucleotide position per generation. Because 
gan et al., Nucleic Acids Res. 15: 8783-8798 (1987)), as mutation is ongoing, evolution based on Darwinian prin- 
described previously (Example 1). The RNA transcript was ciples can occur. Progeny ribozymes have the opportunity to 
dephosphorylated with calf intestine phosphatase, extracted 30 acquire new mutations that confer favorable attributes not 
with phenol and chloroform, and then (5'-32P)-labeled and possessed by the parent molecules. This phenomenon is 
purified as described above. reflected by the steadily increasing frequency of accepted 
6. Kinetics Analysis mutations over the 27 generations. 
All cleavage reactions were carried out at 37" C. in 10 Sequence data was obtained from 50 randomly-chosen 
mM MgCl , 30 mM EPPS (pH 7 3 ,  and 40 pg/pl BSA, subclones, isolated from the evolving population at G9, 
using (5'-32P)-labeled substrate. BSA was added to prevent 35 G18, and G27 (see FIGS. SA-SC). FIGS. 8A-K illustrate 
oligonucleotides from adhering to the walls of the 500 pl sites at which mutations occurred over the course of evolu- 
Eppendorf tubes, and did not affect the course of the tion, superimposed on the secondary structure of the Tet- 
reaction. Ribozyme and substrate were preincubated sepa- rahymena ribozyme. Box height corresponds to the fre- 
rately for 15 min at 37" C., and then mixed to initiate the quency of mutations (%) at each nucleotide position, based 
reaction. Typically, 5 aliquots of 3-10 pl each were removed 4o on 50 subclones sequenced at G9 (FIG. SA), G18 (FIG. SB), 
from the reaction mixture at specified times and quenched and G27 (FIG. 8C). Nonmutable primer binding sites are 
by addition to 1-2 volumes of an ice-cold mixture contain- shaded; substrate is shown in black. Commonly-occurring 
ing 8M urea, 50-100 mM EDTA, 0.05% xylene cyanol, mutations (>30% frequency) are labeled. 
0.05% bromophenol blue, 10% SDS, 9 mM Tris-borate (pH The mean number of mutations per subclone rose from 
8.3), and 20% sucrose. Substrate and product were separated 5.9 at G9, to 12.7 at G18, and to 16.5 at G27. Most of the 
by electrophoresis in a 20% polyacrylamide/8M urea gel, 45 mutations occurred within the phylogenetically conserved 
visualized by auto-radiography, excised from gel, and quan- portions of the ribozyme that were randomized in the initial 
tified by Cerenkov counting. population (see FIG. 7). However, 26% of the total muta- 
KM and k, values were determined in experiments with tions at G18, and 38% at G27, occurred in peripheral regions 
substrate (S) in excess over ribozyme (E). Initial rates of as a result of ongoing mutagenesis. Most of the commonly- 
reaction (v,), over a range of substrate concentrations, were 5o occurring mutations (>30% frequency) that occur in the G18 
estimated from the initial linear phase, generally the first 5% subclones (see FIG. 8B) were not observed at G9 (FIG. SA), 
or less of the reaction. Typically 8 data points were fit by a suggesting that these mutations arose in response to the 
least squares method to a theoretical line given by the increased selection pressure designed to enhance substrate 
equation: v - K M  (v,/[S])+V,,. binding affinity. Between G18 and G27, nearly all of the 
Single-turnover experiments were performed with most commonly-occurring mutations continued to increase 
ribozyme in excess of substrate (Herschlag & Cech, Bio- 55 in frequency (FIG. 8C). However, two significant mutations, 
chemistry 29: 10159-10171 (1990b)). Initial rates (kobs) the NGAA insertion between positions 51 and 52 and the 
were obtained using no more than the first 5% of the C+U change at position 170, first appeared during this 
reaction. Given that k,,jK,,,=k,,J[E], each k, value, interval, suggesting that these mutations arose in response to 
obtained at different ribozyme concentrations, provided an the increased selection pressure designed to enhance the 
estimate of kcQjKw Generally 8 or more measurements of 6o catalytic rate. 
kcQ,/KM were obtained. 2. Concerted and Mutually-Exclusive Mutations 
7. Determination of Binding Constants The changes at nucleotide positions 188, 190, and 191 in 
The equilibrium dissociation constant, K, of the com- the P5a region (FIG. 1) co-occur in 90% of subclones, while 
plex between ribozyme and DNA product (P) was deter- mutations in the J4/5 and J5/4 internal loop at positions 115, 
mined by gel-shift analysis in a native polyacrylamide gel 116, and 205 eo-occur in 68% of the subclones at G1S. 
(Pyle et al., PNAS USA 87: 8187-8191 (1990)). Ribozyme 65 Interestingly, the J4/5 and J5/4 mutations co-occur only if 
at twice final concentration was preincubated at 37" C. for the set of P5a mutations is also present (c2=110, p<O.OOl), 
15 min in 10 mM MgCl, and 30 mM EPPS (pH 7.5) before suggesting an interaction between these two regions. 
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The 313:GjY and 314:A+G mutations nearly always 
occur together. These mutations co-occur in 16 of 50 sub- 
clones at G9, 11 of 50 subclones at G18, and 44 of 50 
subclones at G27. Only two G27 subclones contain the 
mutation at position 313 but lack the mutation at position 5 
314. At G9 and G18, the 313 mutation always occurs as a 
G+U change. At G27, however, the 313 mutation occurs 
primarily as a G+C change, with the G+U change occur- 
ring only once. The GA sequence normally present at 
positions 313-314 is thought to form a short duplex struc- 
ture (P9.0) that brings the 3'-terminal guanosine residue of 
the ribozyme into the catalytic core (Michel et al., Nature 
342: 391-395 (1989); Michel et al., Genes Dev. 4: 777-788 
(1990); Michel, et al., J.  Mol. Bid. 216: 585-610 (1990)). 
The 3'-OH of this guanosine serves as the nucleophile in the 
RNA-catalyzed phosphoester reaction. Although the 
313-314 mutation would prevent the P9.0 duplex from 
forming, the 313-3 14:GA+UG change confers selective 
advantage with respect to the DNA-cleavage reaction, as 
demonstrated by site-directed mutagenesis studies (Beaudry 
&Joyce, Id. (1992)). The appearance of the 313-314:GAj 20 
CG change, between G18 and G27, suggests that this altered 
form of the 313-314 mutation may contribute to the 
improved catalytic rate of the DNA-cleavage reaction. 
The 312:CjA mutation occurs only if the 
313-314:GAjYG mutations are not present. The 25 
3 1 2 : C j A  change is present in 4 of 25 subclones at G3,8 of 
25 subclones at G6, and 5 of 50 subclones at G9 (Beaudry 
& Joyce, Id. (1992)). There is a dramatic rise in the fre- 
quency of the 312:GjA mutation between G9 and G18, 
followed by an equally dramatic drop between G18 and G27 3o 
(see FIGS. SA-C). As the frequency of the 312:G-+A 
mutation declines, the 313-314:GAjYG mutations 
become more abundant. 
The 215:GjA mutation, present at high frequency in all 
of the studied populations, putatively allows a Watson-Crick 
base pair to form with the U at position 258 (FIG. 1). This 35 
change is present in nearly all of the subclones at G18 and 
G27. Of the 12 individuals that lack this mutation, 11 carry 
a U+C change at position 258, which would allow a 
Watson-Crick pair to form with the wild-type G at position 
215. Thus, in 99 of 100 subclones from G18 and G27, a 40 
Watson-Crick base pair is expected to form between posi- 
tions 215 and 258. 
15 
3. Improvement of DNA Binding Affinity 
Beginning with G10, the concentration of DNA substrate 
employed during the RNA-catalyzed reaction was lowered 45 
from 10 pM to 0.2 @I to impose increased selection 
pressure favoring individuals with enhanced substrate bind- 
ing affinity. In order to assess the impact of this change, K, 
values for the complex between ribozyme and DNA product 
(GGCCTCT) were determined for the population of 5o 
ribozymes at every third generation over the 27 generations 
(see FIG. 9). 
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FIGS. 9A and 9B illustrate the improvement in substrate 
binding affinity over 27 successive generations of in vitro 
evolution. FIG. 9A represents a typical binding curve show- 
ing data obtained for the G27 population of ribozymes. J and 
B indicate data from two different gel-shift experiments. 
Data was fit by a least squares method to a theoretical 
binding curve (indicated by solid line), given by the equa- 
tion: y=[E]/([E]+K,), where y is the fraction of product (P) 
bound to ribozyme (E) . In this case, K,=51 (+2) nM. FIG. 
9B shows the K, for the population of ribozymes at every 
third generation. Standard errors averaged 11 %. 
The DNA product rather than substrate was employed to 
avoid a cleavage reaction during the gel-shift analysis. The 
binding a m i t y  for the product is assumed to be similar to 
that of the substrate, based on previous studies showing that 
the wild-type ribozyme binds the RNA substrate with the 
same affinity as it binds the product (Pyle et al., PNAS USA 
87: 8187-8191 (1990); Herschlag & Cech, Biochemistry 29: 
Binding data for each studied population was fit to a 
theoretical binding curve, an example of which is shown in 
FIG. 9A for the G27 population. As expected, the greatest 
improvement in binding affinity occurred between G9 and 
G18 (FIG. 9B), subsequent to tightening of the selection 
constraints. After G18, the population became saturated with 
ribozymes having a K, of less than 0.2 pM, accounting for 
the slow but continued improvement between G18 and G27. 
4. Kinetic Analysis 
Beginning with generation 19, the reaction time was 
reduced from 1 hr to 5 min to favor selection of ribozymes 
with increased k,, values. To study the effect of this change, 
two individuals isolated from the population at G9, G18 and 
G27 were chosen for formal kinetic analysis (Table 4). These 
ribozymes are representative of the population from which 
they were isolated because they contain most of the promi- 
nent mutations that occur in their respective populations. In 
addition, the total number of mutations in each of the studied 
individuals coincides with the mean number of mutations 
per subclone in the corresponding population. It is empha- 
sized that the k, and K, values of the studied individuals 
are not equivalent to the average k,,, and K,,, values for the 
entire population. It is likely that the catalytic efficiencies of 
the studied ribozymes are somewhat higher than the average 
because these ribozymes possess a greater fraction of the 
dominant mutations than a typical individual in the popu- 
lation. Nevertheless, the relative differences in k,,, and K,, 
values between representative pairs of individuals should be 
comparable. As expected, the improvement in k, is greatest 
between the G18 and G27 ribozymes (Table 4), while the 
improvement in K,,, is greatest between the G9 and G18 
ribozymes. 
Table 4, illustrating the catalytic parameters of DNA- 
cleaving enzymatic RNA molecules, is reproduced herein- 
below. 
101 59-1 01 71 (1990b)). 
TABLE 4 
Catalytic Parameters of DNA-Cleaving Ribozymes 
C P  KMb L d K M  
Ribozyme Mutations (min-') (!JM (M-' min-') 
wt= 0 2.4 (f 0.2) x 10" 6.0 i 1.7 4.0 x 10' 
G9 #23" 7 5.1 (i- 0.2) x 10-3 1.8 i 0.3 
G18 #13' 12' 1.7 (f 0.1) x lo-' 0.24 i 0.04 7.1 x 10" 
G27 #48" 17h 7.0 (+ 0.6) x lo-' 0.31 f 0.05 2.3 x lo6 
G21#61" 15' 3.3 (i 0.7) x lo-' 0.11 i 0.06 2.9 x lo6 
2.8 x 103 
G9 #29" 6 7.1 (i 0.3) x 1.9 i 0.3 3.8 x 103 
G18 #66' 13s 1.1 (f 0.1) x 0.32 + 0.08 3.5 x 10" 
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TABLE 4-continued 
Catalytic Parameters of DNA-Cleaving Ribozymes 
k,,b KMb L P M  
Ribozyme Mutations (min-') (pM) (M-' min-') 
54 
"Data obtained previously (see Example 1 above), modified slightly as a result of subsequent 
statistical analysis. 
bMeasuremcnts were canied out as described in Materials and Methods with: 
'0.025 pM ribozyme and 0.125, 0.25, 0.5, and 1.0 pM DNA substrate; 
d0.02 pM ribozyme and 0.1, 0.2, 0.4, and 0.8 pM DNA substrate; or 
'0.02 pM ribozyme and 0.05, 0.1, 0.2, and 0.4 pM DNA substrate. 
'44: G + A, 9 4  A + U, 115: A + U, 116: G + A; 138: C +A, 188: G + A, 190: U ;f A, 191: 
G -tu, 205: U + C, 215: C +A, 3 1 2  G +A, and317: U + G. S44: G +A, 94: A +  U, 115: 
A +  U, 116: G +A, 138: C +A, 167: U + G, 188: G +A, 190: U +A, 191: G + U, 205: U 
+ C, 2 1 5  G + A, 239: U +A, and 312: G +A. G + A, 51/52: insert AGAA, 87: A + del, 
9 4 A + U ,  115:A+U, 116: G +A, 166: C + A ,  170: C +U, 188: G + A ,  190  U + A ,  191: 
G +U, 205: U + C, 215: G +A, 239: U +A, 312  G +A, 350  C + U ,  and 364: C +U.  '44: 
C+A,51/52inseaAGAA,87:A+del,94:A+U, 115:A+U, 116:G+A, 166: C+A,  170: 
C + U, 188: G +A, 190: U +A, 191: G + U, 205: U + C, 215: G +A, 313: G + C, and 3 1 4  
A + G .  
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5. RNA-Cleavage Activity of G27 Enzymatic RNA Mol- min-' and a substrate binding affinity of lO-'M. These 
ecules catalytic parameters are improved 10 -fold and 104-fold, 
In order to assess the effect of the evolution procedure on respectively, compared to the wild-type. The greatest 
RNA-cleavage activity, the efficiency of RNA-cleavage by improvement in KD and K M ,  (FIG. YB; Table 4) occurred 
both the (327 #48 and ~ 2 7  #61 ribozymes was compared to between GY and GI8 in response to alteration of the selec- 
that of the wild-type. Single-tumover kinetic experiments 25 tion constraints to favor ribozymes with enhanced affinity 
revealed that the G27 ribozymes have slightly enhanced for the DNA substrate. Likewise, based on k,,, values for 
R N A - ~ ~ ~ ~ ~ ~ ~ ~  activity: k,,/KM values are 2.7 (+0,2)~107 representative individuals (Table 4), the greatest improve- 
and 2.3 ( + 0 , ~ ) ~ 1 0 7 ~ - 1 m i ~ - l  for clones G27 #48 and G27 ment in k,,, occurred between G18 and G27, following alteration of the selection constraints to favor a faster rate of #61, respectively, compared to 9.4 (?3.O)x1O6 M-lmin-' for catalysis. the wild-type. Thus, the 27 generations of in vitro evolution 30 
resulted in a 105-fold improvement of DNA-cleavage activ- 
ity and a 2 to 3-fold enhancement of RNA-cleavage activity. 
The DNA-binding affinity Of the G27 #48 and G27 #61 
affinity ofthe ribozymes is to the 
Similarly, gel-shift experiments revealed a significantly 
RNA binding 
bind the DNA product with a KD Of 
the RNA product with a K~ Of 
the G27 ribozymes exhibit a 104-fold improvement in DNA 4o 
binding affinity. 
wild-type ribozyme. Previous studies have suggested that 
the wild-type ribozyme binds RNA more strongly than DNA 
35 RNA substrate and specific nucleotides within the catalytic 
core of the ribozyme (Pyle & Cech, Nature 350: 628-631 
et al., Biochemistry 32: 8299-8311 (1993)). In binding the 
for the lack of subs,ate 2'-OH groups by 
greater improvement in DNA binding &nity to as a result of interactions between the 2'43H groups of the Ribozymes G27 #48 and G27 
nM and 
to 30 r*M for the and bind (1991); Pyle et al., Nature 358: 123-128 (1992); Herschlag 
to 1.5 for the Thus, DNA substrate with nM affinity, the evolved ribozymes must 
nM and 0.4 nM, 
binding anity and a to 4-fo1d improvement in RNA fo-ng alternative interactions that provide an additional 5 
kcal mcl-' of binding energy (at 37" C.). 
6. Generations 28-36 
The aforementioned evolutionary procedures continue to 
be applied to produce subsequent generations of enzymatic 
The Tetrahymena ribozyme binds its through a 
first, Watson-Crick base pairing two-step process 
RNA molecules. Data for generations (328436 has been 45 between the inkm'lal guide sequence (IGS) and the substrate, 
gathered and analysis is ongoing, Critical mutation sites and second, docking of the IGShbstrate duplex (PI helix) 
identified as described above continue to be of into the catalytic core of the ribozyme via tertiary interac- 
tions (Herschlag, Biochemistry 31: 1386-1399 (1992); Bev- as shown in FIG. 10. 
FIG. 10 illustrates sites at which mutations occurred Over ilacqua et al., Science 258: 135-1358 (1992)). Because the 
the course of evolution, superimposed on the secondary 50 sequence Of both the IGS and substrate is unchanged 
of the Tetrahymena ribozyme. Box height corre- throughout the in vitro evolution procedure, it is unlikely 
sponds to the frequency of mutations (%) at each nucleotide that we have compensato~ mutations that 'perate 
position, based on 50 subclones sequenced at generation 36. at the first step Of binding. Instead, the Of 
Non-mutable primer binding sites are shaded; substrate is additional binding energy is likely to result from additional 
shown in black. 
frequency) are labeled (dark bars). Much more can be learned about such interactions by 
examining the specific mutations that arose in response to 
Example 3 the increased selection pressure aimed to improve substrate 
binding. For example, mutations at positions 115, 116, and 
Discussion of Examples 1-2 205 in the J4/5 and 55/4 internal loop of the ribozyme (FIG. 
6o 1) became prominent in the population between GY and 
It has now been shown that specific catalytic properties of G18. Both a tertiary structural model of the wild-type 
a DNA-cleaving ribozyme can be optimized by appropriate ribozyme (Michel & Westhof, J. Mol. Biol. 216: 585-610 
manipulation of the selection constraints during an in vitro (1990)) and experimental evidence suggest that residues in 
evolution procedure. Beginning with a heterogeneous popu- the 546 region may interact with the IGS. On the basis of 
lation of ribozymes, enriched for modest DNA-cleavage 65 crosslinking data, Wang et al. (Science 260: 504508 
activity, 18 additional generations were carried out to obtain (1993)) concluded thatA114 andA115 lie in close proximity 
DNA-cleaving ribozymes that have a catalytic rate of 0.7 to G22 of the IGS (the 5'-terminal residue of the L-21 form 
kc' 
mutations (,30% 55 tertiary interactions that affect the second step of binding. 
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of the ribozyme) when P1 is docked into the ribozyme core. 
Thc mutations at positions 115 and 116 may enhance P1 
docking by allowing new contacts to be made with the IGS, 
compensating for the lack of 2'-OH groups in the substrate. 
Such interactions would strengthen binding of both DNA 
and RNA substrates and might account for the 
improvement in RNA-cleavage activity. This may also 
explain the observation that the G27 #61 ribozyme effi- 
ciently cleaves a modified substrate that has an arabi- 
previously, enzymatic RNA molecules according to the 
present invention are capable of cleaving substrates includ- 
or the sugar that has been modified, or both. 
transcriptase, T7 RNA polymerase, and Taq polymerase) to 
operate efficiently during the amplification procedure. 
Future studies, relying on site-directed mutagenesis analy- 
sis, will enable us to assess the contribution made by various 
mutations, in either the conserved core or the peripheral 
regions, to substrate binding, first-order reaction rates, and 
ribozyme folding. 
Now that it has been demonstrated that substrate binding 
in vitro evolution, optimization of other catalytic propertics 
Of the DNA-c1eaving ribozymes7 and 
improved by evolving ribozymes that can carry out a site- 
specific hydrolysis reaction, subsequent to DNA-cleavage, 
Co-occumng mutations at positions 188,190, and 191 in which removes the attached 3' portion of the DNA substrate 
between G9 and G18. The correlation between these muta- its original form. specificity of the ribozymes for D N ~  
tions and the co-occumng mutations in the J4/5 and J5/4 versus RNA substrates might be increased by selecting for 
internal loop (see Results) suggests a possible interaction DNA-cleavage in the presence of mA that as a 
between these two regions. It has been proposed that the competitive inhibitor. one aim is the development of D ~ ~ -  
adenosine-rich bulge in P5a (FIG. 1; positions 183-1861 20 cleaving ribozymes that have high catalytic efficiency, 
interacts with P4 (Flor, et a l . 7  EMBO J. 8: 3391-3399 undergo rapid turnover, and operate in a highly specific 
(1989)) by bending at the J5/5a internal loop (Murphy 8~ manner. Such molecules will contribute to our undcrstand- 
Cech, Biochem. 32: 5291-5300 (199311, which would place ing of the catalytic of RNA. addition, they may 
nose sugar at the cleavage site (data not shown), As noted and first-order rate 'Onstants can be specificaily enhanced by 
ing nucleotide analogs, irrespective of whether it is the base specificity, is being attempted. Turnover might be 
the P5a region also became prominent in the population l5 from the 3' end of the ribozyme, returning the molecule to 
residues G188, u190, and G191 in 
5415 and J5/4 internal loop. Thus, the mutations in P5a may 25 therapeutic agents directed against viral pathogens. 
proximity to the have utility as sequence-specific DNA endonucleases and as 
facilitate the contact between residues in the J4/5 region and 
the IGS. 
The evolved ribozymes might compensate for the absent 
substrate 2'-OH groups by forming new tertiary interactions 
with the bases, phosphates, and/or sugars of the DNA. 3o 
Studies suggest that residues in J7/8 of the wild-type 
ribozyme interact with the 2'-OH groups at positions -3(u) 
and -2(c) of the RNA substrate (Pyle & Cech, Nature 350: One alternative method of preparing wild-type and mutant 
628-631 (1991); Pyle et ai., Nature 358: 123-128 (1992)). ribozYmes may be d ~ c r i b e d  as fOl~OWS. Wild-tYPc and 
Frequent mutations, however, did not occur in the J7/8 mutant ribozYmes were Produced by first isolating the 443 
region of the evolved ribozymes, suggesting that new con- 35 base-pair ECO RI to Hind 111 restriction endonuclease frag- 
tacts arc not made in the vicinity of the DNA substrate at ment from the Plasmid m - 2 1  d ~ ~ c r i b e d  by ZaW et a l . 9  
positions -3(t) and -2(c). In addition, specific base contacts BiochemiW 27: 8924 (1988) using the standard methods 
Seem unlikely, based on the observation that a DNA sub- described in Current Protocols in Molecular Biology, 
strate with a different sequence can be cleaved efficiently by A ~ ~ b e l  e t &  John WileY and Sons, New YOrk (1987). 
the ribozymc, provided the IGS has been changed in a 40 This 443 base-pair fragment contains the T7 promoter 
complementary manner to maintain Watson-Crick base pair- described by Dunn et al., J. Mol. Biol. 166: 477-535 (1983) 
ing (Raillard & Joyce, unpublished results). and residues 22-414 of the Tetrahymena IVS and residues 
The 103-fold improvement in k, over the 27 generations 1-25 of the 3' Tetrahymena exon desC*bed by Been et d., 
is more difficult to rationalize. k, reflects all first-order rate cell47: 207-216 (1986). This ECO RI and Hind 111 fragment 
constants along the reaction pathway, including those related 45 was inserted into the MI3 vector M13mPl8 (which is 
to p1 docking and substrate cleavage. At least part of the Similar to the Vector described by Yanisch-Perron et al., 
enhancement in k,,, thus may be attributed to additional Gene 33: 103-119 (198511, which vector had been Previ- 
tertiary interactions between P1 and the catalytic core, which ously cleaved with Eco RI Hind 111, according 10 standard 
would favorably affect the docking rate. The cleavage step subcloning Procedures such as those d m ~ 3 ~ e d  in Cwrent 
of the reaction depends on the appropriate positioning of the 5o Protocols in MOltmdar Biology, A m ~ b e l  et eds. John 
3'-teminal guanosine of the ribozyme for attack on the Wiley and Sons, New York (1987). The resulting M13T7L- 
target phosphoester bond of the substrate. This is accom- 21 DNA consb-~ct was used to transform E. Coli host cells 
plished by the formation of a base triple involving the according to the transformation procedure described in 
attacking guanosine and the G264:C311 base pair within the Molecular Cloning: A Laboratory Manual (Maniatis et al., 
P7 region of the ribozymc (Michel et al., NatMre 342: eds., Cold Spring Harbor Laboratories, Cold Spring Harbor, 
391-395 (1989)). Mutations at positions 312, 313, and 314 55 N.Y. (1989)). 
all lie in close proximity to the binding site for the attacking Single-stranded DNA was then prepared from the 
guanosine and may play somc role in facilitating the chemi- M13T7L-21-transformed cells according to the procedures 
cal step of the reaction. However, new mutations that described in Current Protocols in Molecular Biology (Id., 
became frequent in the population between G18 and G27 in 1987). The accuracy of the above construction was con- 
response to the shorter reaction time occurred in peripheral 60 firmed by DNA sequencing using the klenow fragmcnt of E. 
regions, at positions 51/52 and 170. Such mutations may coli DNA polymerase I (Boehringer Mannheim Biochemi- 
increase first-order reaction rates indirectly through long- cals, Indianapolis, Ind.) and the dideoxynucleotide sequenc- 
range effects or by facilitating folding of the ribozyme into ing method (see Sanger et al., PNAS USA 74: 5463-5467 
its active conformation. (1977)). 
The wild-type and mutant ribozymes were prepared 
selective advantage with respect to catalysis, but instead directly from the single-stranded M13T7L-21 DNA using a 
enhance the ability of the polymerase enzymes (Le., reverse modification of the technique previously described by Joyce 
Example 4 
Alternative Methods of Preparing Enzymatic RNA 
Molecules 
It is important to note that some mutations may confer no 65 
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and Inoue, Nucleic Acid Research 17: 711-722 (1989). The the gel, and purified by ethanol precipitation and chroma- 
technique involves construction of a template strand that tography on Sephadex G-50. 
optionally includes one or more mutagenic oligodeoxy- The 3' exon sequence was removed by RNA-catalyzed 
nucleotides. The resulting partially-mismatched double- site-specific hydrolysis as has been previously, Inoue et al., 
stranded DNA is transcribed directly using T7 RNA poly- 5 J. Mol. Biol. 189: 143-165 (1986). Briefly, the RNA was 
merase. incubated in the presence of 50 mM CHES at pH 9.0 and 10 
Briefly, the procedure is as follows. A five-fold molar mM MgC1z at 42" for hour. and mutant 
affinity chromatography on du Pont Nensorb (du Pont, 
excess of a terminator polynucleotide and a mutator oligo- 
nucleotide were admixed with 5 pg of single-stranded 
M13T7L-21 DNA and a 
[hydroxy-methyllaminomethane adjusted to pH 7.5 with 
RNAs were by in a 5% polyacry- 
urea gel, 'luted from the gel, and purified by 
tris 10 Wilmington, Del.). RNAs were sequenced by primer exten- 
sion analysis using AMV reverse transcriptase (Life Tech- 
containing 2o 
HC1(Tris-HC1), 50 mM NaC1 and mM MgC1z. This nologies, Inc., Gaithersburg, Md.) in the presence of 
solution was maintained at 70 degrees centigrade (70" c.1 dideoxynucleotides, using a modification of the methods 
for 5 minutes and then steadily cooled to 30" C. over 40 described by sanger et al. ( ~ N A S  USA 74: 5463-5467 
minutes. Fifteen unit@) ofT4 DNAligase (U.S. Biochemi- 15 (1977)), except for those containing the Delta P9 deletion 
CalS, Cleveland, Ohio) and 7.5 u of T4 DNA Polymerase (not shown), which were sequenced from the 3' end by 
(U.S. Biochemicals) were admixed into the solution, partial RNase digestion, Donis-Keller et d., Nucleic Acids 
together with sufficient amounts of reagents to make a Res. 15: 8783-8798 (1987). 
solution containing a final concentration of 20 mM Tris-HC1 Other methods of preparing enzymatic RNA molecules of 
at PH 7.5, 50 mM NaC1,5 mM MgC12, 2 mM dithiothreitol the present invention are based on chemical synthesis. 
( D P ) ,  1 mM adenosine triphosphate (ATP), and 0.5 mM 2o Methods useful in the chemical synthesis of RNA are similar 
each of dGTP, d P P ,  dATP and dCTP (dNTPs). The result- to those used to synthesize DNA. The additional 2' -OH 
ing solution was maintained at 37" C. for 60 minutes to group in RNA, however, requires a different protecting 
complete the synthesis of the mutant strand. The resulting group strategy to deal with selective 3'-5' internucleotide 
DNA was purified by ethanol precipitation and then used to bond formation, and with RNA susceptibility to degradation 
direct the transcription of mutant RNA. 25 in the presence of bases. 
Transcription took place either in a 10 pl volume con- The recently-developed method of RNA synthesis utiliz- 
taining 1 pg of mutant DNA, 2 pci [$Zp] G T ~  and 50 u of ing the t-butyldimethylsilyl group for the protection of the 2' 
n RNA polymerase that was as previously hydroxyl seems to be the most reliable method for chemical 
described by ~~~~l~~ et al., PNAS USA 81: 2035-2039 
(1984), and the resulting product was purified according to 3o RNA with the correct 3'-5' 
synthesis Of ribozymes. The method reproducibly yields 
linkages, with 
a procedure originally developed by Butler & Chamberlain, average yields in Of 99%, and requires Only 
J. Bio. Chem. 257: 5772-5779 (1982), or in a400 pl volume 
containing 10 pg of mutant DNA, 40 pCi [3H]UTF' and 
2,400 u of T7 RNA polymerase. In either case, the tran- 
scription mixture also contained 40 mM Tris-HC1 at pH 7.5, 35 Useful methods of chemically Synthesizing ribozYmeS. 
15 mM MgCl,, 10 mM dithiothreitol, 2 mM spermidine, and The foregoing specification, including the specific 
1 mM (each) NTPs, and was incubated at 37" C. for 90 embodiments and examples, is intended to be illustrative of 
minutes. The T7 RNA polymerase was extracted with phe- the present invention and is not to be taken as limiting. 
no1 and the transcription products were purified by ethanol Numerous other variations and modifications can be effected 
precipitation. The mutant RNA was isolated by electro- without departing from the true spirit and scope of the 
phoresis in a 5% polyacrylamide/S M urea gel, eluted from present invention. 
a two-step de-protection Of the 
lished PCT application no. wo 93/23569 describes other 
Other useful methods are available. For example, pub- 
( 1 ) GENERAL INFORMATION: 
( i i i ) NUMBER OF SEQUENCES: 26 
( 2 ) INFORMATION FOR SEQ ID NO:I: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 5 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N01: 
N N N N A  
( 2 ) INFORMATION FOR SEQ ID N 0 2 :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 5 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
SEQUENCE LISTING 
5 
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______ 
( D ) TOPOLOGY lincar 
( 1 I ) MOLECULE TYPE RNA (gcnomlc) 
( x I ) SEQUENCE DESCRIPTION: SEQ ID NO 2 
A A C A A  
( 2 ) INFORMATION FOR SEQ ID N0:3: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 27 basc pairs 
( B ) T Y P E  nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE RNA (gcnornic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:3: 
A G U U A C C A G G  C A U G C A C C U G  G U A G U C A  
( 2 ) INFORMATION FOR SEQ ID N O 4  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 36 basc pars 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE RNA (gcnomic) 
( x i ) SEQUENCE DESCRKTION: SEQ ID N O 4  
G U C U U U A A A C  C A A U A G A U U G  G A U C G G U U U A  A A A G G C  
( 2 ) INFORMATION FOR SEQ ID NO5: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 15 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO5: 
A A A T A A A T A A  A T A A A  
( 2 ) INFORMATION FOR SEQ ID N O 6  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 23 basc p3irs 
( B ) TYPE: nucleic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY linear 
( i i ) MOLECULE TYPE: DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N0:G: 
G G C C C T C T A A  A T A A A T A A A T  A A A  
( 2 ) INFORMATION FOR SEQ ID NO:7: 
( I SEQUENCE CHARACTERISTICS: 
( A ) LENGTK 16 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE: DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:7: 
5 
2 1  
3 6  
1 5  
2 3  
5,580,967 
-continued 
61 62 
T T T A T T T A T T  T A T T T C  
( 2 ) INFORMATION FOR SEQ ID NOS: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 42 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NOS: 
A T C G A T A A T A  C G A C T C A C T A  T A G G A G G G A A  A A G T T A T C A G  G C  
( 2 ) INFORMATION FOR SEQ ID N0:Y: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 20 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincx 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO9: 
C G A G T A C T C C  A A A A C T A A T C  
( 2 ) INFORMATION FOR SEQ ID N O 1 0  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 8 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:10 
G G C C C T C T  
( 2 ) INFORMATION FOR SEQ ID N0:l l :  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: Y basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE: DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N O l l :  
G G C C C T C T A  
( 2 ) INFORMATION FOR SEQ lD NO:12 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 16 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N O 1 2  
A A A T A A A T A A  A T A A A A  
1 6  
4 2  
2 0  
8 
Y 
( 2 ) INFORMATlON FOR SEQ ID NO13: 
1 6  
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( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH 24 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: linear 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPnON: SEQ ID NO:13: 
G G C C C T C T A A  A T A A A T A A A T  A A A A  
( 2 ) INFORMATION FOR SEQ ID NO:14 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 33 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIFTION: SEQ ID NO:14: 
C C A A G C T T G A  T C T C G A G T A C  T C C A A A A C T A  A T C  
( 2 )INFORMATION FOR SEQ ID NO:15: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 48 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE T W E  DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N0:IS: 
C T G C A G A A T T  C T A A T A C G A C  T C A C T A T A G G  A G G G A A A A G T  T A T C A G G C  
( 2 ) INFORMATION FOR SEQ ID NO:16: 
( i ) SEQUENCE CHARACTERISTICS: 
( A 1 LENGTH: 17 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i MOLECULE TYPE: DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:16: 
G T A A A A C G A C  G G C C A G T  
( 2 ) INFORMATION FOR SEQ ID N017:  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D )TOPOLOGY lmcar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO:17: 
C A T G A T T A C G  A A T T C T A  
( 2 ) INFORMATION FOR SEQ ID NO:18: 
2 4  
3 3  
4 8  
1 7  
1 7  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTW 24 basc pairs 
( B ) TYPE nucleic acid 
( C ) STRANDEDNESS: singlc 
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( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE RNA (genomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID NO:18: 
G G C C C U C U C A  A A U A A A U A A A  U A A A  
( 2 ) INFORMATION FOR SEQ ID NO19: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 21 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE: DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO19: 
C C C T C N A A A T  A A A T A A A T A A  A 
( 2 ) INFORMATION FOR SEQ ID N O 2 0  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 6 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: single 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION SEQ ID N O 2 0  
C C C T C N  
( 2 ) INFORMATION FOR SEQ ID NO:21: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 15 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE: DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N021:  
T T T A T T T A T T  T A T T T  
( 2 ) INFORMATION FOR SEQ ID N O 2 2  
( i ) SEQUENCE CHARACTERISTICS 
( A ) LENGTH: 17 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N O 2 2  
G G C C C T C T A T  T T A T T T A  
( 2 ) INFORMATION FOR SEQ ID NO23: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 8 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (gcnomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID N023:  
2 4  
2 1  
6 
1 5  
1 7  
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G G C C C T C T  R 
( 2 ) INFORMATION FOR SEQ ID N O 2 4  
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 17 hasc pairs 
( B ) T Y P E  nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE: RNA (genomic) 
( x i ) SEQUENCE DESCRIITON: SEQ ID N O 2 4  
G G C C C U C U A U  U U A U U U A  
( 2 ) INFORMATION FOR SEQ ID N0:25: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 24 basc pairs 
( B ) TYPE nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY lincar 
( i i ) MOLECULE TYPE DNA (genomic) 
( x i ) SEQUENCE DESCRIPTION: SEQ ID NO25: 
G G C C C T C T C A  A A T A A A T A A A  T A A A  
1 7  
2 4  
( 2 ) INFORMATION FOR SEQ 1D NO:26: 
( i ) SEQUENCE CHARACTERISTICS: 
( A ) LENGTH: 393 basc pairs 
( B ) T Y P E  nuclcic acid 
( C ) STRANDEDNESS: singlc 
( D ) TOPOLOGY: lincar 
( i i ) MOLECULE TYPE rRNA 
( x i ) SEQUENCE DESCRIFTION: SEQ ID NO:26: 
G G A G G G A A A A  G U U A U C A G G C  A U G C A C C U G G  U A G C U A G U C U  U U A A A C C A A U  A G A U U G C A U C  6 0  
G G U U U A A A A G  G C A A G A C C G U  C A A A U U G C G G  G A A A G G G G U C  A A C A G C C G U U  C A G U A C C A A G  , 1 2 0  
U C U C A G G G G A  A A C U U U G A G A  U G G C C U U G C A  A A G G G U A U G G  U A A U A A G C U G  A C G G A C A U G G  1 8 0  
U C C U A A C C A C  G C A G C C A A G U  C C U A A G U C A A  C A G A U C U U C U  G U U G A U A U G G  A U G C A G U U C A  2 4 0  
C A G A C U A A A U  G U C G G U C G G G  G A A G A U G U A U  U C U U C U C A U A  A G A U A U A G U C  G G A C C U C U C C  3 0 0  
U U A A U G G G A G  C U A G C G G A U G  A A G U G A U G C A  A C A C U G G A G C  C G C U G G G A A C  U A A U U U G U A U  3 6 0  
G C G A A A G U A U  A U U G A U U A G U  U U U G G A G U A C  U C G  3 9 3  
I claim: 
1. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein said sequence includes 
one or more mutations selected from the group consisting of: 55 
the substitution of A for U at position 190; 
the substitution of U for G at position 191; 
the substitution of A for u at position 239; 
the substitution of for at position 258; 
the substitution of A for G at position 312; 
the substitution of U for C at position 350; and 
the substitution of U for C at position 364. 
the substitution of A for G at position 44; 
the insertion of AGAA between positions 51 and 52; 
the deletion of A at position 87; 
the substitution of U for A at position 115; 
the substitution of A for G at position 116; 
the substitution of A for C at position 138; 
the substitution of A for C at position 166; 
the substitution of G for U at position 167; 
the substitution of U for C at position 170; 
the substitution of A for G at position 188; 
60 2. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein C is substituted for U 
at position 258. 
3. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein said sequence includes 
one or more mutations selected from the group consisting of; 65 
the substitution of U for A at position 94, 
the substitution of C for A at position 94, 
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the substitution of C for U at position 205, 
the substitution of A for G at position 215, 
the substitution of U for G at position 313, 
the substitution of C for G at position 313, 
the substitution of G for A at position 314, 
the substitution of G for U at position 317, 
the substitution of C for U at position 317, 
the substitution of A for U at position 317, and 
the substitution of C for U at position 333; 
and one or more mutations selected from the group consist- 
ing of 
the substitution of A for G at position 44, 
the insertion of AGAA between positions 51 and 52, 
the deletion of A at position 87, 
the substitution of U for A at position 115, 
the substitution of A for G at position 116, 
the substitution of A for C at position 138, 
the substitution of A for C at position 166, 
the substitution of G for U at position 167, 
the substitution of U for C at position 170, 
the substitution of A for G at position 188, 
the substitution of A for U at position 190, 
the substitution of U for G at position 191, 
the substitution of A for U at position 239, 
the substitution of C for U at position 258, 
the substitution of A for G at position 312, 
the substitution of U for C at position 350, and 
the substitution of U for C at position 364. 
4. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein U or C is substituted 
for A at position 94; U is substituted for A at position 115; 
A is substituted for G at position 116; A is substituted for G 
at position 188; A is substituted for U at position 190; U is 
substituted for G at position 191; C is substituted for U at 
popition 205: A is substituted for G at position 215; and UG 
is substituted for GA at positions 313-314. 
5. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein A is substituted for G 
at position 44; U or C is substituted for A at position 94; U 
70 
is substituted for A at position 115; A is substituted for G at 
position 116; A is substituted for C at position 138; A is 
substituted for G at position 188; A is substituted for U at 
position 190; U is substituted for G at position 191; C is 
substituted for U at position 205; A is substituted for G at 
position 215; A is substituted for G at position 312; and G 
is substituted for U at position 317. 
6. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein A is substituted for G 
IO at position 44; U or C is substituted for A at position 94; U 
is substituted for A at position 115; A is substituted for G at 
position 116; A is substituted for C at position 138; G is 
substituted for U at position 167; A is substituted for G at 
position 188; A is substituted for U at position 190; U is 
15 substituted for G at position 191; C is substituted for U at 
position 205; A is substituted for G at position 215; A is 
substituted for U at position 239; and A is substituted for G 
at position 312. 
7. An enzymatic RNA molecule consisting of the 
20 sequence of SEQ ID NO 26, wherein A is substituted for G 
at position 44; AGAA is inserted between positions 51 and 
52; A is deleted at position 87; U or C is substituted for A at 
position 94; U is substituted for A at position 115; A is 
substituted for G at position 116; A is substituted for C at 
position 166; U is substituted for C at position 170; A is 
25 substituted for G at position 188; A is substituted for U at 
position 190; U is substituted for G at position 191; C is 
substituted for U at position 205; A is substituted for G at 
position 215; A is substituted for U at position 239; A is 
substituted for G at position 312; U is substituted for C at 
30 position 350; and U is substituted for C at position 364. 
8. An enzymatic RNA molecule consisting of the 
sequence of SEQ ID NO 26, wherein A is substituted for G 
at position 44; AGAA is inserted between positions 51 and 
52; A is deleted at position 87; U or C is substituted for A at 
35 position 94; U is substituted for A at position 115: A is 
substituted for G at position 116; A is substituted for C at 
position 166; U is substituted for C at position 170; A is 
substituted for G at position 188; A is substituted for U at 
position 190; U is substituted for G at position 191; C is 
substituted for U at position 205; A is substituted for G at 
position 215; C is substituted for G at position 313; and G 
is substituted for A at position 314. 
5 
4o 
* * * * *  
